Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
Search
Advanced Search
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

47
results for

"Won Kim"

Article category

More +

Keywords

More +

Publication year

More +

"Won Kim"

Original Articles

Outcomes of Oral Antidiabetic Drugs in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Target Trial Emulation Study
Heejoon Jang, Yeonjin Kim, Yoo Kyoung Lim, Dong Hyeon Lee, Sae Kyung Joo, Bokyung Koo, Woojoo Lee, Stefano Romeo, Won Kim, Innovative Target Exploration of NAFLD (ITEN) consortium
Received September 5, 2025  Accepted December 30, 2025  Published online January 6, 2026  
DOI: https://doi.org/10.3350/cmh.2025.1006    [Accepted]
Background/Aims
Patients with concurrent type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) face elevated cardiovascular risks. However, optimal oral antidiabetic drug (OAD) selection for this population remains unclear.
Methods
Using the Korean National Health Information Database, we conducted a target trial emulation comparing cardiovascular outcomes among patients with T2DM and MASLD (defined by fatty liver index ≥30) who initiated sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas with metformin. The primary outcome was major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.
Results
Among 71,071 patients (331,726 person-years), SGLT2 inhibitor users experienced a significantly lower MACE risk compared to sulfonylurea users (adjusted subdistribution hazard ratio [aSHR], 0.44; 95% CI, 0.31–0.62). SGLT2 inhibitors also demonstrated a lower MACE risk compared to thiazolidinediones (aSHR, 0.61; 95% CI, 0.39–0.96) and DPP-4 inhibitors (aSHR, 0.59; 95% CI, 0.42–0.96). Cardiovascular mortality risk was notably reduced with SGLT2 inhibitors compared to sulfonylureas (aSHR, 0.13; 95% CI, 0.03-0.50), thiazolidinediones (aSHR, 0.19; 95% CI, 0.04-0.86), and DPP-4 inhibitors (aSHR, 0.22; 95% CI, 0.06-0.84). Mediation analysis revealed that MASLD regression accounted for 8.7% of the total cardiovascular benefit when comparing SGLT2 inhibitors to sulfonylureas.
Conclusions
In patients with concurrent T2DM and MASLD, SGLT2 inhibitors demonstrated better cardiovascular outcomes compared to other OADs. These findings suggest that SGLT2 inhibitors may be the preferred OAD choice for cardiovascular risk reduction in this high-risk population.
  • 456 View
  • 66 Download
Novel near-infrared probe for monitoring lipid peroxidation-mediated viscosity change in ferroptotic hepatocytes video
Le Bich Hang Pham, Taeeung Kim, Seoyoung Kim, Yun Seok Kim, Jiyeon Kim, Kyeongseon Kim, Hyeonwoo Lim, Wan Seob Shim, Byoungmo Kim, So-Yeol Yoo, Jae-Young Lee, Murim Choi, Won Kim, Keon Wook Kang, Jeeyeon Lee
Clin Mol Hepatol 2026;32(1):318-338.
Published online November 17, 2025
DOI: https://doi.org/10.3350/cmh.2025.0779
Background/Aims
Ferroptosis, recently emerged as a new cell death modality characterized by iron-dependent peroxidation of lipids, has been explored in various diseases. However, detection of ferroptosis, particularly in chronic liver disease models, is hampered by the lack of universal ferroptosis markers and limited number of fluorescence sensors for in vivo ferroptosis.
Methods
In this study, we developed TTM-4 as a highly sensitive near-infrared (NIR) fluorescent probe to detect ferroptosis.
Results
TTM-4 exhibited turn-on fluorescence upon viscosity change, enabling visualization of lipid peroxidation (LPO) in ferroptotic hepatocytes and liver tissue samples with greater sensitivity than BODIPY 581/591 C11. Timelapse live-cell imaging of erastin-treated cells revealed real-time LPO dynamics involving cytosolic lipid droplets (cLDs), endoplasmic reticulum, and nuclear LDs in a chronological order. Further gene expression analysis of 216 liver tissue samples from the NCBI GEO database showed a significant increase in CIDEC concurrent with TTM-4 fluorescence during progression to metabolic dysfunction-associated steatotic hepatitis (MASH). TTM-4, with its low toxicity and turn-on NIR emission during ferroptosis, also enabled in vivo visualization of ferroptosis in liver injury and metabolic dysfunction-associated steatotic liver disease (MASLD) models.
Conclusions
Our findings suggest that TTM-4 enables monitoring of ferroptosis in MASLD and would aid in early MASH diagnosis.
  • 1,175 View
  • 144 Download

Letter to the Editor

Plasma lipidomic and fungal signatures predict early mortality in acute liver failure
Yu Ji Kim, Jong-Won Kim
Clin Mol Hepatol 2026;32(1):e21-e23.
Published online August 20, 2025
DOI: https://doi.org/10.3350/cmh.2025.0813
  • 2,111 View
  • 61 Download

Erratum

Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol 2025;31(3):1105-1106.
Published online July 1, 2025
DOI: https://doi.org/10.3350/cmh.2024.0145e
Corrects: Clin Mol Hepatol 2024;30(3):487
  • 7,576 View
  • 25 Download

Reply to Correspondence

Reply to correspondence on “Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B”
Heejoon Jang, Won Kim
Received May 14, 2025  Accepted June 4, 2025  Published online June 9, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0533    [Accepted]
  • 2,211 View
  • 15 Download

Editorial

Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Heejoon Jang, Won Kim
Clin Mol Hepatol 2026;32(1):426-428.
Published online April 28, 2025
DOI: https://doi.org/10.3350/cmh.2025.0430
  • 2,645 View
  • 43 Download

Reply to Correspondence

Steatotic liver disease

Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yoon-su Ha, Won Kim, Seung-Jin Kim
Clin Mol Hepatol 2025;31(2):e226-e227.
Published online February 13, 2025
DOI: https://doi.org/10.3350/cmh.2025.0128
  • 5,615 View
  • 40 Download

Original Articles

Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study
Bingtian Dong, Ruiling He, Shenghong Ju, Yuping Chen, Ivica Grgurevic, Jianzhong Ma, Ying Guo, Huizhen Fan, Qiang Yan, Chuan Liu, Huixiong Xu, Anita Madir, Kristian Podrug, Jia Wang, Linxue Qian, Zhengzi Geng, Shanghao Liu, Tao Ren, Guo Zhang, Kun Wang, Meiqin Su, Fei Chen, Sumei Ma, Liting Zhang, Zhaowei Tong, Yonghe Zhou, Xin Li, Fanbin He, Hui Huan, Wenjuan Wang, Yunxiao Liang, Juan Tang, Fang Ai, Tingyu Wang, Liyun Zheng, Zhongwei Zhao, Jiansong Ji, Wei Liu, Jiaojiao Xu, Bo Liu, Xuemei Wang, Yao Zhang, Qiong Yan, Hui Liu, Xiaomei Chen, Shuhua Zhang, Yihua Wang, Yang Liu, Li Yin, Yanni Liu, Yanqing Huang, Li Bian, Ping An, Xin Zhang, Shaoting Zhang, Jinhua Shao, Xiangman Zhang, Wei Rao, Chaoxue Zhang, Christoph Frank Dietrich, Won Kim, Xiaolong Qi
Clin Mol Hepatol 2025;31(3):881-898.
Published online February 5, 2025
DOI: https://doi.org/10.3350/cmh.2024.0898
Background/Aims
A large percentage of patients undergoing esophagogastroduodenoscopy (EGD) screening do not have esophageal varices (EV) or have only small EV. We evaluated a large, international, multicenter cohort to develop a novel score, termed FIB-4plus, by combining the fibrosis-4 (FIB-4) score, liver stiffness measurement (LSM), and spleen stiffness measurement (SSM) to identify high-risk EV (HRV) in compensated cirrhosis.
Methods
This international cohort study involved patients with compensated cirrhosis from 17 Chinese hospitals and one Croatian institution (NCT04546360). Two-dimensional shear wave elastography-derived LSM and SSM values, and components of the FIB-4 score (i.e., age, aspartate aminotransferase, alanine aminotransferase, and platelet count [PLT]) were combined using machine learning algorithms (logistic regression [LR] and extreme gradient boosting [XGBoost]) to develop the LR-FIB-4plus and XGBoost-FIB-4plus models, respectively. Shapley Additive exPlanations method was used to interpret the model predictions.
Results
We analyzed data from 502 patients with compensated cirrhosis who underwent EGD screening. The XGBoost-FIB-4plus score demonstrated superior predictive performance for HRV, with an area under the receiver operating characteristic curve (AUROC) of 0.927 (95% confidence interval [CI] 0.897–0.957) in the training cohort (n=268), and 0.919 (95% CI 0.843–0.995) and 0.902 (95% CI 0.820–0.984) in the first (n=118) and second (n=82) external validation cohorts, respectively. Additionally, the XGBoost-FIB-4plus score exhibited high AUROC values for predicting EV across all cohorts. The FIB-4plus score outperformed the individual parameters (LSM, SSM, PLT, and FIB-4).
Conclusions
The FIB-4plus score effectively predicted EV and HRV in patients with compensated cirrhosis, providing clinicians with a valuable tool for optimizing patient management and outcomes.

Citations

Citations to this article as recorded by  Crossref logo
  • The evolution of non-invasive strategies in cirrhosis management—from screening to precision monitoring: Editorial on “Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an inter
    Haiyu Wang, Jinjun Chen
    Clinical and Molecular Hepatology.2026; 32(1): 403.     CrossRef
  • Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease
    Yanqiu Li, Zihang Qiao, Jinze Li, Bingbing Zhu, Yu Lu, Ying Feng, Xianbo Wang
    Clinical and Experimental Medicine.2025;[Epub]     CrossRef
  • Artificial Intelligence Applications in the Diagnosis and Management of Cirrhosis and Portal Hypertension: A Narrative Review
    Amrit Khooblall, Satish E. Viswanath, Layth Khawaja, Sameer Gadani
    Techniques in Vascular and Interventional Radiology.2025; 28(4): 101078.     CrossRef
  • Liver stiffness measurement-based risk score for predicting liver decompensation risk: a single-center retrospective Chinese study
    Yanqiu Li, Zihang Qiao, Jinze Li, Yongqi Li, Ying Feng, Xianbo Wang
    Clinical and Experimental Medicine.2025;[Epub]     CrossRef
  • Metabolomics and metabolites in cancer diagnosis and treatment
    Minyi Cai, Haiyan Liu, Chen Shao, Tingting Li, Jun Jin, Yahui Liang, Jinhu Wang, Ji Cao, Bo Yang, Qiaojun He, Xuejing Shao, Meidan Ying
    Molecular Biomedicine.2025;[Epub]     CrossRef
  • 11,635 View
  • 271 Download
  • 4 Web of Science
  • Crossref
Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang
Clin Mol Hepatol 2025;31(3):810-822.
Published online January 17, 2025
DOI: https://doi.org/10.3350/cmh.2024.0819
Background/Aims
Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.
Methods
In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA <20 IU/mL were randomized to receive either BSV 150 mg or TDF 300 mg for 48 weeks.
Results
The per-protocol analysis included 130 patients (BSV group, 64; TDF group, 66). The median duration of TDF use before enrollment was 4.14 years. After 48 weeks, 100.0% and 98.5% patients in the BSV and TDF groups, respectively, met the primary endpoint (HBV DNA <20 IU/mL), demonstrating the non-inferior antiviral efficacy of BSV to TDF (95% confidence interval –0.01 to 0.04; P>0.999), with a predefined margin of –0.18. The mean percentage changes in estimated glomerular filtration rates were slightly better in the BSV group (1.67±11.73%) than in the TDF group (–1.24±11.02%). The BSV group showed a significant improvement in bone turnover biomarkers compared to the TDF group; accordingly, hip and spine bone mineral density increased in the BSV group.
Conclusions
In patients with CHB receiving long-term TDF, switching to BSV may improve renal and bone safety with non-inferior antiviral efficacy compared to that of maintaining TDF.

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
    Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
    Clinical and Molecular Hepatology.2026; 32(1): e55.     CrossRef
  • Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
    Wai-Kay Seto
    Clinical and Molecular Hepatology.2026; 32(1): 374.     CrossRef
  • Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
    Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • 10,503 View
  • 169 Download
  • Crossref

Editorial

Steatotic liver disease

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
Yoon-su Ha, Won Kim, Seung-Jin Kim
Clin Mol Hepatol 2025;31(2):628-630.
Published online January 16, 2025
DOI: https://doi.org/10.3350/cmh.2025.0036

Citations

Citations to this article as recorded by  Crossref logo
  • Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yoon-su Ha, Won Kim, Seung-Jin Kim
    Clinical and Molecular Hepatology.2025; 31(2): e226.     CrossRef
  • Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
    Clinical and Molecular Hepatology.2025; 31(2): e186.     CrossRef
  • 6,173 View
  • 61 Download
  • 2 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma
Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim
Clin Mol Hepatol 2025;31(2):563-576.
Published online January 13, 2025
DOI: https://doi.org/10.3350/cmh.2024.0899
Background/Aims
Hepatocellular carcinoma (HCC) exhibits high de novo recurrence rates post-resection. Current post-surgery recurrence prediction methods are limited, emphasizing the need for reliable biomarkers to assess recurrence risk. We aimed to develop methylation-based markers for classifying HCC patients and predicting their risk of de novo recurrence post-surgery.
Methods
In this retrospective cohort study, we analyzed data from HCC patients who underwent surgical resection in Korea, excluding those with recurrence within one year post-surgery. Using the Infinium Methylation EPIC array on 140 samples in the discovery cohort, we classified patients into low- and high-risk groups based on methylation profiles. Distinctive markers were identified through random forest analysis. These markers were validated in the cancer genome atlas (n=217), Validation cohort 1 (n=63) and experimental Validation using a methylation-sensitive high-resolution melting (MS-HRM) assay in Validation cohort 1 and Validation cohort 2 (n=63).
Results
The low-risk recurrence group (methylation group 1; MG1) showed a methylation average of 0.73 (95% confidence interval [CI] 0.69–0.77) with a 23.5% recurrence rate, while the high-risk group (MG2) had an average of 0.17 (95% CI 0.14–0.20) with a 44.1% recurrence rate (P<0.03). Validation confirmed the applicability of methylation markers across diverse populations, showing high accuracy in predicting the probability of HCC recurrence risk (area under the curve 96.8%). The MS-HRM assay confirmed its effectiveness in predicting de novo recurrence with 95.5% sensitivity, 89.7% specificity, and 92.2% accuracy.
Conclusions
Methylation markers effectively classified HCC patients by de novo recurrence risk, enhancing prediction accuracy and potentially offering personalized management strategies.
  • 7,947 View
  • 140 Download
  • 3 Web of Science

Correspondences

Steatotic liver disease

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clin Mol Hepatol 2025;31(2):e210-e211.
Published online January 6, 2025
DOI: https://doi.org/10.3350/cmh.2024.1175
  • 6,396 View
  • 35 Download

Steatotic liver disease

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clin Mol Hepatol 2025;31(2):e208-e209.
Published online January 6, 2025
DOI: https://doi.org/10.3350/cmh.2024.1171
  • 6,545 View
  • 38 Download

Letter to the Editor

Viral hepatitis

Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
Donghee Kim, Won Kim, Aijaz Ahmed
Clin Mol Hepatol 2025;31(1):e5-e7.
Published online October 8, 2024
DOI: https://doi.org/10.3350/cmh.2024.0849

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2025; 31(2): e149.     CrossRef
  • 6,340 View
  • 53 Download
  • 1 Web of Science
  • Crossref

Correspondence

Steatotic liver disease

Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim
Clin Mol Hepatol 2025;31(1):e70-e73.
Published online September 10, 2024
DOI: https://doi.org/10.3350/cmh.2024.0761
  • 4,221 View
  • 84 Download

Special Issue

Liver fibrosis, cirrhosis, and portal hypertension

KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2024;30(Suppl):S5-S105.
Published online August 19, 2024
DOI: https://doi.org/10.3350/cmh.2024.0506

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
    Haiyu Wang, Jinjun Chen
    Clinical and Molecular Hepatology.2026; 32(1): e58.     CrossRef
  • Refining portal hypertension assessment: The clinical significance of spleen stiffness measurement in the Baveno VII Era: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
    Do Seon Song
    Clinical and Molecular Hepatology.2026; 32(1): 400.     CrossRef
  • Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
    Hee Yeon Kim, Miyoung Choi, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(1): e48.     CrossRef
  • Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography
    Ji Won Han
    The Korean Journal of Medicine.2025; 100(1): 26.     CrossRef
  • Influence of Sex in the Development of Liver Diseases
    Jie-Wen Zhang, Nan Zhang, Yi Lyu, Xu-Feng Zhang
    Seminars in Liver Disease.2025; 45(01): 015.     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • Noninvasive identification of metabolic dysfunction–associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study
    G. Craig Wood, Anthony Hoovler, Rakesh Luthra, Christopher D. Still, Hamzah Shariff, Matthew Still, Jonathan Hayes, Peter Benotti, Chioma Uzoigwe
    Expert Review of Gastroenterology & Hepatology.2025; 19(4): 427.     CrossRef
  • Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv
    Ji Won Han, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(2): e152.     CrossRef
  • The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study
    Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
    Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
  • Novel Insights into Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients
    Guanlan Liu, Li Liu, Xing Yang, Qihao Wang, Mingqin Qian
    Journal of Clinical and Experimental Hepatology.2025; 15(6): 102610.     CrossRef
  • A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang
    Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee
    The Journal of Internal Korean Medicine.2025; 46(2): 303.     CrossRef
  • Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
    Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(3): 1018.     CrossRef
  • Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population
    Jean-Bonny Nsumbu, Jean-Robert Makulo, Trésor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi
    Hepatic Medicine: Evidence and Research.2025; Volume 17: 27.     CrossRef
  • Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis
    Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag
    Scientific Reports.2025;[Epub]     CrossRef
  • Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study
    Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim
    Medicina.2025; 61(9): 1601.     CrossRef
  • Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply
    Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
    Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(11): 2750.     CrossRef
  • Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis
    Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz
    Clinical and Molecular Hepatology.2025; 31(4): 1167.     CrossRef
  • Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis
    Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
    Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva
    Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1299.     CrossRef
  • Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography
    Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • A Novel Deep Learning Framework for Liver Fibrosis Staging and Etiology Diagnosis Using Integrated Liver–Spleen Elastography
    Kai Yang, Fei Chen, Aiping Tian, Long Deng, Xiaorong Mao
    Diagnostics.2025; 15(23): 2986.     CrossRef
  • Shear-Wave Elastography: Principles, Techniques, and Clinical Considerations
    Jae Seung Lee
    Clinical Ultrasound.2025; 10(2): 53.     CrossRef
  • Vibration-Controlled Transient Elastography in Chronic Liver Disease: Current Research Insights
    Ho Soo Chun
    Clinical Ultrasound.2025; 10(2): 69.     CrossRef
  • Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
    Jung Hwan Yu
    The Korean Journal of Medicine.2024; 99(5): 232.     CrossRef
  • Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography
    Mi Na Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 201.     CrossRef
  • Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B
    Ye Ji Jun, Minjong Lee, Ho Soo Chun, Tae Hun Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 206.     CrossRef
  • Serological Markers to Assess Liver Fibrosis and Their Roles
    Beom Kyung Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 195.     CrossRef
  • Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography
    Han Ah Lee
    Clinical Ultrasound.2024; 9(2): 70.     CrossRef
  • 16,218 View
  • 317 Download
  • 25 Web of Science
  • Crossref

Editorial

Congratulatory remarks
Won Kim
Clin Mol Hepatol 2024;30(Suppl):S2-S2.
Published online August 8, 2024
DOI: https://doi.org/10.3350/cmh.2024.0610
  • 3,149 View
  • 30 Download

Original Articles

Steatotic liver disease

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease
Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium
Clin Mol Hepatol 2024;30(4):824-844.
Published online July 25, 2024
DOI: https://doi.org/10.3350/cmh.2024.0229
Background/Aims
Blocking the complement system is a promising strategy to impede the progression of metabolic dysfunction–associated steatotic liver disease (MASLD). However, the interplay between complement and MASLD remains to be elucidated. This comprehensive approach aimed to investigate the potential association between complement dysregulation and the histological severity of MASLD.
Methods
Liver biopsy specimens were procured from a cohort comprising 106 Korean individuals, which included 31 controls, 17 with isolated steatosis, and 58 with metabolic dysfunction–associated steatohepatitis (MASH). Utilizing the Infinium Methylation EPIC array, thorough analysis of methylation alterations in 61 complement genes was conducted. The expression and methylation of nine complement genes in a murine MASH model were examined using quantitative RT-PCR and pyrosequencing.
Results
Methylome and transcriptome analyses of liver biopsies revealed significant (P<0.05) hypermethylation and downregulation of C1R, C1S, C3, C6, C4BPA, and SERPING1, as well as hypomethylation (P<0.0005) and upregulation (P<0.05) of C5AR1, C7, and CD59, in association with the histological severity of MASLD. Furthermore, DNA methylation and the relative expression of nine complement genes in a MASH diet mouse model aligned with human data.
Conclusions
Our research provides compelling evidence that epigenetic alterations in complement genes correlate with MASLD severity, offering valuable insights into the mechanisms driving MASLD progression, and suggests that inhibiting the function of certain complement proteins may be a promising strategy for managing MASLD.

Citations

Citations to this article as recorded by  Crossref logo
  • NSD2 exacerbates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway
    Yuan Qiao, Yijia Zhang, Cuiting Sun, Qi Jin, Peng Qu, Zecheng Li, Yang Qiu, Hua Meng, Dantao Peng, Liang Peng
    Metabolism.2026; 174: 156416.     CrossRef
  • Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease
    Jun-Jie Wang, Xiao-Yuan Chen, Yi-Rong Zhang, Yan Shen, Meng-Lin Zhu, Jun Zhang, Jun-Jie Zhang
    Frontiers in Physiology.2025;[Epub]     CrossRef
  • Uncovering hepatic transcriptomic and circulating proteomic signatures in MASH: A meta-analysis and machine learning-based biomarker discovery
    Elena Cristina Rusu, Helena Clavero-Mestres, Mario Sánchez-Álvarez, Marina Veciana-Molins, Laia Bertran, Pablo Monfort-Lanzas, Carmen Aguilar, Javier Camaron, Teresa Auguet
    Computers in Biology and Medicine.2025; 191: 110170.     CrossRef
  • Sepsis-related immune signature C3 in endometrial carcinoma: implications for prognosis, tumor progression through bioinformatics and experimental validation
    Kulsoom, Wajahat Ali, Saleem Ahmad, Irfan Ali Khan, Tanveen Kaur Soni, Asia Masood, Muhammad Omer Iqbal, Valisher Sapayev Odilbek uglu, Mukhayya Xusinovna Djumaniyazova, Anas Sameed Cholavaram, Mubaraq Arisekola Abdulrahmon
    Molecular Biology Reports.2025;[Epub]     CrossRef
  • Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration
    Evelien Van Dijck, Steven Van Laere, Emilie Logie, Steven Timmermans, Erik Fransen, Joe Ibrahim, Timothy J. Kendall, Jonathan A. Fallowfield, Ligia M. Mateiu, Claude Libert, Guy Van Camp, An Verrijken, Luc Van Gaal, Sven Francque, Wim Van Hul, Wim Vanden
    Clinical Epigenetics.2025;[Epub]     CrossRef
  • Recent progress in histone post-translational modifications as regulators of metabolic diseases: A review
    Aiqiang Zhu, Tong Ye, Minjia Tan, Jun-Yu Xu
    International Journal of Biological Macromolecules.2025; 330: 147964.     CrossRef
  • Proteomics Insight into the Pathogenic Evolution of Chronic Hepatitis B across Distinct Clinical Stages
    Junhua Xie, Jun Lai, Yanzhe Zhang, Ye Liu, Zhixiang Yan
    Journal of Proteome Research.2025;[Epub]     CrossRef
  • 7,371 View
  • 374 Download
  • 8 Web of Science
  • Crossref

Steatotic liver disease

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol 2024;30(3):487-499.
Published online May 7, 2024
DOI: https://doi.org/10.3350/cmh.2024.0145
Background/Aims
To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and the risk of hepatocellular carcinoma (HCC) in a nationwide population-based cohort.
Methods
Information on study participants was derived from the Korea National Health Insurance Service database. The study population consisted of 5,080,410 participants who underwent two consecutive biennial health screenings between 2009 and 2012. All participants were followed up until HCC, death, or 31 December 2020. The association of evolutionary changes in MASLD status, as assessed by the fatty liver index and cardiometabolic risk factors, including persistent non-MASLD, resolved MASLD, incident MASLD, and persistent MASLD, with HCC risk was evaluated using multivariable-adjusted Cox proportional hazards regression.
Results
Among the 5,080,410 participants with 39,910,331 person-years of follow-up, 4,801 participants developed HCC. The incidence of HCC in participants with resolved, incident, and persistent MASLD was approximately 2.2-, 2.3-, and 4.7-fold higher, respectively, than that in those with persistent non-MASLD among the Korean adult population. When stratifying the participants according to the evolutionary change in MASLD status, persistent (adjusted hazard ratio [aHR], 2.94; 95% confidence interval [CI], 2.68–3.21; P<0.001), incident (aHR, 1.85; 95% CI, 1.63–2.10; P<0.001), and resolved MASLD (aHR, 1.33; 95% CI, 1.18–1.50; P<0.001) had an increased risk of HCC compared to persistent non-MASLD.
Conclusions
The evolutionary changes in MASLD were associated with the differential risk of HCC independent of metabolic risk factors and concomitant medications, providing additional information on the risk of HCC stratification in patients with MASLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Dietary quality, perceived health, and psychological status as key risk factors for newly developed metabolic dysfunction–associated steatotic liver disease in a longitudinal study
    Xuangao Wu, Ting Zhang, Sunmin Park
    Nutrition.2025; 130: 112604.     CrossRef
  • A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis
    Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Eun Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2025; 19(1): 126.     CrossRef
  • Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
    Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
    Cells.2025; 14(3): 221.     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
    Jeayeon Park, Su Jong Yu
    Clinical and Molecular Hepatology.2025; 31(2): 625.     CrossRef
  • Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
    Hai Xu, Yong Zhou, Huikun Wu
    Clinical and Molecular Hepatology.2025; 31(2): e125.     CrossRef
  • Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2025; 31(2): e210.     CrossRef
  • Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
    Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang
    Clinical and Molecular Hepatology.2025; 31(2): e203.     CrossRef
  • Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2025; 31(2): e208.     CrossRef
  • MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort st
    Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song
    Clinical and Molecular Hepatology.2025; 31(2): e128.     CrossRef
  • Significant hepatic fat loss after metabolic dysfunction-associated steatotic liver disease: Beware of misclassification as absence of disease
    Seogsong Jeong
    Journal of Hepatology.2025; 83(3): e156.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening
    Yong Jun Choi, Jooheon Park, Han-Ik Cho, Myung Geun Shin, Eun-Hee Nah
    Metabolites.2025; 15(5): 299.     CrossRef
  • Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease
    Tom Ryu, Beom Sun Chung, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang
    Phytomedicine.2025; 143: 156889.     CrossRef
  • Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases
    Jialong Wu, Gonghua Wu, Jiawei Li, Bo Yi, Qingyi Jia, Ke Ju, Qingyang Shi, Zixuan Wang, Xiong Xiao, Bing Guo, Huan Xu, Xing Zhao
    European Journal of Endocrinology.2025; 192(5): 691.     CrossRef
  • Association between green space and hepatocellular carcinoma risk: a retrospective cohort study of seven South Korean metropolitan areas
    Dong Hyun Kim, Seulggie Choi, Seogsong Jeong, Jooyoung Chang, Sung Min Kim, Sun Jae Park, Jun Hwan Kim, Joung Sik Son, Gyeongsil Lee, Soo Jung Choi, Yun Hwan Oh, Kyae Hyung Kim, Sang Min Park
    International Journal of Environmental Health Research.2025; 35(12): 4026.     CrossRef
  • Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review
    Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro
    Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755.     CrossRef
  • Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study
    Chae Won Lee, Eun Seok Kang, Seogsong Jeong, Hyun Wook Han, Samuel O. Antwi
    PLOS One.2025; 20(6): e0323880.     CrossRef
  • All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study
    Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho
    JHEP Reports.2025; 7(9): 101477.     CrossRef
  • Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-analysis
    Ryan Yanzhe Lim, Faith Xin Ning Tan, Glenn Jun Kit Ho, Ethan Kai Jun Tham, Alfred Kow, Guoyue Lv, Zhong-Qi Fan, Nicholas Syn, Masahito Nakano, Wenhao Li, Karn Wijarnpreecha, Jörn M. Schattenberg, Vincent Chen, Ming-Hua Zheng, Pojsakorn Danpanichkul, Hirok
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma
    Dingwu Li, Xiang Zhang
    Hepatology Communications.2025;[Epub]     CrossRef
  • 11,837 View
  • 341 Download
  • 19 Web of Science
  • Crossref

Acute liver injury and Acute liver failure

Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment
Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Korean Acute-on-Chronic Liver Failure (KACLiF) study group, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin, APASL ACLF Research Consortium (AARC) for APASL ACLF working party
Clin Mol Hepatol 2024;30(3):388-405.
Published online April 11, 2024
DOI: https://doi.org/10.3350/cmh.2023.0563
Background/Aims
Quick sequential organ failure assessment (qSOFA) is believed to identify patients at risk of poor outcomes in those with suspected infection. We aimed to evaluate the ability of modified qSOFA (m-qSOFA) to identify high-risk patients among those with acutely deteriorated chronic liver disease (CLD), especially those with acute-onchronic liver failure (ACLF).
Methods
We used data from both the Korean Acute-on-Chronic Liver Failure (KACLiF) and the Asian Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) cohorts. qSOFA was modified by replacing the Glasgow Coma Scale with hepatic encephalopathy, and an m-qSOFA ≥2 was considered high.
Results
Patients with high m-qSOFA had a significantly lower 1-month transplant-free survival (TFS) in both cohorts and higher organ failure development in KACLiF than those with low m-qSOFA (Ps<0.05). Subgroup analysis by ACLF showed that patients with high m-qSOFA had lower TFS than those with low m-qSOFA. m-qSOFA was an independent prognostic factor (hazard ratios, HR=2.604, 95% confidence interval, CI 1.353–5.013, P=0.004 in KACLiF and HR=1.904, 95% CI 1.484– 2.442, P<0.001 in AARC). The patients with low m-qSOFA at baseline but high m-qSOFA on day 7 had a significantly lower 1-month TFS than those with high m-qSOFA at baseline but low m-qSOFA on day 7 (52.6% vs. 89.4%, P<0.001 in KACLiF and 26.9% vs. 61.5%, P<0.001 in AARC).
Conclusions
Baseline and dynamic changes in m-qSOFA may identify patients with a high risk of developing organ failure and short-term mortality among CLD patients with acute deterioration.

Citations

Citations to this article as recorded by  Crossref logo
  • Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management
    S. K. Sarin, Ashok Choudhury, Anupam Kumar, Nadim Mahmud, G. H. Lee, Qin Ning, Soek-Siam Tan, Kessarin Thanapirom, Vinod Arora, Nobuaki Nakayama, Jun Li, Constantine J. Karvellas
    Nature Reviews Gastroenterology & Hepatology.2026;[Epub]     CrossRef
  • Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
    Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
    Journal of Korean Medical Science.2026;[Epub]     CrossRef
  • Emergency living donor liver transplantation
    Jongman Kim
    Annals of Liver Transplantation.2025; 5(1): 27.     CrossRef
  • Oral Branched-Chain Amino Acids as a Cost-Effective Option for Managing Hepatic Encephalopathy
    Hankil Lee, Sang Hoon Ahn, Beom Kyung Kim
    Yonsei Medical Journal.2025; 66(11): 713.     CrossRef
  • Living versus deceased donor liver transplantation in highly urgent patients using Korean national data
    Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
    Annals of Liver Transplantation.2025; 5(2): 115.     CrossRef
  • Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
    Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
    Annals of Liver Transplantation.2025; 5(2): 107.     CrossRef
  • Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”
    Do Seon Song, Dong Joon Kim
    Clinical and Molecular Hepatology.2024; 30(4): 1012.     CrossRef
  • Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure a
    Simone Incicco, Salvatore Piano
    Clinical and Molecular Hepatology.2024; 30(4): 695.     CrossRef
  • Revisiting septic shock in cirrhosis: a call for personalized management
    Vishnu Girish, Rakhi Maiwall
    Expert Review of Gastroenterology & Hepatology.2024; 18(12): 795.     CrossRef
  • 8,086 View
  • 142 Download
  • 8 Web of Science
  • Crossref

Steatotic liver disease

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
Clin Mol Hepatol 2024;30(2):247-262.
Published online January 26, 2024
DOI: https://doi.org/10.3350/cmh.2023.0449
Background/Aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver. MASLD encompasses both steatosis and MASH. Since MASH can lead to cirrhosis and liver cancer, steatosis and MASH must be distinguished during patient treatment. Here, we investigate the genomes, epigenomes, and transcriptomes of MASLD patients to identify signature gene set for more accurate tracking of MASLD progression.
Methods
Biopsy-tissue and blood samples from patients with 134 MASLD, comprising 60 steatosis and 74 MASH patients were performed omics analysis. SVM learning algorithm were used to calculate most predictive features. Linear regression was applied to find signature gene set that distinguish the stage of MASLD and to validate their application into independent cohort of MASLD.
Results
After performing WGS, WES, WGBS, and total RNA-seq on 134 biopsy samples from confirmed MASLD patients, we provided 1,955 MASLD-associated features, out of 3,176 somatic variant callings, 58 DMRs, and 1,393 DEGs that track MASLD progression. Then, we used a SVM learning algorithm to analyze the data and select the most predictive features. Using linear regression, we identified a signature gene set capable of differentiating the various stages of MASLD and verified it in different independent cohorts of MASLD and a liver cancer cohort.
Conclusions
We identified a signature gene set (i.e., CAPG, HYAL3, WIPI1, TREM2, SPP1, and RNASE6) with strong potential as a panel of diagnostic genes of MASLD-associated disease.

Citations

Citations to this article as recorded by  Crossref logo
  • Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD
    Haili Wang, Zhenqiu Liu, Hong Fan, Chengnan Guo, Xin Zhang, Yi Li, Suzhen Zhao, Luojia Dai, Ming Zhao, Tiejun Zhang
    Journal of Gastroenterology.2025; 60(3): 306.     CrossRef
  • Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
    Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim
    Clinical and Molecular Hepatology.2025; 31(1): e70.     CrossRef
  • PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
    Baokai Sun, Likun Zhuang
    Clinical and Molecular Hepatology.2025; 31(1): e67.     CrossRef
  • Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review
    Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro
    Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755.     CrossRef
  • A Perfect MASH Comparing Resmetirom and GLP-1 Agonists for Metabolic-Associated Steatohepatitis
    Joanne Lin, Victoria Green, Aalam Sohal, Marina Roytman
    Journal of Clinical Gastroenterology.2025; 59(10): 923.     CrossRef
  • Developmental programming: Differing impact of prenatal testosterone and prenatal bisphenol-A -treatment on hepatic methylome in female sheep
    John Dou, Soundara Viveka Thangaraj, Yiran Zhou, Vasantha Padmanabhan, Kelly Bakulski
    Molecular and Cellular Endocrinology.2025; 609: 112655.     CrossRef
  • The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
    Carlos Jose Pirola, Silvia Sookoian
    Clinical and Molecular Hepatology.2024; 30(2): 174.     CrossRef
  • Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”
    Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
    Clinical and Molecular Hepatology.2024; 30(2): 287.     CrossRef
  • Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
    Su Bin Lim, Hyo Jung Cho
    Clinical and Molecular Hepatology.2024; 30(4): 1009.     CrossRef
  • Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis
    Jung Hoon Cha, Na Ri Park, Sung Woo Cho, Heechul Nam, Hyun Yang, Eun Sun Jung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung, Si Hyun Bae
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
    Camilo Julio Llamoza-Torres, María Fuentes-Pardo, Bruno Ramos-Molina
    Metabolism and Target Organ Damage.2024;[Epub]     CrossRef
  • Biological and clinical role of TREM2 in liver diseases
    Ke Ma, Shouliang Guo, Jin Li, Tao Wei, Tingbo Liang
    Hepatology Communications.2024;[Epub]     CrossRef
  • 9,728 View
  • 337 Download
  • 13 Web of Science
  • Crossref

Special Review

Steatotic liver disease

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clin Mol Hepatol 2023;29(4):831-843.
Published online August 25, 2023
DOI: https://doi.org/10.3350/cmh.2023.0277
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word ‘fatty.’ Three pan-national liver associations set out to explore a new nomenclature to replace both NAFLD and its suggested alternative, metabolic (dysfunction)-associated fatty liver disease (MAFLD). They surveyed if a change in nomenclature and/or definition is favored and which nomenclature best communicates disease characteristics and increases awareness. In lieu of NAFLD/MAFLD, metabolic dysfunction-associated steatotic liver disease (MASLD) has been chosen, and an umbrella term, steatotic liver disease (SLD), encompassing the whole spectrum of liver disease, has been proposed. It has been suggested that cardiometabolic risk factors should be considered when categorizing SLD patients. Furthermore, a new subcategory, MASLD with increased alcohol intake (MetALD), casts light on a neglected group of patients with moderate or more alcohol consumption. The importance of metabolic dysfunction was acknowledged in this new nomenclature, but the precise contribution of metabolic dysfunction and alcohol consumption to the development and progression of SLD remains unclear. Herein, we review hepatologists’ and endocrinologists’ perspectives on the new nomenclature, along with its possible impact on clinical practice. Although it is premature to predict the settlement of the new nomenclature, this review may help build more evidence for a soft landing of it in the future.

Citations

Citations to this article as recorded by  Crossref logo
  • Revisiting MASLD-based pregnancy risk stratification: a critical appraisal of Jung et al.’s nationwide cohort study
    Jianfeng Luo
    Hepatology International.2026;[Epub]     CrossRef
  • Comparison of NAFLD, MAFLD, and MASLD Prevalence and Clinical Characteristics in Asia Adults
    Xinjuan Huang, Ruoling Yu, Xinyun Tan, Manjie Guo, Yuanqin Xia, Huihui Zou, Xuelian Liu, Chunxiang Qin
    Journal of Clinical and Experimental Hepatology.2025; 15(1): 102420.     CrossRef
  • Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
    Yewan Park, Jooyi Jung, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2025; 61(2): 400.     CrossRef
  • Statin use and liver-related prognosis among patients with MASLD
    Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    JHEP Reports.2025; 7(4): 101313.     CrossRef
  • Diet quality and physical activity affect metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and etiology-associated steatohepatitis, and compensated advanced chronic liver disease among United States adults: NHANES 2017–2020
    Peng Wang, Bingxin Xia, Shuang Wang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Optimal BMI cutoff for lean MASLD/MetALD and adverse hepatic outcomes in East-Asian populations
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Beom Kyung Kim, Jin-Ha Yoon
    European Journal of Internal Medicine.2025; 133: 141.     CrossRef
  • Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study
    Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim
    American Journal of Gastroenterology.2025; 120(10): 2321.     CrossRef
  • Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analy
    Young Eun Chon, Jung Hwan Yu, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(1): e61.     CrossRef
  • Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
    Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
    Clinical and Molecular Hepatology.2025; 31(1): e35.     CrossRef
  • Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
    Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
    Cells.2025; 14(3): 221.     CrossRef
  • Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population‐based study
    Huixian Zeng, Letian Fang, Zhiyu Yang, Xinyu Zhao, Hongsen Chen, Puyi Xing, Zheyun Niu, Zheng Li, Zishuai Li, Jiayi Zhao, Wenbin Liu, Chunxia Jing, Hong You, Guangwen Cao
    MedComm.2025;[Epub]     CrossRef
  • Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
    Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
    Clinical and Molecular Hepatology.2025; 31(Suppl): S51.     CrossRef
  • Dapansutrile Regulates Mitochondrial Oxidative Stress and Reduces Hepatic Lipid Accumulation in Diabetic Mice
    Ying Wu, Jiaqiang Zhou
    Current Issues in Molecular Biology.2025; 47(3): 148.     CrossRef
  • Dietary Patterns Rich in Soybean Products, Vegetables, Fish, Fruits, and Miso Soup Were Inversely Associated with Fatty Liver Index: The Nagahama Study
    Yoko UEBA, Kaori IKEDA, Yasuharu TABARA, Takeo NAKAYAMA, Daisuke TANAKA, Yoshimitsu TAKAHASHI, Shinji KOSUGI, Kazuya SETOH, Takahisa KAWAGUCHI, Fumihiko MATSUDA, Nobuya INAGAKI
    Journal of Nutritional Science and Vitaminology.2025; 71(1): 25.     CrossRef
  • Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
    Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
    European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
  • Impact of binge drinking on alcoholic liver disease
    Jisoo Kang, Seol Hee Park, Mushira Khanam, Seo Bhin Park, Sumin Shin, Wonhyo Seo
    Archives of Pharmacal Research.2025;[Epub]     CrossRef
  • Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease
    Sang Yoon Lee, Su-Been Lee, Goo-Hyun Kwon, Seol Hee Song, Jeong Ha Park, Min Ju Kim, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Satya Priya Sharma, Ki Tae
    Journal of Microbiology.2025; 63(2): e2411002.     CrossRef
  • Impact of healthy lifestyles on the risk of metabolic dysfunction‐associated steatotic liver disease among adults with comorbid hypertension and diabetes: Novel insight from a largely middle‐aged and elderly cohort in South China
    Jun‐Yan Xi, Yi‐Jing Wang, Xiao‐Heng Li, Nuo‐Min Sun, Rui‐Qi Ming, Hua‐Ling Yan, Huan‐Le Cai, Jian‐Jun Bai, Yi‐Ning Xiang, Jing Gu, Xiao Lin, Gang Liu, Yuan‐Tao Hao
    Diabetes, Obesity and Metabolism.2025; 27(5): 2800.     CrossRef
  • Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank
    Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
  • Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization
    Jialin Ren, Min Wu
    International Journal of Molecular Sciences.2025; 26(7): 3166.     CrossRef
  • Linghe granules reduces hepatic lipid accumulation in Non-alcoholic fatty liver disease through regulating lipid metabolism and redox balance
    Yuting Hu, Ni'ao Li, Rumian Zhang, Jia Wang, Dongdong Fang, Qianmei Zhou, Hua Zhang, Hong Cai, Yiyu Lu
    Phytomedicine.2025; 141: 156654.     CrossRef
  • Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality
    Mahsa Abbaszadeh, Farhad Hosseinpanah, Maryam Tohidi, Sahar Karimpour Reyhan, Maryam Mahdavi, Majid Valizadeh
    Endocrinology, Diabetes & Metabolism.2025;[Epub]     CrossRef
  • The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): e183.     CrossRef
  • Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yoon-su Ha, Won Kim, Seung-Jin Kim
    Clinical and Molecular Hepatology.2025; 31(2): e226.     CrossRef
  • A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases
    Keungmo Yang, Jaejun Lee, Ji Won Han, Hyun Yang, Seung Yun Chae, Beom Sun Chung, Tom Ryu
    Therapeutic Advances in Gastroenterology.2025;[Epub]     CrossRef
  • Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): 382.     CrossRef
  • Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
    Liver International.2025;[Epub]     CrossRef
  • Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yoon-su Ha, Won Kim, Seung-Jin Kim
    Clinical and Molecular Hepatology.2025; 31(2): 628.     CrossRef
  • Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(2): e180.     CrossRef
  • Fatty liver disease in the pediatric population: history, definitions, and challenges in nomenclature (NAFLD/MAFLD/MASLD)
    Raúl Gómez-Mendoza, Fabiola Sánchez-Hernández, Francisco Javier Valentin-Cortez, Norberto Chávez-Tapia
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Cu(OH)2 nanopesticide induced liver dysfunction in mice by targeting lipoylated tricarboxylic acid cycle proteins via ferredoxin 1
    Zhihua Ren, Mengyao Ren, Weibo Ling, Danqin Ren, Jiefeng Liang, Yixue Cai, Xiao Wang, Shuo Wang, Yonghui Duan, Tingting Ku, Xia Ning, Nan Sang
    Journal of Hazardous Materials.2025; 494: 138403.     CrossRef
  • Risks of liver cirrhosis, hepatocellular carcinoma, hepatic-related complications, and mortality in patients with type 2 diabetes in Taiwan
    Hua-Fen Chen, Yung-Yueh Chang, Peter Chen, Xiao-Han Shen, Chin-Huan Chang, Wan-Lun Hsu
    World Journal of Diabetes.2025;[Epub]     CrossRef
  • Serum polychlorinated biphenyls as a risk factor for MASLD: Exploring the association and underlying mechanisms
    Ruichen Yang, Qingqing Jiang, Wentao Liu, Furong Wang, Shiyi Cao
    Science of The Total Environment.2025; 981: 179617.     CrossRef
  • Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
    Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
    Journal of Advanced Research.2025;[Epub]     CrossRef
  • Nanoplastics disrupt hepatic lipid metabolism via the inhibition of PPARγ: a study based on digestive system exposure
    Shenya Xu, Mei Li, Yudan Zheng, Menghuan Xu, Jieyu Zhou, Shizhi Wang, Shuwei Li, Meilin Wang
    Toxicology.2025; 516: 154194.     CrossRef
  • New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile
    Maria Spencer-Sandino, Franco Godoy, Laura Huidobro, Danilo Alvares, Francisco Cruz, Claudia Marco, Macarena Garrido, Daniel Cabrera, Juan Pablo Arab, Marco Arrese, Francisco Barrera, Catterina Ferreccio
    Annals of Hepatology.2025; 30(2): 101919.     CrossRef
  • Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
    Dong Wook Kim, Minkook Son, Hye Jung Lee, Chi Hyeon Choi, Yeo Wool Kang, Sang Yi Moon, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek, Won Suk An
    Hepatology Research.2025; 55(9): 1239.     CrossRef
  • Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide
    Yuki Oe, Takashi Omori, Eriko Aimono, Shin Furukawa, Hirohiko Kitakawa, Masatoshi Tateno, Kiyoshi Sakai, Kyu Yong Cho
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco
    Journal of Clinical Medicine.2025; 14(11): 3821.     CrossRef
  • Association Between Meat Intake and Metabolic Dysfunction‐Associated Steatotic Liver Disease Incidence in a Korean Population From the Health Examinees Study
    Uyangamaa Nyamsuren, Yuan Peng, Sangah Shin
    Molecular Nutrition & Food Research.2025;[Epub]     CrossRef
  • Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
    Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
    Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
  • Young Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease Have an Increased Risk of Early-Onset Cancer: A Nationwide Cohort Study Differentiating the Risk of 23 Site-Specific Cancers
    Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Qiang Xia, Meng Sha, Yoosoo Chang, Won Kim
    Clinical Gastroenterology and Hepatology.2025; 23(13): 2540.     CrossRef
  • Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma
    Young-Min Jee, Jeong-Yoon Lee, Tom Ryu
    Biomedicines.2025; 13(5): 1260.     CrossRef
  • Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review
    Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro
    Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755.     CrossRef
  • Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
    Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
  • Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease
    Yutian Zhang, Tianlin Wang, Junquan Han, Jielin Song, Chaoshuai Yang, Lei Liang, Huizhen Li, Hong Wang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Laminin γ2 accelerates non-alcoholic fatty liver disease progression by enhancing lipid accumulation and fibrogenesis in hepatocytes
    Hui Chen, Guanggang Meng, Aiting Yang
    Biochemical and Biophysical Research Communications.2025; 777: 152266.     CrossRef
  • Dietary ω-3 polyunsaturated fatty acid intake improves skeletal muscle mass in patients with metabolic dysfunction-associated fatty liver disease: A nationwide cross-sectional study
    Li-Zhan Bie, Chao Wu, Jia-Lu Wang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
    Donghee Kim, Rohit Loomba, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(3): e235.     CrossRef
  • Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang
    Gut and Liver.2025; 19(4): 479.     CrossRef
  • The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation
    Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace
    Biomedicine & Pharmacotherapy.2025; 190: 118375.     CrossRef
  • Refining the Classification of Steatotic Liver Disease: Beyond Self-Reported Alcohol Intake
    Won-Mook Choi
    Gut and Liver.2025; 19(5): 639.     CrossRef
  • Understanding MASLD — from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist
    Carlo Ratti, Mattia Malaguti, D'Aniello Emanuele, Antonio Bellasi, Gianluca Sanna
    Atherosclerosis.2025; 409: 120495.     CrossRef
  • Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis
    Haifeng Wang, Songlin Liu, Yonggang Chen, Weiwei Fang, Ying Cheng, Zhigang Zhang, Haiming Hu, Baifei Hu, Hongtao Liu
    Phytomedicine.2025; 148: 157404.     CrossRef
  • Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
    Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Alcohol-Induced Oxidative Stress and Gut–Liver–Brain Crosstalk: Expanding the Paradigm from ALD to MetALD
    Jeong-Yoon Lee, Young-Min Jee, Keungmo Yang, Tom Ryu
    Antioxidants.2025; 14(10): 1196.     CrossRef
  • Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
    Anoushka Shenoy, Aijaz Ahmed, Donghee Kim
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: An Updated Global Systematic Review and Meta-Analysis of over 1.5 Million Individuals
    Narsimha Keetha Rao, Shahriar Ghodous, Anoop Gurram, Mehrdad Khorasani, Madhusudhan Ponnala, Arman Habibi, Kwame Agyeman, Parsa Saberian, Pubali Biswas, Negin Letafatkar, Simran Joshi, Yasmin Sahli, Reza Amani-Beni, Bahar Darouei, Yussif Issaka, Kiran San
    Inflammatory Bowel Diseases.2025;[Epub]     CrossRef
  • Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Association between Relative Skeletal Muscle Mass and Metabolic Dysfunction-Associated Steatotic Liver Disease Development in a Community-Based Population
    Yiting Xu, Tingting Hu, Xiaoya Li, Yun Shen, Yunfeng Xiao, Yufei Wang, Yuqian Bao, Xiaojing Ma
    Journal of Obesity & Metabolic Syndrome.2025; 34(4): 456.     CrossRef
  • Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis. Authors' Reply
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study
    Young Mi Jung, Taesu Kim, Min-Jeong Oh, Dong Hyeon Lee, Geum Joon Cho, Won Kim
    Hepatology International.2025;[Epub]     CrossRef
  • Steatotic Liver Disease Subtypes and Their Association with Colorectal Cancer Risk in Korea: A Nationwide Population-Based Study
    Sang Yi Moon, Minkook Son, Jong Yoon Lee, Yeo Wool Kang, Myeongseok Koh
    Digestion.2025; 106(6): 560.     CrossRef
  • Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: a nationwide target trial emulation study
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Annals of Hepatology.2025; : 102175.     CrossRef
  • Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up
    Hun Jee Choe, Joon Ho Moon, Won Kim, Bo Kyung Koo, Nam H. Cho
    Metabolism.2024; 153: 155800.     CrossRef
  • Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
    Zobair M. Younossi, James M. Paik, Maria Stepanova, Janus Ong, Saleh Alqahtani, Linda Henry
    Journal of Hepatology.2024; 80(5): 694.     CrossRef
  • From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
    Iyiad Alabdul Razzak, Mazen Noureddin, Hirsh Trivedi
    Journal of Clinical Medicine.2024; 13(3): 880.     CrossRef
  • Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
    Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H
    Gut Microbes.2024;[Epub]     CrossRef
  • Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
    Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
    Paolo Raggi, Jovana Milic, Marcella Manicardi, Felice Cinque, Mark G. Swain, Giada Sebastiani, Giovanni Guaraldi
    Atherosclerosis.2024; 392: 117523.     CrossRef
  • Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
    Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon
    Clinical and Molecular Hepatology.2024; 30(2): 247.     CrossRef
  • Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
    Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Na
    Clinical and Molecular Hepatology.2024; 30(2): 225.     CrossRef
  • Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
    Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(2): 266.     CrossRef
  • Immunopathogenesis of liver fibrosis in steatotic liver disease
    Chaerin Woo, Won-Il Jeong
    Clinical and Molecular Hepatology.2024; 30(2): 299.     CrossRef
  • Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
    Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(2): 263.     CrossRef
  • Nonalcoholic fatty liver disease associated with obesity and type 2 diabetes and gut dysbiosis
    T.M. Bentsa
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(2): 120.     CrossRef
  • The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
    Chavdar S. Pavlov, Daria A. Teplyuk, Leonid B. Lazebnik, Aleksandr S. Ametov, Evgeniia Yu. Pashkova, Sergey M. Sorokoletov, Yury P. Uspenskiy, Svetlana V. Turkina, Elizaveta V. Ponomarenko, Aleksandr S. Maslakov
    Terapevticheskii arkhiv.2024; 96(4): 429.     CrossRef
  • Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
    Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros
    Pharmacological Reviews.2024; 76(3): 454.     CrossRef
  • Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques
    Sergio Gil-Rojas, Miguel Suárez, Pablo Martínez-Blanco, Ana M. Torres, Natalia Martínez-García, Pilar Blasco, Miguel Torralba, Jorge Mateo
    Metabolites.2024; 14(6): 305.     CrossRef
  • Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?
    Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su
    JGH Open.2024;[Epub]     CrossRef
  • Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
    Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(3): 577.     CrossRef
  • Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups
    Mengqi Li, Wenya Chen, You Deng, Wen Xie
    Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(9): 2085.     CrossRef
  • Interleukin-mediated therapies in liver diseases and comorbidity effects
    Nouhoum Bouare, Jean Delwaide
    World Journal of Hepatology.2024; 16(7): 980.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Gastroenterology.2024; 84(1): 1.     CrossRef
  • Impact of Physical Activity on Overall Survival and Liver Cirrhosis Incidence in Steatotic Liver Disease: Insights from a Large Cohort Study Using Inverse Probability of Treatment Weighting
    Keungmo Yang, Beom Sun Chung, Tom Ryu
    Nutrients.2024; 16(15): 2532.     CrossRef
  • Machine learning model reveals roles of interferon‑stimulated genes in sorafenib‑resistant liver cancer
    Deok Seo, Ji Park, Hee Jung, Min Kang, Byung Kang, Dong Lee, Jae Lee, Seung Yoon, Jeong Jang, Jae Ahn, Pil Sung
    Oncology Letters.2024;[Epub]     CrossRef
  • Role of Neutrophils in the Development of Steatotic Liver Disease
    You-Jin Choi, Yeonsoo Kim, Seonghwan Hwang
    Seminars in Liver Disease.2024; 44(03): 300.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Medicine.2024; 99(4): 189.     CrossRef
  • Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
    Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG
    Chinese Journal of Natural Medicines.2024; 22(8): 724.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
    Cancers.2024; 16(18): 3161.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    Gut and Liver.2024; 18(5): 924.     CrossRef
  • Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus
    Xiaohui Lei, HaiYan Chen, YuXin Xu, Zhuoran Yang, Lili Zhang, Cong Wang, Hu Du
    BMJ Open Diabetes Research & Care.2024; 12(5): e004514.     CrossRef
  • A new Korean nomenclature for steatotic liver disease

    Clinical and Molecular Hepatology.2024; 30(Suppl): S214.     CrossRef
  • Association of niacin intake and metabolic dysfunction-associated steatotic liver disease: findings from National Health and Nutrition Examination Survey
    Jing Zhou, Jun Han
    BMC Public Health.2024;[Epub]     CrossRef
  • Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis
    Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2024; 30(Suppl): S147.     CrossRef
  • Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
    Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(4): 962.     CrossRef
  • Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Clinical and Molecular Hepatology.2024; 30(4): 982.     CrossRef
  • A Review on the Protecting Effects and Molecular Mechanisms of Berries Against a Silent Public Health Concern: Non-Alcoholic Fatty Liver Disease
    Anshul Sharma, Hae-Jeung Lee
    Antioxidants.2024; 13(11): 1389.     CrossRef
  • Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim
    Gut and Liver.2024; 18(6): 1048.     CrossRef
  • Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification
    Han Ah Lee
    The Korean Journal of Internal Medicine.2024; 39(6): 869.     CrossRef
  • Association between the Fatty Liver Index (FLI) and incident coronary heart disease: insights from a cohort study on the Chinese population
    Ying Miao, Yu Wang, Pijun Yan, Yi Li, Zhuang Chen, Nanwei Tong, Qin Wan
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Adding to the confusion in more than just the name
    Jacob George
    Clinical and Molecular Hepatology.2023; 29(4): 973.     CrossRef
  • From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
    Ming-Lun Yeh, Ming-Lung Yu
    Clinical and Molecular Hepatology.2023; 29(4): 969.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Bo Kyung Koo, Won Kim
    eClinicalMedicine.2023; 65: 102292.     CrossRef
  • Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
    Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 30(1): 121.     CrossRef
  • 12,511 View
  • 424 Download
  • 101 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
Heejoon Jang, Won Kim
Clin Mol Hepatol 2023;29(2):381-383.
Published online March 9, 2023
DOI: https://doi.org/10.3350/cmh.2023.0088

Citations

Citations to this article as recorded by  Crossref logo
  • Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort
    Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun
    Gut and Liver.2024; 18(2): 316.     CrossRef
  • Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003–2018
    Lurao Li, Xiawen Shu, Yun Yi, Chun Wang, Jianghui Li, Yang Ding, Jin Li, Ying Chang
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Obesity and risk for liver disease: a two-sample Mendelian randomisation study
    Wen An, Jing Luo, Zhe Yu, Mengqi Li, Herui Wei, Aqian Song, Yuanpeng Mao, Hao Bian, Lingling He, Fan Xiao, Hongshan Wei
    British Journal of Nutrition.2024; 132(10): 1403.     CrossRef
  • Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease
    Ioanna Aggeletopoulou, Maria Kalafateli, Efthymios P. Tsounis, Christos Triantos
    International Journal of Molecular Sciences.2023; 24(16): 12864.     CrossRef
  • 7,985 View
  • 108 Download
  • 4 Web of Science
  • Crossref

Review

Steatotic liver disease

Interaction between sarcopenia and nonalcoholic fatty liver disease
Sae Kyung Joo, Won Kim
Clin Mol Hepatol 2023;29(Suppl):S68-S78.
Published online December 5, 2022
DOI: https://doi.org/10.3350/cmh.2022.0358
Sarcopenia and nonalcoholic fatty liver disease (NAFLD) are common health problems related to aging. Despite the differences in their diagnostic methods, several cross-sectional and longitudinal studies have revealed the close link between sarcopenia and NAFLD. Sarcopenia and NAFLD are linked by several shared pathogenetic mechanisms, including insulin resistance, hormonal imbalance, systemic inflammation, myostatin and adiponectin dysregulation, nutritional deficiencies, and physical inactivity, thus implicating a bidirectional relationship between sarcopenia and NAFLD. However, there is not sufficient data to support a direct causal relationship between sarcopenia and NAFLD. Moreover, it is currently difficult to conclude whether sarcopenia is a risk factor for nonalcoholic steatohepatitis (NASH) or is a consequence of NASH. Therefore, this review intends to touch on the shared common mechanisms and the bidirectional relationship between sarcopenia and NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Development and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: Results from NHANES 2017–2018
    Siwei Yang, Jianan Yu, Qiyang Chen, Xuedong Sun, Yuefeng Hu, Tianhao Su, Jian Li, Long Jin
    Annals of Hepatology.2025; 30(2): 101585.     CrossRef
  • Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study
    Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song
    Hepatology International.2025; 19(1): 181.     CrossRef
  • New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study
    Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Geum‐Youn Gwak
    Hepatology Research.2025; 55(3): 373.     CrossRef
  • Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
    Fan Zhang, Longgen Liu, Wenjian Li
    Nutrition Journal.2025;[Epub]     CrossRef
  • Additive impact of metabolic syndrome and sarcopenia on all-cause and cause-specific mortality: an analysis of NHANES
    Meng Zhang, Qing-Yue Zeng, Linli Zhuang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Sarcopenia and metabolic dysfunction-associated steatotic liver disease: The role of exercise-related biomarkers
    Marwan S Al-Nimer
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
    Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
    Hepatology International.2025; 19(2): 261.     CrossRef
  • Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
    Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
    European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
  • Sarcopenia and non-alcoholic fatty liver disease - complex pathogenetic relationships
    V. A. Akhmedov, V. S. Marinenko
    Experimental and Clinical Gastroenterology.2025; (9): 110.     CrossRef
  • Association between sarcopenia and the prevalence of gallstone in US adults: a cross-sectional analysis of NHANES
    Bo Wang, Qianxi Huang, Yongqiang Xiong, Na Huang, Jun Li, Shu Zhang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Associations of Serum Vitamin D with Sarcopenia in Patients with Chronic Liver Disease: A Population‐Based Cross‐Sectional Study
    Xinxing Tantai, Zhang Wen, Shuyue Tuo, Qiuju Ran, Chan Li, Yong Li, Jia Yuan, Jinhai Wang, Lu Li, Shejiao Dai
    Calcified Tissue International.2025;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications
    Hyo Young Lee, Eileen L. Yoon
    The Korean Journal of Gastroenterology.2025; 85(2): 126.     CrossRef
  • Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia
    Marina Ribas Losasso, Maria Luiza Cesto Parussolo, Antony Oliveira Silva, Rosa Direito, Karina Quesada, Claudia Rucco Penteado Detregiachi, Marcelo Dib Bechara, Nahum Méndez-Sánchez, Ludovico Abenavoli, Adriano Cressoni Araújo, Ricardo de Alvares Goulart,
    International Journal of Molecular Sciences.2025; 26(10): 4673.     CrossRef
  • Mechanomedicine for Addressing Skeletal Muscle Insulin Resistance
    Lu Wang, Le Chang, Yufei Ma, Yuanbo Jia, Bin Gao, Wei Cui, Feng Xu
    Endocrine Reviews.2025; 46(5): 652.     CrossRef
  • Features of Management of Patients with NAFLD and Sarcopenia
    M. E. Statsenko, R. G. Myazin, M. N. Ustinova, A. V. Tumarenko
    The Russian Archives of Internal Medicine.2025; 15(3): 178.     CrossRef
  • L-Ornithine salts as somatotropic axis modulators for the correction of sarcopenia in chronic liver disease
    V. A. Prikhodko, S. V. Okovityi
    Meditsinskiy sovet = Medical Council.2025; (8): 80.     CrossRef
  • Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analyses
    Ninglin Xia, Jiwei Wang, Qian Lu, Xue Fan, Zhenzhou Jiang, Qinwei Yu
    Clinical Nutrition ESPEN.2025; 68: 679.     CrossRef
  • Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease
    Inyoung Hwang, Shi-Ra Lee, Yun Kim, Sang Won Lee
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Multimodal data-driven prognostic model for predicting long-term outcomes in older adult patients with sarcopenia: a retrospective cohort study
    Mengdie Liu, Wen Guo, Jin Peng, Jinhui Wu
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Metabolic and immune links between sarcopenia and liver disease
    Stanislav Nikolaevich Kotlyarov
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • The Relationship Between FIB-4 Score and Dynapenia in Older Adults
    Guner Kilic, Ali Karatas, Mehmet Cindoruk, Tarkan Karakan, Derya Kirman, Beril Demir, Suleyman Emre Kocyigit
    Diagnostics.2025; 15(18): 2323.     CrossRef
  • Effects and Mechanisms of Long-Term Lycium barbarum Water Consumption on Skeletal Muscle Function in Aged Mice
    Yundi Tang, Qingwei Zheng, Jinyi Wang, Mingcong Fan, Haifeng Qian, Li Wang, Yan Li
    Foods.2025; 14(17): 3049.     CrossRef
  • The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study
    Yao Dou, Jiawei Cui, Qi Gu, Xiwei Yuan, Mengmeng Hou, Wenjing Ni, Chen Dong, Chudi Chang, Jinhua Shao, Qiuling Wang, Jie Li, Liang Qiao, Yuemin Nan
    Therapeutic Advances in Chronic Disease.2025;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Influence of Habitual Food
    Naiade S. Almeida, Raquel Rocha, Carla Daltro, Helma P. Cotrim
    Diagnostics.2025; 15(21): 2711.     CrossRef
  • Oral–Sarcopenia nexus in health disparities: chewing and blood mediated pathways in a Chinese aging cohort
    Yong Xiang, Guosong Wang, Yiting Cheng, Yuhan Zhang, Jialiang Zhao, Birong Dong, He Cai, Li Cheng, Tao Hu
    BMC Oral Health.2025;[Epub]     CrossRef
  • Body Composition in Chronic Liver Disease
    Hiroki Nishikawa, Soo Ki Kim, Akira Asai
    International Journal of Molecular Sciences.2024; 25(2): 964.     CrossRef
  • Metabolic-associated fatty liver disease and sarcopenia: A double whammy
    Aditya Viswanath, Sherouk Fouda, Cornelius James Fernandez, Joseph M Pappachan
    World Journal of Hepatology.2024; 16(2): 152.     CrossRef
  • The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
    Ziyan Feng, Fanrong Zhao, Ziyao Wang, Xinyi Tang, Yan Xie, Li Qiu
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Systemic immune-inflammation index and all-cause and cause-specific mortality in sarcopenia: a study from National Health and Nutrition Examination Survey 1999-2018
    Qing-Yue Zeng, Yu Qin, Yi Shi, Xing-Yu Mu, Shi-Jun Huang, Yu-Hao Yang, Si-Min Liu, Zhen-Mei An, Shuang-Qing Li
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Quick and easy assessment of sarcopenia in cirrhosis: Can ultrasound be the solution?
    Francesca Campani, Tancredi Vincenzo Li Cavoli, Umberto Arena, Fabio Marra, Erica Nicola Lynch, Claudia Campani
    World Journal of Gastroenterology.2024; 30(17): 2287.     CrossRef
  • Machine Learning Reveals Serum Glycopatterns as Potential Biomarkers for the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD)
    Xiaocheng Li, Yaqing Xiao, Xinhuan Chen, Yayun Zhu, Haoqi Du, Jian Shu, Hanjie Yu, Xiameng Ren, Fan Zhang, Jing Dang, Chen Zhang, Shi Su, Zheng Li
    Journal of Proteome Research.2024; 23(6): 2253.     CrossRef
  • Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both
    Rochelle Wong, Li-Yun Yuan
    World Journal of Hepatology.2024; 16(6): 871.     CrossRef
  • Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B
    Hyunjae Shin, Gyung Sun Lim, Jae Woong Yoon, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yuri Cho, Yun Bin Lee, Eun Ju Cho, Bo Hyun Kim, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim
    Journal of Medical Virology.2024;[Epub]     CrossRef
  • Sarcopenia-related traits and 10 digestive system disorders: insight from genetic correlation and Mendelian randomization
    Tao Yang, Zheng Liu, Mingzhu Xiu, Xiaoman Qing, Sha Liu, Wanmeng Xiao, Muhan Lü
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Reddemma Sandireddy, Suganya Sakthivel, Priyanka Gupta, Jatin Behari, Madhulika Tripathi, Brijesh Kumar Singh
    Frontiers in Cell and Developmental Biology.2024;[Epub]     CrossRef
  • The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Xiaoyan Li, Jie He, Qiuhua Sun
    Clinical Nutrition.2024; 43(9): 2005.     CrossRef
  • Bibliometric and visualized analysis of the correlation between sarcopenia and chronic liver diseases from 2000 to 2023
    Jiaming Lan, Haozhuo Guo, Jingyu Zou, Jian Xue, Hongbo Ni, Liuchun Wang, Tianhang Ren, Sijie Chai, Haoyang Jiang, Chan Gou, Fan Wang, Shuai Wang, Xiaohe Xu, Yue Wang, Meng Niu
    Portal Hypertension & Cirrhosis.2024; 3(3): 139.     CrossRef
  • Sarcopenia: A review
    Chieh Chen, Da-Ming Liao
    Tungs' Medical Journal.2024; 18(Suppl 1): S23.     CrossRef
  • The ZJU index is associated with the risk of sarcopenia in American adults aged 20–59: a cross-sectional study
    Jia-qi Hao, Shu-yue Hu, Zi-xuan Zhuang, Jia-wan Zhang, Meng-rui Xiong, Rui Wang, Wen Zhuang, Mo-jin Wang
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?
    Catherine Stankevicius, Rachel H. Davis, Dep Huynh, Martine Hatzi, Stephanie Morgillo, Alice S. Day
    Journal of Digestive Diseases.2024; 25(11-12): 645.     CrossRef
  • GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
    Riccardo Nevola, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
    International Journal of Molecular Sciences.2023; 24(2): 1703.     CrossRef
  • Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease
    Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeong
    Scientific Reports.2023;[Epub]     CrossRef
  • Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease
    Ik Hyun Jo, Do Seon Song, U Im Chang, Jin Mo Yang
    Scientific Reports.2023;[Epub]     CrossRef
  • Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
    Eileen Laurel Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(2): 371.     CrossRef
  • Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2023; 29(2): 377.     CrossRef
  • Sarkopenie bei chronischen Lebererkrankungen
    Monika Rau
    Die Innere Medizin.2023; 64(6): 525.     CrossRef
  • MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
    Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2023; 38(9): 1598.     CrossRef
  • Lean nonalcoholic fatty liver disease and sarcopenia
    Milian Chen, Ying Cao, Guang Ji, Li Zhang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
    Ho Soo Chun
    Gut and Liver.2023; 17(4): 485.     CrossRef
  • Waiting for the changes after the adoption of steatotic liver disease
    Eileen L. Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(4): 844.     CrossRef
  • Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
    Eugene Han, Yong-ho Lee
    Clinical and Molecular Hepatology.2023; 29(4): 980.     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?
    Katarzyna Ferenc, Sara Jarmakiewicz-Czaja, Rafał Filip
    Life.2023; 14(1): 37.     CrossRef
  • 13,389 View
  • 369 Download
  • 54 Web of Science
  • Crossref

Letter to the Editor

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies
Seogsong Jeong, Won Kim, Sang Min Park
Clin Mol Hepatol 2022;28(4):933-934.
Published online September 14, 2022
DOI: https://doi.org/10.3350/cmh.2022.0267

Citations

Citations to this article as recorded by  Crossref logo
  • A Mediterranean-style diet protects against cognitive and behavioral deficits, adiposity, and Alzheimer's disease-related markers, compared to a macronutrient-matched typical American diet in C57BL/6J mice
    Paige N Braden-Kuhle, Vivienne A Lacy, Kelly N Brice, Morgan E Bertrand, Hatice Buse Uras, Catherine Shoffner, Bridgette E Fischer, Ashish Rana, Jada L Willis, Gary W Boehm, Michael J Chumley
    Journal of Alzheimer’s Disease.2025; 104(3): 678.     CrossRef
  • 6,221 View
  • 82 Download
  • 1 Web of Science
  • Crossref

Editorial

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
Seonghwan Hwang, Won Kim
Clin Mol Hepatol 2022;28(3):478-480.
Published online June 16, 2022
DOI: https://doi.org/10.3350/cmh.2022.0143
  • 6,055 View
  • 99 Download

Original Article

Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults
Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park
Clin Mol Hepatol 2022;28(3):510-521.
Published online March 17, 2022
DOI: https://doi.org/10.3350/cmh.2021.0332
Background/Aims
Accumulating evidence suggests a link between non-alcoholic fatty liver disease (NAFLD) and brain health. However, population-based evidence on the association between NAFLD and dementia remains unclear. This study was conducted to determine the association between NAFLD and incident dementia.
Methods
The study population included 608,994 adults aged ≥60 years who underwent health examinations between 2009 and 2010. Data were collected from the Korean National Health Insurance Service database. NAFLD was assessed using the fatty liver index (FLI). A Cox proportional hazards regression model was used to determine the association between NAFLD and dementia.
Results
During the 6,495,352 person-years of follow-up, 48,538 participants (8.0%) developed incident dementia. The participants were classified into low (FLI <30), intermediate (FLI ≥30 and <60), and high (FLI ≥60) groups. In the overall study population, the FLI groups were associated with a risk of dementia (P for trend <0.001). After propensity score matching, a low FLI was associated with a reduced risk of dementia (adjusted hazard ration [aHR], 0.96; 95% confidence interval [CI], 0.93–0.98; P=0.002), whereas a high FLI (NAFLD) was associated with an increased risk of dementia (aHR, 1.05; 95% CI, 1.02–1.08; P=0.001). A higher risk of dementia in the high FLI group than in the intermediate FLI group was attributed to Alzheimer’s disease (aHR, 1.04; 95% CI, 1.01–1.07; P=0.004) rather than vascular dementia (aHR, 0.94; 95% CI, 0.75–1.18; P=0.602).
Conclusions
NAFLD was associated with an increased risk of dementia, which was attributed to an increased risk of Alzheimer’s disease.

Citations

Citations to this article as recorded by  Crossref logo
  • Role of metabolic dysfunction and inflammation along the liver–brain axis in animal models with obesity-induced neurodegeneration
    Evridiki Asimakidou, Eka Norfaishanty Saipuljumri, Chih Hung Lo, Jialiu Zeng
    Neural Regeneration Research.2025; 20(4): 1069.     CrossRef
  • Associations of metabolic dysfunction-related fatty liver disease and dementia risk: A prospective study based on the UK biobank
    Chaofan Geng, Peiyang Gao, Yi Tang
    Archives of Gerontology and Geriatrics.2025; 135: 105845.     CrossRef
  • Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2025; 31(2): e208.     CrossRef
  • Metabolic Dysfunction‐Associated Steatotic Liver Disease Is Associated With Accelerated Brain Ageing: A Population‐Based Study
    Jiao Wang, Rongrong Yang, Yuyang Miao, Xinjie Zhang, Stéphanie Paillard‐Borg, Zhongze Fang, Weili Xu
    Liver International.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
    Woo-Young Shin, Eun Seok Kang, Yun Hwan Oh, Meng Sha, Qiang Xia, Seogsong Jeong, Yoosun Cho
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • A cross sectional study of the diabetes mediated GGT to HDL ratio and cognitive function in older adults
    Ye Wang, Yanping Mao, Tianmei Xu, Lujie Han, Wenxuan Zhang, Wangdi Sun, Jiaxi Xu, Enyan Yu
    Scientific Reports.2025;[Epub]     CrossRef
  • Exploring LRP-1 in the liver-brain axis: implications for Alzheimer’s disease
    Vivek Kumar Sharma
    Molecular Biology Reports.2025;[Epub]     CrossRef
  • Association between fatty liver index and low back pain: A cross-sectional study from NHANES 1999–2004
    Jiangtao Liao, Zhenyu Song, Hao Xu, Yi Li, Dongdong Xu, Hongtao Tian, Zhipeng Dai, Wei Tong
    Journal of Back and Musculoskeletal Rehabilitation.2025;[Epub]     CrossRef
  • MASLD in the oldest-old: lack of association with cognition or functional autonomy and poor predictive utility of the hepatic steatosis index
    Maximilian Joseph Brol, Martin Groth, Frank Erhard Uschner, Juliana Stadtmann, Tina Schomacher, Jonel Trebicka, Michael Praktiknjo, Elena Vorona
    GeroScience.2025;[Epub]     CrossRef
  • Liver integrity and the risk of Alzheimer's disease and related dementias
    Yifei Lu, James Russell Pike, Ron C. Hoogeveen, Keenan A. Walker, Laura M. Raffield, Elizabeth Selvin, Christy L. Avery, Stephanie M. Engel, Michelle M. Mielke, Tanya Garcia, Priya Palta
    Alzheimer's & Dementia.2024; 20(3): 1913.     CrossRef
  • Disentangling the contributions of alcohol use disorder and alcohol‐related liver disease towards dementia: A population‐based cohort study
    Sixian Zhao, Linnea Widman, Hannes Hagström, Ying Shang
    Addiction.2024; 119(4): 706.     CrossRef
  • The Metabolic Impact of Nonalcoholic Fatty Liver Disease on Cognitive Dysfunction: A Comprehensive Clinical and Pathophysiological Review
    Mauro Giuffrè, Nicola Merli, Maura Pugliatti, Rita Moretti
    International Journal of Molecular Sciences.2024; 25(6): 3337.     CrossRef
  • Peripheral amyloid-β clearance mediates cognitive impairment in non-alcoholic fatty liver disease
    Xiaobo Peng, Xing Zhang, Zihui Xu, Linyan Li, Xiaoxing Mo, Zhao Peng, Zhilei Shan, Hong Yan, Jian Xu, Liegang Liu
    eBioMedicine.2024; 102: 105079.     CrossRef
  • Factor modification in the association between high-density lipoprotein cholesterol and liver cancer risk in a nationwide cohort
    Su Youn Nam, Junwoo Jo, Won Kee Lee, Chang Min Cho
    International Journal of Epidemiology.2024;[Epub]     CrossRef
  • Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer’s Disease
    Andrey Tsoy, Bauyrzhan Umbayev, Aliya Kassenova, Bibifatima Kaupbayeva, Sholpan Askarova
    International Journal of Molecular Sciences.2024; 25(20): 10964.     CrossRef
  • Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes
    Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen
    Fibrosis.2024; 2(4): 10006.     CrossRef
  • Association between composite dietary antioxidant index and fatty liver index among US adults
    Meng Zheng, Chaochen Li, Jia Fu, Long Bai, Jinghui Dong
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Association between dementia, Alzheimer's disease, and liver cancer: A Mendelian randomization analysis
    Tianze Li, Jianwei Yi, Xuliang Hu, Huajun Wu, Kai Wang, Binghai Zhou
    Journal of Alzheimer's Disease Reports.2024; 8(1): 1587.     CrossRef
  • Association of Balance Impairment with Risk of Incident Dementia among Older Adults
    H.J. Kim, S. Jeong, Yun Hwan Oh, Michelle J. Suh, Jee Young Suh
    The Journal of Prevention of Alzheimer's Disease.2024; 11(1): 130.     CrossRef
  • Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 185.     CrossRef
  • Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration
    Taylor J. Kelty, Ryan J. Dashek, W. David Arnold, R. Scott Rector
    Seminars in Liver Disease.2023; 43(01): 077.     CrossRef
  • Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
    Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis
    Hangkai Huang, Zhening Liu, Jiarong Xie, Chengfu Xu
    Journal of Psychiatric Research.2023; 161: 435.     CrossRef
  • Effect of Comorbidities on Ten-Year Survival in Patients with Dementia
    Nida Buawangpong, Kanokporn Pinyopornpanish, Phichayut Phinyo, Wichuda Jiraporncharoen, Chaisiri Angkurawaranon, Atiwat Soontornpun
    Journal of Alzheimer’s Disease.2023; 94(1): 163.     CrossRef
  • Regulation of mild cognitive impairment associated with liver disease by humoral factors derived from the gastrointestinal tract and MRI research progress: a literature review
    Tianning Sun, Maohui Feng, Anne Manyande, Hongbing Xiang, Jun Xiong, Zhigang He
    Frontiers in Neuroscience.2023;[Epub]     CrossRef
  • Impact of ectopic fat on brain structure and cognitive function: A systematic review and meta-analysis from observational studies
    Zhi-Hui Song, Jing Liu, Xiao-Feng Wang, Rafael Simó, Chao Zhang, Jian-Bo Zhou
    Frontiers in Neuroendocrinology.2023; 70: 101082.     CrossRef
  • Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    Clinical and Molecular Hepatology.2023; 29(3): 817.     CrossRef
  • Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
    Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
    Clinical and Molecular Hepatology.2023; 29(3): 810.     CrossRef
  • Association of Thyroid Hormone Medication Adherence With Risk of Dementia
    Saemi Han, Seogsong Jeong, Seulggie Choi, Sun Jae Park, Kyae Hyung Kim, Gyeongsil Lee, Yoosun Cho, Joung Sik Son, Sang Min Park
    The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): e225.     CrossRef
  • Sex-specific relationship between non-alcoholic fatty liver disease and amyloid-β in cognitively unimpaired individuals
    Sung Hoon Kang, Heejin Yoo, Bo Kyoung Cheon, Jun Pyo Kim, Hyemin Jang, Hee Jin Kim, Mira Kang, Kyungmi Oh, Seong-Beom Koh, Duk L. Na, Yoosoo Chang, Sang Won Seo
    Frontiers in Aging Neuroscience.2023;[Epub]     CrossRef
  • Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
    Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera
    Hepatology.2023; 78(6): 1858.     CrossRef
  • HOMA-IR is an effective biomarker of non-alcoholic fatty liver disease in non-diabetic population
    Pei Zeng, Xiangsheng Cai, Xiaozhou Yu, Lu Huang, Xi Chen
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Bo Kyung Koo, Won Kim
    eClinicalMedicine.2023; 65: 102292.     CrossRef
  • Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
    Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han
    Reviews in Cardiovascular Medicine.2023;[Epub]     CrossRef
  • Non‐alcoholic fatty liver disease and the risk of dementia—Authors' reply
    Gi‐Ae Kim, Jae‐Jun Shim
    Liver International.2022; 42(8): 1914.     CrossRef
  • Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults
    Byoung Seok Ye
    Clinical and Molecular Hepatology.2022; 28(3): 481.     CrossRef
  • Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies
    Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung
    Clinical and Molecular Hepatology.2022; 28(4): 931.     CrossRef
  • Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2022; 28(4): 933.     CrossRef
  • Dementia and non-alcoholic fatty liver disease – An unprecedented relationship
    Fakhar Latif, Vania Saqib, Eisha Waqar
    Annals of Medicine and Surgery.2022; 81: 104359.     CrossRef
  • Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Luping Wang, Bowen Sang, Zuyan Zheng
    Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
  • 11,490 View
  • 352 Download
  • 42 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?
Seung Mi Lee, Won Kim
Clin Mol Hepatol 2022;28(1):47-49.
Published online November 30, 2021
DOI: https://doi.org/10.3350/cmh.2021.0338

Citations

Citations to this article as recorded by  Crossref logo
  • Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China
    Ruya Zhu, Caicai Xu, Suwen Jiang, Jianping Xia, Boming Wu, Sijia Zhang, Jing Zhou, Hongliang Liu, Hongshan Li, Jianjun Lou
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • GDM-BC: Non-invasive body composition dataset for intelligent prediction of Gestational Diabetes Mellitus
    Chen Zheng, Tong Qing, Mao Li, Shujuan Liao, Biru Luo, Chenwei Tang, Jiancheng Lv
    Computers in Biology and Medicine.2025; 192: 110176.     CrossRef
  • Влияние неалкогольной жировой болезни печени на течение беременности и неонатальные исходы: обзор литературы
    Виталий Анатольевич Резник, Юрий Павлович Успенский, Полина Юрьевна Бухмирова, Александр Александрович Гнутов, Виталий Антонович Добренко
    University therapeutic journal.2025; 7(3): 7.     CrossRef
  • Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study
    Young Mi Jung, Seung Mi Lee, Wonyoung Wi, Min-Jeong Oh, Joong Shin Park, Geum Joon Cho, Won Kim
    JHEP Reports.2024; 6(4): 101033.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study
    Seung Mi Lee, Geum Joon Cho, Won Young Wi, Errol R. Norwitz, Bo Kyung Koo, Jeesun Lee, Young Mi Jung, Soo Heon Kwak, Chan-Wook Park, Jong Kwan Jun, Sae Kyung Joo, Min-Jeong Oh, Won Kim, Joong Shin Park
    Hepatology International.2023; 17(2): 367.     CrossRef
  • Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
    George Agyapong, Farzaneh Dashti, Bubu A. Banini
    Annals of the New York Academy of Sciences.2023; 1526(1): 16.     CrossRef
  • Case Report:Pregnancy and birth in a mild phenotype of Alström syndrome
    Luca Marozio, Francesca Dassie, Gianluca Bertschy, Emilie M. Canuto, Gabriella Milan, Stefano Cosma, Pietro Maffei, Chiara Benedetto
    Frontiers in Genetics.2022;[Epub]     CrossRef
  • 7,757 View
  • 123 Download
  • 5 Web of Science
  • Crossref

Original Article

Steatotic liver disease

Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods
Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park
Clin Mol Hepatol 2022;28(1):105-116.
Published online October 15, 2021
DOI: https://doi.org/10.3350/cmh.2021.0174
Background/Aims
To develop an early prediction model for gestational diabetes mellitus (GDM) using machine learning and to evaluate whether the inclusion of nonalcoholic fatty liver disease (NAFLD)-associated variables increases the performance of model.
Methods
This prospective cohort study evaluated pregnant women for NAFLD using ultrasound at 10–14 weeks and screened them for GDM at 24–28 weeks of gestation. The clinical variables before 14 weeks were used to develop prediction models for GDM (setting 1, conventional risk factors; setting 2, addition of new risk factors in recent guidelines; setting 3, addition of routine clinical variables; setting 4, addition of NALFD-associated variables, including the presence of NAFLD and laboratory results; and setting 5, top 11 variables identified from a stepwise variable selection method). The predictive models were constructed using machine learning methods, including logistic regression, random forest, support vector machine, and deep neural networks.
Results
Among 1,443 women, 86 (6.0%) were diagnosed with GDM. The highest performing prediction model among settings 1–4 was setting 4, which included both clinical and NAFLD-associated variables (area under the receiver operating characteristic curve [AUC] 0.563–0.697 in settings 1–3 vs. 0.740–0.781 in setting 4). Setting 5, with top 11 variables (which included NAFLD and hepatic steatosis index), showed similar predictive power to setting 4 (AUC 0.719–0.819 in setting 5, P=not significant between settings 4 and 5).
Conclusions
We developed an early prediction model for GDM using machine learning. The inclusion of NAFLDassociated variables significantly improved the performance of GDM prediction. (ClinicalTrials.gov Identifier: NCT02276144)

Citations

Citations to this article as recorded by  Crossref logo
  • Artificial intelligence methods in gestational diabetes mellitus prediction: A systematic literature review
    Valentina Ivanovic, Md Abu Jafar Sujan, Ole Jakob Mengshoel, Trine Moholdt
    International Journal of Medical Informatics.2026; 206: 106158.     CrossRef
  • Establishment of a predictive model for spontaneous preterm birth in primiparas with grade A1 gestational diabetes mellitus
    Ting Sun, Yangyang Zhang, Chunzhi Xie, Anyi Teng, Shi Lin, Hui Zhang, Yan Li
    Frontiers in Global Women's Health.2025;[Epub]     CrossRef
  • Machine learning based model for the early detection of Gestational Diabetes Mellitus
    Hesham Zaky, Eleni Fthenou, Luma Srour, Thomas Farrell, Mohammed Bashir, Nady El Hajj, Tanvir Alam
    BMC Medical Informatics and Decision Making.2025;[Epub]     CrossRef
  • Metabolomic profiling reveals early biomarkers of gestational diabetes mellitus and associated hepatic steatosis
    Youngae Jung, Seung Mi Lee, Jinhaeng Lee, Yeonjin Kim, Woojoo Lee, Ja Nam Koo, Ig Hwan Oh, Kue Hyun Kang, Byoung Jae Kim, Sun Min Kim, Jeesun Lee, Ji Hoi Kim, Yejin Bae, Sang Youn Kim, Gyoung Min Kim, Sae Kyung Joo, Dong Hyeon Lee, Joon Ho Moon, Bo Kyung
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • GDM-BC: Non-invasive body composition dataset for intelligent prediction of Gestational Diabetes Mellitus
    Chen Zheng, Tong Qing, Mao Li, Shujuan Liao, Biru Luo, Chenwei Tang, Jiancheng Lv
    Computers in Biology and Medicine.2025; 192: 110176.     CrossRef
  • Metabolic dysfunction–associated steatotic liver disease and pregnancy
    Monika Sarkar, Tatyana Kushner
    Journal of Clinical Investigation.2025;[Epub]     CrossRef
  • Maternal liver fibrosis indices as predictors of adverse perinatal outcomes in patients with gestational diabetes mellitus
    Murad Gezer, Ümit Taşdemir, Ömer Gökhan Eyisoy, Sevdenur Yiğit, Mucize Eriç Özdemir, Oya Demirci
    Acta Diabetologica.2025; 62(12): 2055.     CrossRef
  • Associations of hepatic steatosis index in early pregnancy with perinatal outcomes: A prospective birth cohort study
    Shaofei Su, Enjie Zhang, Shen Gao, Yue Zhang, Jianhui Liu, Shuanghua Xie, Jinghan Yu, Qiutong Zhao, Wentao Yue, Ruixia Liu, Chenghong Yin
    Clinical Medicine.2025; 25(4): 100343.     CrossRef
  • Artificial Intelligence in Gestational Diabetes Care: A Systematic Review
    Rawan AlSaad, Ali Elhenidy, Aliya Tabassum, Nour Odeh, Eman AboArqoub, Aya Odeh, Maya AlTamimi, Alaa Abd-alrazaq, Rajat Thomas, Mohammed Bashir, Javaid Sheikh
    Journal of Diabetes Science and Technology.2025;[Epub]     CrossRef
  • What role does metabolic disfunction-associated fatty liver disease play in the metabolic landscape of pregnancy?
    Annunziata Lapolla, Maria Grazia Dalfrà
    Expert Review of Endocrinology & Metabolism.2025; : 1.     CrossRef
  • Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions
    Mohamad Jamalinia, Samira Saeian, Nima Nikkhoo, Amirhossein Nazerian, Kamran Bagheri Lankarani
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Evaluating the performance of maternal risk factors in predicting gestational diabetes mellitus: a systematic review and meta-analysis
    Alemu Degu Ayele, Getnet Gedefaw Azeze, Beklau Kassie Alemu, Yao Wang, Chi Chiu Wang
    BMJ Evidence-Based Medicine.2025; : bmjebm-2025-114065.     CrossRef
  • Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study
    Young Mi Jung, Seung Mi Lee, Wonyoung Wi, Min-Jeong Oh, Joong Shin Park, Geum Joon Cho, Won Kim
    JHEP Reports.2024; 6(4): 101033.     CrossRef
  • The early prediction of gestational diabetes mellitus by machine learning models
    Yeliz Kaya, Zafer Bütün, Özer Çelik, Ece Akça Salik, Tuğba Tahta, Arzu Altun Yavuz
    BMC Pregnancy and Childbirth.2024;[Epub]     CrossRef
  • Could Machine Learning-Based Gestational Diabetes Mellitus Prediction Models Replace Traditional Screening Test?
    Jong Yun Hwang
    Journal of Korean Maternal and Child Health.2024; 28(4): 153.     CrossRef
  • The Role of Adiponectin during Pregnancy and Gestational Diabetes
    Brittany L. Moyce Gruber, Vernon W. Dolinsky
    Life.2023; 13(2): 301.     CrossRef
  • Liver biomarkers, lipid metabolites, and risk of gestational diabetes mellitus in a prospective study among Chinese pregnant women
    Ping Wu, Yi Wang, Yi Ye, Xue Yang, Yichao Huang, Yixiang Ye, Yuwei Lai, Jing Ouyang, Linjing Wu, Jianguo Xu, Jiaying Yuan, Yayi Hu, Yi-Xin Wang, Gang Liu, Da Chen, An Pan, Xiong-Fei Pan
    BMC Medicine.2023;[Epub]     CrossRef
  • Performance Analysis and Assessment of Type 2 Diabetes Screening Scores in Patients with Non-Alcoholic Fatty Liver Disease
    Norma Latif Fitriyani, Muhammad Syafrudin, Siti Maghfirotul Ulyah, Ganjar Alfian, Syifa Latif Qolbiyani, Chuan-Kai Yang, Jongtae Rhee, Muhammad Anshari
    Mathematics.2023; 11(10): 2266.     CrossRef
  • Synergistic effect of non-alcoholic fatty liver disease and history of gestational diabetes to increase risk of type 2 diabetes
    Yoosun Cho, Yoosoo Chang, Seungho Ryu, Sarah H. Wild, Christopher D. Byrne
    European Journal of Epidemiology.2023; 38(8): 901.     CrossRef
  • Identification of influence factors in overweight population through an interpretable risk model based on machine learning: a large retrospective cohort
    Wei Lin, Songchang Shi, Huiyu Lan, Nengying Wang, Huibin Huang, Junping Wen, Gang Chen
    Endocrine.2023; 83(3): 604.     CrossRef
  • Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?
    Seung Mi Lee, Won Kim
    Clinical and Molecular Hepatology.2022; 28(1): 47.     CrossRef
  • 11,614 View
  • 260 Download
  • 20 Web of Science
  • Crossref

Guideline

Steatotic liver disease

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2021;27(3):363-401.
Published online June 22, 2021
DOI: https://doi.org/10.3350/cmh.2021.0178

Citations

Citations to this article as recorded by  Crossref logo
  • Quinoa bran terpenoids ameliorates metabolic dysfunction-associated steatotic liver disease by enriching of L. murinus LQ719
    Qinqin Qiao, Shuhua Shan, Huiqin Guo, Ning An, Jiangying Shi, Zhuoyu Li
    Food Research International.2026; 225: 118084.     CrossRef
  • Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim
    Clinical Gastroenterology and Hepatology.2025; 23(1): 114.     CrossRef
  • Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study
    Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Alimentary Pharmacology & Therapeutics.2025; 61(3): 491.     CrossRef
  • Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers
    Jaejun Lee, Dong Yeup Lee, Jae Hyeop Jung, Eunkyoung Bae, Jeong A. Yu, Hyun Yang
    Journal of Physical Activity and Health.2025; 22(3): 323.     CrossRef
  • The Role of microRNA-22 in Metabolism
    Simone Tomasini, Paolo Vigo, Francesco Margiotta, Ulrik Søberg Scheele, Riccardo Panella, Sakari Kauppinen
    International Journal of Molecular Sciences.2025; 26(2): 782.     CrossRef
  • Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults
    Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang
    Gut and Liver.2025; 19(1): 116.     CrossRef
  • Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease
    Mei-jing Chen, Ying Chen, Jin-qing Lin, Rong Hu, Dun Liu, Jing-yi Chen, Ka Li, Xiao-ying Jiang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
    Yuxin Sun, Die Hu, Mingkun Yu, Shi-Bing Liang, Youyou Zheng, Xin Wang, Guangdong Tong
    Clinical Epidemiology.2025; Volume 17: 53.     CrossRef
  • Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study
    Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim
    American Journal of Gastroenterology.2025; 120(10): 2321.     CrossRef
  • Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults
    Byung Sik Kim, Hyun-Jin Kim, Seong Won Jeon, Kyung Hwan Kim, Dong Wook Kim, Jeong-Hun Shin
    Heliyon.2025; 11(7): e43073.     CrossRef
  • Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study
    Huiyul Park, Terry Cheuk-Fung Yip, Eileen L. Yoon, Grace Lai-Hung Wong, Hye Sun Lee, Vincent Wai-Sun Wong, Jimmy Che-To Lai, Dae Won Jun
    JHEP Reports.2025; 7(6): 101388.     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study
    Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Sex differences in the mediation of the MASLD - Depression association by fat distribution in U.S. adults
    Changhuai He, Liuxin Zhou, Tianming Gao, Runmin Cao, Chuanqi Cai, Guoqing Jiang
    Acta Psychologica.2025; 256: 105041.     CrossRef
  • Association Between Perfluoroalkyl Substance (PFAS) Exposure and Nonalcoholic Fatty Liver Disease in Korean Adults: Results From the KoNEHS 2018–2020: A Cross‐Sectional Study
    Jisuk Yun, Young‐Sun Min
    American Journal of Industrial Medicine.2025; 68(7): 588.     CrossRef
  • Valorization of grape pomace by microbial fermentation: Composition, biological activities and potential applications for the food industry
    Kavindya Samarakoon, H.P. Vasantha Rupasinghe
    Journal of Food Composition and Analysis.2025; 144: 107656.     CrossRef
  • Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
    Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya
    Preventive Medicine: Research & Reviews.2025; 2(4): 183.     CrossRef
  • Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up
    Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun
    Scientific Reports.2025;[Epub]     CrossRef
  • Are mesenchymal stem/stromal cells a novel avenue for the treatment of non-alcoholic fatty liver disease?
    Milton Artur Ruiz, Roberto Luiz R Kaiser Junior, Gabriel Piron-Ruiz, Luiz Gustavo de Quadros
    World Journal of Stem Cells.2025;[Epub]     CrossRef
  • The ameliorative effect of C-Kit+ hepatic endothelial cells with Mertk deficiency on nonalcoholic steatohepatitis
    Seng-Wang Fu, Yu-Xuan Gao, Hui-Yi Li, Jun-Cheng Wu, Zheng-Hong Li, Ming-Yi Xu
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(7): 167964.     CrossRef
  • Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease
    Eiji Kakazu, Masaaki Mino, Tatsuya Kanto
    Clinical and Molecular Hepatology.2025; 31(3): 771.     CrossRef
  • Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis
    Amria Mamdouh Mousa, Rehab Fikry Taher, Nermin Mohamed El-Sammad, Esraa Aly Balabel, Elham Mohamed Youssef, Ahmed Hassan Afifi, Sahar Samir Abdel-Rahman, Nayera Anwar, Sherien Kamal Hassan
    BMC Complementary Medicine and Therapies.2025;[Epub]     CrossRef
  • Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study
    Minkwan Kim, Minkook Son, Sang Yi Moon, Yang Hyun Baek
    Journal of the American Heart Association.2025;[Epub]     CrossRef
  • Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease
    Inyoung Hwang, Shi-Ra Lee, Yun Kim, Sang Won Lee
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Exercise training improves metabolic and circulatory function in COPD patients with NAFLD: evidence from clinical and molecular profiling
    Yi-cai Qian, Xiaoxiang Liu, Panpan Liu, ShuYing Jia, Yi Ding, Cuiling Zhu, Jing He
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
    Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2025; 19(5): 758.     CrossRef
  • Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review
    Muhammad Y. Sheikh, Muhammad F. Younus, Annie Shergill, Muhammad N. Hasan
    International Journal of Molecular Sciences.2025; 26(19): 9625.     CrossRef
  • Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study
    Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min
    Journal of Clinical Medicine.2025; 14(20): 7284.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges
    Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes
    Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    The Journal of Infectious Diseases.2024; 229(1): 108.     CrossRef
  • A Comparison of the Prognostic Value of Liver Fibrosis Scores in Acute Myocardial Infarction Patients With and Without Type 2 Diabetes
    Hao-ming He, Shu-wen Zheng, Yi-nong Chen, Long-yang Zhu, Zhe Wang, Si-qi Jiao, Fu-rong Yang, Yi-hong Sun
    Angiology.2024; 75(3): 219.     CrossRef
  • Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style
    Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan
    Steroids.2024; 203: 109330.     CrossRef
  • Association between plant-based diets and risk of metabolic dysfunction–associated steatotic liver disease in Korean adults: A prospective cohort study
    Bayarmaa Nasan Ulzii, Kyungjoon Lim, Sangah Shin
    Nutrition.2024; 128: 112579.     CrossRef
  • Extrahepatic malignancies in metabolic dysfunction‐associated fatty liver disease: A nationwide cohort study
    Min Kyung Park, Moon Haeng Hur, Hye‐Sung Moon, Hyunjae Shin, Sung Won Chung, Sungho Won, Yun Bin Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim
    Liver International.2024; 44(3): 799.     CrossRef
  • Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini
    Metabolites.2024; 14(1): 52.     CrossRef
  • Very low-carbohydrate diet with higher protein ratio improves lipid metabolism and inflammation in rats with diet-induced nonalcoholic fatty liver disease
    I-Ting Wu, Wan-Ju Yeh, Wen-Chih Huang, Hsin-Yi Yang
    The Journal of Nutritional Biochemistry.2024; 126: 109583.     CrossRef
  • Quality Evaluation of Metabolic-Associated Fatty Liver Disease Guidelines and Expert Consensus
    Meijing Chen, Ying Chen, Dun Liu, Ka Li, Rong Hu, Jingyi Chen, Xiaoying Jiang, Jinqing Lin
    Hormone and Metabolic Research.2024; 56(07): 509.     CrossRef
  • Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
    Xin Ding, Xu He, Bulang Tang, Tian Lan
    Chinese Medicine.2024;[Epub]     CrossRef
  • Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
    Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim
    JAMA Internal Medicine.2024; 184(4): 375.     CrossRef
  • Mobile App–Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial
    Oh Young Kwon, Mi Kyung Lee, Hye Won Lee, Hyerang Kim, Jae Seung Lee, Yeonsoo Jang
    Journal of Medical Internet Research.2024; 26: e49839.     CrossRef
  • Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
    Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin
    Heliyon.2024; 10(5): e27325.     CrossRef
  • Assessment of Hepatic Steatosis Using Ultrasound-Based Techniques: Focus on Fat Quantification
    Woo Sun Rou
    Clinical Ultrasound.2024; 9(1): 1.     CrossRef
  • Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
    Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    Gut and Liver.2024; 18(2): 294.     CrossRef
  • The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
    Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi
    Liver International.2024; 44(6): 1448.     CrossRef
  • Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
    Yaxin Li, Yitian Guo, Shiyun Tan
    Clinics and Research in Hepatology and Gastroenterology.2024; 48(4): 102320.     CrossRef
  • Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
    Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Liver Cancer.2024; 13(5): 561.     CrossRef
  • Sleep factors were associated with a higher risk of MAFLD and significant fibrosis
    Yaxin Li, Shiyun Tan
    Sleep and Breathing.2024; 28(3): 1381.     CrossRef
  • Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy
    Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo
    Journal of Agricultural and Food Chemistry.2024; 72(13): 7187.     CrossRef
  • Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score
    Aryoung Kim, Danbee Kang, Sung Chul Choi, Juhee Cho, Dong Hyun Sinn, Geum-Youn Gwak, Ashraf Elbahrawy
    PLOS ONE.2024; 19(3): e0301126.     CrossRef
  • Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
    Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
    Yonsei Medical Journal.2024; 65(7): 371.     CrossRef
  • Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics
    Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun
    Hepatology Research.2024; 54(11): 1027.     CrossRef
  • Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event
    Hyun-Jin Kim, Byung Sik Kim, Yonggu Lee, Sang Bong Ahn, Dong Wook Kim, Jeong-Hun Shin
    Diabetes & Metabolism Journal.2024; 48(3): 449.     CrossRef
  • An Exploration of the Treatment of Non-Alcoholic Fatty Liver Disease Based on Dietary Factors
    Wanzhou Yang, Y.-T. Yu, P.P. Piccaluga, S. Xie
    BIO Web of Conferences.2024; 111: 03024.     CrossRef
  • Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis
    Yeo Wool Kang, Yang Hyun Baek, Jong Hoon Lee, Young Hoon Roh, Hee Jin Kwon, Sang Yi Moon, Min Kook Son, Jin Sook Jeong
    Diagnostics.2024; 14(11): 1083.     CrossRef
  • Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort
    Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun
    Journal of Hepatology.2024; 81(5): 772.     CrossRef
  • A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease
    Hung-Tsung Wu, Chin-Shiang Tsai, Ting-Hsing Chao, Horng-Yih Ou, Liang-Miin Tsai
    Antioxidants.2024; 13(6): 746.     CrossRef
  • Emerging mRNA Technology for Liver Disease Therapy
    Ji Wang, Yile Fang, Zhiqiang Luo, Jinglin Wang, Yuanjin Zhao
    ACS Nano.2024; 18(27): 17378.     CrossRef
  • Evaluation of pancreatic iodine uptake and related influential factors in multiphase dual-energy CT
    Chen Pan, Tao Yu, Heng Zhao, Jiani He, Xiaomei Lu, Haiyan Tang, Yang Hong, Chao Shang, Qijun Wu, Aoran Yang, Chunli Li, Minghui Zhou, Yu Shi
    European Radiology.2024; 34(12): 7609.     CrossRef
  • Comparative effects of lifelong moderate-intensity continuous training and high-intensity interval training on blood lipid levels and mental well-being in naturally ageing mice
    Ling Yang, Wentao Lin, Xu Yan, Zhishang Zhang
    Experimental Gerontology.2024; 194: 112519.     CrossRef
  • The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial
    Eunbyul Cho, Sunwoo Kim, Soonkyu Kim, Ju Young Kim, Hwa Jung Kim, Yumi Go, Yu Jung Lee, Haesol Lee, Siye Gil, Sung Kwon Yoon, Keonho Chu
    Nutrients.2024; 16(14): 2254.     CrossRef
  • Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
    Maria Eva Argenziano, Mi Na Kim, Michele Montori, Alessandro Di Bucchianico, Daniele Balducci, Sang Hoon Ahn, Gianluca Svegliati Baroni
    Hepatology International.2024; 18(S2): 922.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Gastroenterology.2024; 84(1): 1.     CrossRef
  • Barriers to care linkage and educational impact on unnecessary MASLD referrals
    Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
    Merve Cebi, Yusuf Yilmaz
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Medicine.2024; 99(4): 189.     CrossRef
  • Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease
    Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    Gut and Liver.2024; 18(5): 924.     CrossRef
  • A new Korean nomenclature for steatotic liver disease

    Clinical and Molecular Hepatology.2024; 30(Suppl): S214.     CrossRef
  • Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
    Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599.     CrossRef
  • Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification
    Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park
    Scientific Reports.2024;[Epub]     CrossRef
  • A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease
    Dana Ivancovsky Wajcman, Christopher J. Byrne, John F. Dillon, Paul N. Brennan, Marcela Villota-Rivas, Zobair M. Younossi, Alina M. Allen, Javier Crespo, Lynn H. Gerber, Jeffrey V. Lazarus
    Hepatology.2024;[Epub]     CrossRef
  • Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park
    Diagnostics.2024; 14(20): 2305.     CrossRef
  • Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • Evaluation of hepatoprotective and nephroprotective activities of Castanopsis costata extract in rats
    Maulana Alkandahri, Asman Sadino, Ermi Abriyani, Faizal Hermanto, Zulpakor Oktoba, Muhammad Sayoeti, Putu Sangging, Diah Wardani, Nahrul Hasan, Suci Sari, Nurul Safitri, Windi Ikhtianingsih, Safitri Safitri
    Biomedical Reports.2024;[Epub]     CrossRef
  • Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target
    Yuan Yao, Yunfeng Shen
    Open Life Sciences.2023;[Epub]     CrossRef
  • Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease
    Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2023; 21(2): 358.     CrossRef
  • Non-Invasive Liver Fibrosis Scores Are Associated With Contrast-Associated Acute Kidney Injury in Patients Undergoing Elective Percutaneous Coronary Intervention
    Hao-Ming He, Chen He, Zhe-Bin You, Si-Cheng Zhang, Xue-Qin Lin, Man-Qing Luo, Mao-Qing Lin, Li-Wei Zhang, Kai-Yang Lin, Yan-Song Guo
    Angiology.2023; 74(4): 333.     CrossRef
  • Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome
    Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak
    Clinical Gastroenterology and Hepatology.2023; 21(7): 1873.     CrossRef
  • The association of non‐alcoholic fatty liver disease between parents and adolescent children
    Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak
    Alimentary Pharmacology & Therapeutics.2023; 57(2): 245.     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Reply
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
    Clinical Gastroenterology and Hepatology.2023; 21(9): 2435.     CrossRef
  • Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma
    Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults
    Sun Young Shim, Sun Jae Jung, Seung Up Kim, Hyeon Chang Kim
    Clinical Hypertension.2023;[Epub]     CrossRef
  • Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
    Won Sohn, Yong-Han Paik
    Clinical and Molecular Hepatology.2023; 29(1): 182.     CrossRef
  • Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 185.     CrossRef
  • Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
    Seung Min Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(1): 171.     CrossRef
  • Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 179.     CrossRef
  • Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection
    Jungnam Lee, Jong-In Chang, Young-Joo Jin, Jeong-Hoon Lee, Ju Yeon Kim, Dong Hyun Sinn, Soon Sun Kim, Hyun Woong Lee, Sun Hong Yoo, Jung Hwan Yu, Jin-Woo Lee
    European Journal of Gastroenterology & Hepatology.2023; 35(4): 431.     CrossRef
  • Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease
    Kenneth W. Chow, Pragyat Futela, Aryan Saharan, Sammy Saab
    Journal of Clinical and Experimental Hepatology.2023; 13(5): 783.     CrossRef
  • Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Min-Kyu Kang, Min-Cheol Kim
    Medicina.2023; 59(2): 375.     CrossRef
  • The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
    George Chen, Bubu Banini, Albert Do, Joseph K. Lim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S319.     CrossRef
  • Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(Suppl): S220.     CrossRef
  • Global incidence and prevalence of nonalcoholic fatty liver disease
    Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
    Clinical and Molecular Hepatology.2023; 29(Suppl): S32.     CrossRef
  • Non-alcoholic fatty liver disease: the pathologist’s perspective
    Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S302.     CrossRef
  • Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
    Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee
    Biomedicine & Pharmacotherapy.2023; 161: 114445.     CrossRef
  • Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease
    Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeong
    Scientific Reports.2023;[Epub]     CrossRef
  • Screening strategy for non-alcoholic fatty liver disease
    Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
    Clinical and Molecular Hepatology.2023; 29(Suppl): S103.     CrossRef
  • Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
    Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
    Clinical and Molecular Hepatology.2023; 29(Suppl): S157.     CrossRef
  • Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification
    Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim
    Metabolites.2023; 13(3): 444.     CrossRef
  • Nonalcoholic fatty liver disease and non-liver comorbidities
    Richie Manikat, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2023; 29(Suppl): s86.     CrossRef
  • Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
    Peter Konyn, Aijaz Ahmed, Donghee Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S43.     CrossRef
  • Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
    Jihyun An, Joo Hyun Sohn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S268.     CrossRef
  • Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
    Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S150.     CrossRef
  • Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
    Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
    Clinical and Molecular Hepatology.2023; 29(Suppl): S123.     CrossRef
  • Comparison between obese and non-obese nonalcoholic fatty liver disease
    Wah-Kheong Chan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S58.     CrossRef
  • Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
    Jung Hwan Yu, Han Ah Lee, Seung Up Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S136.     CrossRef
  • Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
    Georg Semmler, Christian Datz, Michael Trauner
    Clinical and Molecular Hepatology.2023; 29(Suppl): S244.     CrossRef
  • Non-alcoholic fatty liver disease: Definition and subtypes
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S5.     CrossRef
  • The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
    Hyunwoo Oh, Won Sohn, Yong Kyun Cho
    Clinical and Molecular Hepatology.2023; 29(Suppl): S261.     CrossRef
  • Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
    Yi-wen Shi, Jian-Gao Fan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S228.     CrossRef
  • Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management
    Anja Geerts, Sander Lefere
    Clinical and Molecular Hepatology.2023; 29(Suppl): S276.     CrossRef
  • Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
    Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
    Clinical and Molecular Hepatology.2023; 29(Suppl): S286.     CrossRef
  • CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease
    Ha Neul Kim, Hong Jae Jeon, Hei Gwon Choi, In Sun Kwon, Woo Sun Rou, Jeong Eun Lee, Tae Hee Lee, Seok Hyun Kim, Byung Seok Lee, Kyung Sook Shin, Hyun Jung Lee, Hyuk Soo Eun
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis?
    Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee
    Ultrasonography.2023; 42(2): 227.     CrossRef
  • The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
    Young-Joo Jin
    Clinical and Molecular Hepatology.2023; 29(2): 414.     CrossRef
  • Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
    Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
    Clinical and Molecular Hepatology.2023; 29(2): 404.     CrossRef
  • The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
    Ji-Won Park, Ki Tae Suk
    Clinical and Molecular Hepatology.2023; 29(2): 408.     CrossRef
  • Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
    Philipp Kasper, Münevver Demir, Hans-Michael Steffen
    Clinical and Molecular Hepatology.2023; 29(2): 390.     CrossRef
  • Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
    Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
    Clinical and Molecular Hepatology.2023; 29(2): 433.     CrossRef
  • The growing burden of non-alcoholic fatty liver disease on mortality
    Ju-Yeon Cho, Won Sohn
    Clinical and Molecular Hepatology.2023; 29(2): 374.     CrossRef
  • Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease
    Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Loomba, Soo Young Park, Jung Gil Park
    Hepatology International.2023; 17(3): 626.     CrossRef
  • Genetic association study identifies genetic variants for non-alcoholic fatty liver without comorbidities in the Korean population
    Yeon Jun Kim, Yoon Shin Cho
    Genes & Genomics.2023; 45(7): 847.     CrossRef
  • Association between the fatty liver index and the risk of fracture among individuals over the age of 50 years: a nationwide population-based study
    Goh Eun Chung, Eun Ju Cho, Min Joo Kim, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
    Han Ah Lee, Hwi Young Kim
    International Journal of Molecular Sciences.2023; 24(11): 9324.     CrossRef
  • Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD
    Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jee Won Chai, Myoung Seok Lee, Si Won Jang, Young Ho So, Jeong Hwan Park, Mee Soo Chang, Won Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(3): 322.     CrossRef
  • Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
    Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
    Alimentary Pharmacology & Therapeutics.2023; 58(2): 229.     CrossRef
  • Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
    Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
    JHEP Reports.2023; 5(9): 100810.     CrossRef
  • Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD
    Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee
    Ultrasonography.2023; 42(3): 421.     CrossRef
  • Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
    Mona Mohamed Ibrahim Abdalla
    World Journal of Gastroenterology.2023; 29(27): 4271.     CrossRef
  • Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
    Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong
    Gut and Liver.2023; 17(4): 610.     CrossRef
  • The correlation between NAFLD and serum uric acid to serum creatinine ratio
    Jangwon Choi, Hyun Joe, Jung-Eun Oh, Yong-Jin Cho, Hwang-Sik Shin, Nam Hun Heo, Gulali Aktas
    PLOS ONE.2023; 18(7): e0288666.     CrossRef
  • Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B
    Cheol‐Hyung Lee, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon
    Alimentary Pharmacology & Therapeutics.2023; 58(7): 704.     CrossRef
  • Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
    Ho Soo Chun
    Gut and Liver.2023; 17(4): 485.     CrossRef
  • KASL clinical practice guidelines for management of autoimmune hepatitis 2022

    Clinical and Molecular Hepatology.2023; 29(3): 542.     CrossRef
  • Comments on Relationship between the High Fatty Liver Index and Risk of Fracture: Reply
    Min-Ji Kim, Jae-Hyung Roh, Jae-Han Jeon
    Gut and Liver.2023; 17(4): 663.     CrossRef
  • Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid
    PLOS ONE.2023; 18(7): e0288820.     CrossRef
  • Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial
    Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim
    Trials.2023;[Epub]     CrossRef
  • Associations of Serum Uric Acid Level With Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Liver Fibrosis in Korean Men and Women: A Cross-Sectional Study Using Nationally Representative Data
    Jun Myong Lee, Hye Won Kim, So Young Heo, Kyung Yi Do, Jun Deok Lee, Seul Ki Han, Soon Koo Baik, Moon Young Kim, Sei-Jin Chang
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Statins for treatment of fatty liver disease: Recent advances
    Xiao-Hui Fang, Cai-E Wang, Jiao Deng, Xing-Shun Qi
    World Chinese Journal of Digestology.2023; 31(16): 659.     CrossRef
  • MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
    Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2023; 38(9): 1598.     CrossRef
  • The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients
    Magdi A. Ali, Eman El-Abd, Mohamed Morsi, Mohamed M. El Safwany, Mohamed Z. El-Sayed
    European Journal of Hybrid Imaging.2023;[Epub]     CrossRef
  • Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
    Gi-Ae Kim, Joon Ho Moon, Won Kim
    Clinical and Molecular Hepatology.2023; 29(4): 831.     CrossRef
  • Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea
    Yuri Cho, SeongBeom Park, SeonYoung Park, WonJung Choi, Book Kim, Helin Han
    Infectious Diseases and Therapy.2023; 12(10): 2387.     CrossRef
  • Association between waist circumference trajectories and incident non-alcoholic fatty liver disease
    Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon
    Obesity Research & Clinical Practice.2023; 17(5): 398.     CrossRef
  • Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention
    Tianyu Mao, Yiwen Sun, Xinyi Xu, Kang He
    Hepatology Communications.2023;[Epub]     CrossRef
  • Approach to Fatty Liver Disease in Patients with Type 2 Diabetes
    Ji Cheol Bae
    The Journal of Korean Diabetes.2023; 24(3): 107.     CrossRef
  • Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating l-arginine production
    Dong Yun Kim, Jun Yong Park, Heon Yung Gee
    Experimental & Molecular Medicine.2023; 55(11): 2332.     CrossRef
  • Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
    Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera
    Hepatology.2023; 78(6): 1858.     CrossRef
  • Association between total body muscle percentage and prevalence of non-alcoholic fatty liver disease in Korean adults findings from an 18-year follow-up: a prospective cohort study
    Byoung Chan Ahn, Chul Yong Park, Jung Hee Hong, Ki Ook Baek
    Journal of Yeungnam Medical Science.2023; 40(Suppl): S47.     CrossRef
  • The Association of Perfluoroalkyl Substance Exposure and a Serum Liver Function Marker in Korean Adults
    Jisuk Yun, Soon-Chan Kwon
    Toxics.2023; 11(12): 965.     CrossRef
  • Alcohol consumption and the risk of liver disease: a nationwide, population-based study
    Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity
    T.S. Krolevets, M.I. Syrovenko, M.A. Livzan
    Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43.     CrossRef
  • Association of Hepatic Fat Deposition and Severity of Acanthosis Nigricans in Children and Adolescents with Obesity
    Junhyung Lee, Hye-ji An, Young-Gyun Seo, Hong Ji Song, Hye-Mi Noh, Yu-Jin Paek, Kyung Hee Park
    Korean Journal of Family Practice.2023; 13(4): 240.     CrossRef
  • Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease
    Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Diabetologia.2022; 65(3): 518.     CrossRef
  • Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study
    Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon
    Diabetes Research and Clinical Practice.2022; 184: 109208.     CrossRef
  • Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious
    Suprabhat Giri, Harish Darak, Sunil Kasturi
    Digestive Diseases and Sciences.2022; 67(10): 4962.     CrossRef
  • Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
    Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do
    Biomedicines.2022; 10(3): 550.     CrossRef
  • Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis
    Heejoon Jang, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Joon Yeul Nam, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon
    Hepatology.2022; 76(2): 492.     CrossRef
  • The Phase 2 Study to Evaluate Efficacy and Safety of Lanifibranor in Patients with Nonalcoholic Steatohepatitis: Back in the Spotlight?
    Sae Hwan Lee
    The Korean Journal of Gastroenterology.2022; 79(3): 138.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study
    Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim
    Diabetes & Metabolism.2022; 48(4): 101344.     CrossRef
  • MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
    Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
    Clinical and Molecular Hepatology.2022; 28(2): 150.     CrossRef
  • PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
    Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, Jean-François Dufour
    International Journal of Molecular Sciences.2022; 23(8): 4305.     CrossRef
  • Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study
    Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae
    Clinical and Molecular Hepatology.2022; 28(2): 196.     CrossRef
  • Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
    Youn Huh, Yoon Jeong Cho, Ga Eun Nam
    Journal of Obesity & Metabolic Syndrome.2022; 31(1): 17.     CrossRef
  • Gamma‐glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non‐alcoholic fatty liver disease
    Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1624.     CrossRef
  • The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study
    Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease
    Jun-Hyeon Byeon, Min-Kyu Kang, Min-Cheol Kim
    Healthcare.2022; 10(5): 850.     CrossRef
  • Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease
    Kwang Seob Lee, Yongin Cho, Hongkyung Kim, Hyunkyeong Hwang, Jin Won Cho, Yong-ho Lee, Sang-Guk Lee
    Biomedicines.2022; 10(6): 1216.     CrossRef
  • Risk of liver fibrosis in patients with prediabetes and diabetes mellitus
    Jongsin Park, Heon-Ju Kwon, Won Sohn, Ju-Yeon Cho, Soo Jin Park, Yoosoo Chang, Seungho Ryu, Byung Ik Kim, Yong Kyun Cho, Chen-Hua Liu
    PLOS ONE.2022; 17(6): e0269070.     CrossRef
  • Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study
    Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim
    Diabetes & Metabolism.2022; 48(5): 101362.     CrossRef
  • Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study
    Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak
    Hepatology.2022; 76(6): 1746.     CrossRef
  • Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective
    Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo
    Annals of Surgical Treatment and Research.2022; 102(6): 353.     CrossRef
  • A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia
    Eujin Kim, Cho-Hyun Hwang, Juyoung Lee, Eungyeong Jang, Youngchul Kim, Jang-Hoon Lee
    The Journal of Internal Korean Medicine.2022; 43(2): 184.     CrossRef
  • Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study
    Wenting Wang, Jianping Ren, Wenzhao Zhou, Jinyu Huang, Guomin Wu, Fenfang Yang, Shuang Yuan, Juan Fang, Jing Liu, Yao Jin, Haiyang Qi, Yuyang Miao, Yanna Le, Cenhong Ge, Xiantao Qiu, JinJing Wang, Ping Huang, Zixin Liu, Sheng Wang
    Scientific Reports.2022;[Epub]     CrossRef
  • Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease in the General Population: A Cross-Sectional Study Using Nationally Representative Data
    Taeyun Kim, Hyunji Choi, Jaejun Lee, Jehun Kim
    International Journal of Environmental Research and Public Health.2022; 19(14): 8398.     CrossRef
  • Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
    Jung Il Lee
    Gut and Liver.2022; 16(4): 497.     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database
    Hankil Lee, Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2022; 37(11): 2154.     CrossRef
  • Reply
    Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum‐Youn Gwak
    Hepatology.2022; 76(6): E121.     CrossRef
  • Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
    Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N
    Journal of Hepatology.2022; 77(6): 1482.     CrossRef
  • Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease
    Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim
    Abdominal Radiology.2022; 47(11): 3733.     CrossRef
  • Fatty Liver Change in Korean Adults in a Systematic Social Distancing System Amid the COVID-19 Pandemic: A Multicenter Analysis
    Ji-Hee Haam, Yang-Im Hur, Young-Sang Kim, Kyoung-Kon Kim, Jee-Hyun Kang, Hae-Jin Ko, Yoon Jeong Cho, Hye-In Choi, Kyu Rae Lee, Jung Ha Park, Soo Hyun Cho, Jong-Koo Kim, Taesic Lee, Myung-Jae Seo, Yeong Sook Yoon, Yoobin Seo, Ga Eun Nam, Sun Hyun Kim
    International Journal of Environmental Research and Public Health.2022; 19(16): 10444.     CrossRef
  • Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Liu Han, Shifeng Fu, Jianglei Li, Deliang Liu, Yuyong Tan
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study
    Kiseok Kim, Yong-Jin Lee, Soon-Chan Kwon, Young-Sun Min, Hyun Kyo Lee, Gwangin Baek, Sang Hyeon Kim, Eun-Chul Jang
    Annals of Occupational and Environmental Medicine.2022;[Epub]     CrossRef
  • Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease
    Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease
    Jin Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Healthcare.2022; 10(11): 2268.     CrossRef
  • Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes
    Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung
    Biomedicine & Pharmacotherapy.2022; 156: 113952.     CrossRef
  • Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Sangsoo Han, Miyoung Choi, Bora Lee, Hye-Won Lee, Seong Hee Kang, Yuri Cho, Sang Bong Ahn, Do Seon Song, Dae Won Jun, Jieun Lee, Jeong-Ju Yoo
    Gut and Liver.2022; 16(6): 952.     CrossRef
  • The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2022; 28(4): 814.     CrossRef
  • Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations
    Soon Sun Kim, Jae Youn Cheong
    Clinical and Molecular Hepatology.2022; 28(4): 802.     CrossRef
  • Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease
    Sun Young Kim, Subin Mun, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Sang-Heon Cho, Jin-Woo Lee
    Medicine.2022; 101(37): e30527.     CrossRef
  • A Review of Research Trends in Traditional Korean Medicine for Nonalcoholic Fatty Liver Disease
    Na-yeon Kim, Mi-jung Yoon, Hong-sik Choi, Seung-mo Kim, Sang-chan Kim, Kyung-soon Kim
    The Journal of Internal Korean Medicine.2022; 43(4): 680.     CrossRef
  • Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies
    Seogsong Jeong, Won Kim, Sang Min Park
    Clinical and Molecular Hepatology.2022; 28(4): 933.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
    Pengyu Yao, Yajuan Liu
    Molecules.2022; 28(1): 272.     CrossRef
  • The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review
    Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley
    Current Oncology.2022; 30(1): 48.     CrossRef
  • Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Korean Patients Undergoing Bariatric Surgery
    Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo
    Journal of Metabolic and Bariatric Surgery.2022; 11(2): 63.     CrossRef
  • Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
    Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung
    Diagnostics.2021; 11(12): 2233.     CrossRef
  • Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus
    Kiyoung Lim, Minkyu Kang, Junggil Park
    Nutrients.2021; 13(10): 3400.     CrossRef
  • Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression
    Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila
    PLOS ONE.2021; 16(8): e0255822.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial
    Won Myung Lee, Jea Hurn Bae, Young Chang, Sae Hwan Lee, Ji Eun Moon, Soung Won Jeong, Jae Young Jang, Sang Gyune Kim, Hong Soo Kim, Jeong-Ju Yoo, Young Seok Kim
    Nutrients.2021; 13(12): 4453.     CrossRef
  • Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
    Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim
    Cancers.2021; 13(18): 4567.     CrossRef
  • 32,514 View
  • 1,305 Download
  • 197 Web of Science
  • Crossref

Original Article

Viral hepatitis

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um
Clin Mol Hepatol 2021;27(2):346-359.
Published online January 25, 2021
DOI: https://doi.org/10.3350/cmh.2020.0307
Background/Aims
Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety. This extension study evaluated the prolonged efficacy and safety of BSV in treatment-naive chronic hepatitis B patients.
Methods
Patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of BSV and TDF treatment. The antiviral efficacy and drug safety was evaluated up to 192 weeks in two groups: patients continuing BSV treatment (BSV-BSV) and patients switching from TDF to BSV after 48 weeks (TDF-BSV).
Results
Among 197 patients receiving randomized treatments, 170 (86%) entered the open-label phase and 152 (77%) entered the 192-week extension study. Virological response rates over 192 weeks were 92.50% and 93.06% in the BSV-BSV and TDF-BSV groups, respectively (P=0.90). Hepatitis B envelop antigen seroconversion and alanine aminotransferase normalization rates were similar between the groups (P=0.75 and P=0.36, respectively). There were no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group.
Conclusions
BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Trial Registration Number: NCT01937806 (date: 10 Sep 2013).

Citations

Citations to this article as recorded by  Crossref logo
  • Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
    Hyuk Kim, Jae-Young Kim, Yoon E. Shin, Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
    Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Wo
    Clinical and Molecular Hepatology.2025; 31(3): 810.     CrossRef
  • Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”
    Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
    Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients: Insights From a Nationwide Cohort Study
    Hyun Bin Choi, Jae Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Journal of Korean Medical Science.2025;[Epub]     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
    Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
  • Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis
    Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
    Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623.     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient
    Jong Chul Kim, Hye Young Lee, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Juhee Won, Soree Park, Na Yeon Kim, Jae Jin Shin, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo, Kyun-Hwan Kim
    Biomedicines.2022; 10(2): 282.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir
    Juhee Won, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Jong Chul Kim, Soree Park, Nayeon Kim, Byengjune Jae, Kyun-Hwan Kim
    Biomedicines.2022; 10(7): 1637.     CrossRef
  • Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B
    Jeong Eun Song, Jun Yong Park
    Expert Opinion on Pharmacotherapy.2021; 22(18): 2427.     CrossRef
  • Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
    Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
    Clinical and Molecular Hepatology.2021; 27(3): 402.     CrossRef
  • 10,174 View
  • 268 Download
  • 16 Web of Science
  • Crossref

Editorials

Hepatic neoplasm

Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma
Jun Won Kim, Ik Jae Lee
Clin Mol Hepatol 2021;27(1):103-106.
Published online December 14, 2020
DOI: https://doi.org/10.3350/cmh.2020.0297

Citations

Citations to this article as recorded by  Crossref logo
  • Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles
    Chou-Yi Hsu, Mohammed Ahmed Mustafa, Ashwani Kumar, Atreyi Pramanik, Rajiv Sharma, Faraj Mohammed, Israa Abed Jawad, Imad Jasim Mohammed, Mohammad Y. Alshahrani, Noor Alhuda Mohammad Ali khalil, Ali Turki Shnishil, Munther Kadhim Abosaoda
    Pathology - Research and Practice.2024; 256: 155266.     CrossRef
  • 7,327 View
  • 110 Download
  • 1 Web of Science
  • Crossref

Viral hepatitis

Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.
Won Kim
Clin Mol Hepatol 2019;25(1):40-41.
Published online December 28, 2018
DOI: https://doi.org/10.3350/cmh.2018.0101

Citations

Citations to this article as recorded by  Crossref logo
  • Reply to: “Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction”
    Beom Kyung Kim
    Journal of Hepatology.2019; 71(4): 847.     CrossRef
  • 9,730 View
  • 111 Download
  • 1 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Prognostic implications of trunk muscle mass in liver cirrhosis
Jimin Han, Won Kim
Clin Mol Hepatol 2018;24(3):297-298.
Published online September 10, 2018
DOI: https://doi.org/10.3350/cmh.2018.0069

Citations

Citations to this article as recorded by  Crossref logo
  • Relationship Between Body Mass Index and Low Skeletal Muscle Mass in Adults Based on NHANES 2011–2018
    Rong-Zhen Xie, Xu-Song Li, Fang-Di Zha, Guo-Qing Li, Wei-Qiang Zhao, Yu-Feng Liang, Jie-Feng Huang
    Scientific Reports.2025;[Epub]     CrossRef
  • Predictors of Sarcopenia in an Obese Asian Population
    Min Je Sung, Jun Yong Park, Hye Won Lee, Beom Kyung Kim, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Nutrition and Cancer.2022; 74(2): 505.     CrossRef
  • Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
    Takumi Kawaguchi, Takuji Torimura
    Clinical and Molecular Hepatology.2022; 28(2): 177.     CrossRef
  • Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
    Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song
    Clinical and Molecular Hepatology.2022; 28(2): 219.     CrossRef
  • Glucocorticoid therapy is a risk factor for cardiovascular diseases
    I. S. Dzherieva, N. I. Volkova, I. Y. Davidenko, I. B. Reshetnikov, S. S. Brovkina, S. M. Avakova, Y. V. Tishchenko
    Medical Herald of the South of Russia.2022; 13(3): 93.     CrossRef
  • Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis
    Yasir Al-Azzawi, Betty Albo, Matthew Fasullo, Jennifer Coukos, George J. Watts, Ryan Tai, David Radcliffe, Aimee Kroll-Desrosiers, Deepika Devuni, Gyongyi Szabo
    European Journal of Gastroenterology & Hepatology.2020; 32(6): 733.     CrossRef
  • Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study
    Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Gi Soo Youn, Tae Suk Kim, Baek Gyu Jun, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi, Ki Tae Suk
    Cancers.2020; 12(11): 3347.     CrossRef
  • 8,322 View
  • 114 Download
  • 5 Web of Science
  • Crossref

Review

Steatotic liver disease

Recent research trends and updates on nonalcoholic fatty liver disease
Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn, On behalf of the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG)
Clin Mol Hepatol 2019;25(1):1-11.
Published online August 8, 2018
DOI: https://doi.org/10.3350/cmh.2018.0037
Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of end-stage liver disease and cardiometabolic disease, resulting in liver-related and non-liver–related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease
    Michelle Thuy Nguyen, Andrew Lian, Frederick Timothy Guilford, Vishwanath Venketaraman
    Biomedicines.2025; 13(3): 644.     CrossRef
  • Impact of sleeve gastrectomy on the course of metabolic associated fatty liver disease
    Ragaey Ahmad Eid, Dina Attia, Asmaa Srour Soliman, Eman Ahmed Abd Elmaogod, Eman Mohammed AbdelSalam, Ahmed Mohamed Rashad, Ahmed Safaa Ahmed Sayed, Tamer Mohamed Nabil
    Indian Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yoon-su Ha, Won Kim, Seung-Jin Kim
    Clinical and Molecular Hepatology.2025; 31(2): e226.     CrossRef
  • Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
    Clinical and Molecular Hepatology.2025; 31(2): e186.     CrossRef
  • Impact of the FIB4 Index on Pre-sarcopenia in Patients with Metabolic-dysfunction Associated Steatotic Liver Disease
    Hiroki Nishikawa, Tomohiro Nishikawa, Akira Fukuda, Kosuke Ushiro, Masahiro Matsui, Saori Onishi, Soo Ki Kim, Akira Asai
    Internal Medicine.2025; 64(21): 3078.     CrossRef
  • Clinical characteristics of lean and non-lean non-alcoholic fatty liver disease: a cross-sectional study
    Mengyan Xu, Rui Gong, Jiao Xie, Sanping Xu, Shi Wang
    Nutrition & Metabolism.2025;[Epub]     CrossRef
  • Liver involvement in Gaucher disease in children: A literature review and clinical observations
    G.V. Volynets, G.B. Movsisyan, A.S. Potapov, A.I. Khavkin, A.V. Nikitin, T.A. Skvortsova, E.A. Morozova, V.M. Rogozhina
    Russian Journal of Evidence-Based Gastroenterology.2025; 14(2): 78.     CrossRef
  • PNPLA3-Ile148Met and TM6SF2-Glu167Lys increase susceptibility to metabolic dysfunction-associated steatotic liver disease in children
    Hengpan Yao, Zhiyi Xia, Yijing Liu, MengJun Dong, Kairui Yang, Fang Zhou
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities, and Management of Non-alcoholic Fatty Liver Disorder
    Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin
    Current Drug Therapy.2024; 19(1): 20.     CrossRef
  • Extracellular Vesicles as Delivery Vehicles for Non-Coding RNAs: Potential Biomarkers for Chronic Liver Diseases
    Arianna Ferro, Gabriele Saccu, Simone Mattivi, Andrea Gaido, Maria Beatriz Herrera Sanchez, Shafiul Haque, Lorenzo Silengo, Fiorella Altruda, Marilena Durazzo, Sharmila Fagoonee
    Biomolecules.2024; 14(3): 277.     CrossRef
  • Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population
    Joo Hyun Oh, Dae Won Jun
    Gut and Liver.2024; 18(2): 197.     CrossRef
  • Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
    Francesca Terracciani, Andrea Falcomatà, Paolo Gallo, Antonio Picardi, Umberto Vespasiani-Gentilucci
    Journal of Physiology and Biochemistry.2023; 79(4): 851.     CrossRef
  • Impact of thyroid cancer on the cancer risk in patients with non-alcoholic fatty liver disease or dyslipidemia
    Joon Ho, Eunhwa Kim, Myeongjee Lee, Inkyung Jung, Young Suk Jo, Jandee Lee
    Scientific Reports.2023;[Epub]     CrossRef
  • Global incidence and prevalence of nonalcoholic fatty liver disease
    Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah
    Clinical and Molecular Hepatology.2023; 29(Suppl): S32.     CrossRef
  • Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria
    Jie Pan, Yijie Ding, Yan Sun, Qiuyan Li, Tianyi Wei, Yingying Gu, Yujia Zhou, Nengzhi Pang, Lei Pei, Sixi Ma, Mengqi Gao, Ying Xiao, De Hu, Feilong Wu, Lili Yang
    Journal of Clinical Medicine.2023; 12(6): 2126.     CrossRef
  • Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
    Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S150.     CrossRef
  • Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus
    Qian Gao, Lei Feng, Weiling Zhou, Xiaoli Li, Lanzi Yin, Yuan Wang
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2345.     CrossRef
  • Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
    Mah I Kan Changez, Maryam Mubeen, Monezahe Zehra, Inara Samnani, Aniqa Abdul Rasool, Anmol Mohan, Um Ul Wara, Usha Tejwaney, Vikash Kumar
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Association between PNPLA3 and TM6SF2 gene polymorphisms and non-alcoholic fatty liver disease patients in Kazakhstan
    Ainura Amirkulova, Gulmira Derbissalina, Valeriy Benberin, Nasrulla Shanazarov, Gulshara Abildinova, Doskhan Kozhakhmet, Helena Katchman
    Electronic Journal of General Medicine.2023; 20(6): em546.     CrossRef
  • The empirical dietary inflammatory pattern score and the risk of nonalcoholic fatty liver disease and cirrhosis
    Maryam K. Ibrahim, Robert M. Wilechansky, Prasanna K. Challa, Xuehong Zhang, Edward Giovannucci, Meir Stampfer, Andrew T. Chan, Tracey G. Simon
    Hepatology Communications.2023;[Epub]     CrossRef
  • Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease
    Apostolis PAPAEFTHYMIOU, Michael DOULBERIS, Kyriaki KARAFYLLIDOU, Eleftherios CHATZIMICHAEL, Georgia DERETZI, Aristomenis K. EXADAKTYLOS, Fotios SAMPSONAS, Athanasios GELASAKIS, Spyros I. PAPAMICHOS, Georgios KOTRONIS, Dimitra GIALAMPRINOU, Elisabeth VARD
    Minerva Endocrinology.2023;[Epub]     CrossRef
  • The experience of the "Nicolae Malaxa" Clinical Hospital Bucharest, 2021-2022: non-alcoholic hepatic steatosis – etiological and risk profile
    Gabriela-Carmen Obilişteanu, Alexandru-Mihai Ştefănescu, Florin-Mihai Lungana, Nicolae Runcanu
    Medic.ro.2023; 5(155): 8.     CrossRef
  • Molecular Docking Study of Phytosterols in Lygodium microphyllum Towards SIRT1 and AMPK, the in vitro Brine Shrimp Toxicity Test, and the Phenols and Sterols Levels in the Extract
    Putri Anggreini, Hadi Kuncoro, Sri Sumiwi, Jutti Levita
    Journal of Experimental Pharmacology.2023; Volume 15: 513.     CrossRef
  • Both full length‐cholesteryl ester transfer protein and exon 9‐deleted cholesteryl ester transfer protein promote triacylglycerol storage in cultured hepatocytes
    Yan Liu, Daniel Mihna, Lahoucine Izem, Richard E. Morton
    Lipids.2022; 57(1): 69.     CrossRef
  • Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis
    Mi Na Kim, Chun-Han Lo, Kathleen E. Corey, Xiao Luo, Lu Long, Xuehong Zhang, Andrew T. Chan, Tracey G. Simon
    Clinical Nutrition.2022; 41(2): 356.     CrossRef
  • Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease
    Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Diabetologia.2022; 65(3): 518.     CrossRef
  • Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma
    Mizelle D'Silva, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim
    Surgical Oncology.2022; 41: 101730.     CrossRef
  • MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease
    Young-Sun Lee, Ji Eun Lee, Hyon-Seung Yi, Young Kul Jung, Dae Won Jun, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Baek-hui Kim, Jeong Woo Kim, Chang Hee Lee, Jong Eun Yeon, Juneyoung Lee, Soon Ho Um, Kwan Soo Byun
    Hepatology International.2022; 16(2): 316.     CrossRef
  • DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES)
    Young Kyung Ko, Hayeon Kim, Yoonseok Lee, Young-Sun Lee, Jeong-An Gim
    Current Issues in Molecular Biology.2022; 44(3): 1149.     CrossRef
  • Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
    Yuna Kim, Eugene Han, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Mi Kyung Kim, Hye Soon Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee, Seung Up Kim
    Gut and Liver.2022; 16(2): 290.     CrossRef
  • Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study
    Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim
    Diabetes & Metabolism.2022; 48(5): 101362.     CrossRef
  • Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes
    Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung
    Biomedicine & Pharmacotherapy.2022; 156: 113952.     CrossRef
  • Environmental exposure to organophosphate esters and suspected non-alcoholic fatty liver disease among US adults: A mixture analysis
    Haisheng Chai, Weiye Hu, Yaoyao Dai, Xiaohan Zhu, Ping'an Qian, Junfeng Zhu
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • A Nomogram Based on Preoperative Lab Tests, BMI, ICG-R15, and EHBF for the Prediction of Post-Hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma
    Deyao Zhang, Yangxun Pan, Zhenyun Yang, Huilan Zeng, Xin Wang, Jinbin Chen, Juncheng Wang, Yaojun Zhang, Zhongguo Zhou, Minshan Chen, Dandan Hu
    Journal of Clinical Medicine.2022; 12(1): 324.     CrossRef
  • Association between depression and nonalcoholic fatty liver disease: Contributions of insulin resistance and inflammation
    Ju Won Lee, Seung Ha Park
    Journal of Affective Disorders.2021; 278: 259.     CrossRef
  • Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years
    Hye Won Lee, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Diabetes and its Complications.2021; 35(1): 107747.     CrossRef
  • Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
    Gwyneth Soon, Aileen Wee
    Clinical and Molecular Hepatology.2021; 27(1): 44.     CrossRef
  • Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes
    Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Young Dae Kim, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2021; 36(6): 1703.     CrossRef
  • From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
    Clinical and Molecular Hepatology.2021; 27(2): 257.     CrossRef
  • Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease
    Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan, Seong Gyu Hwang
    Scientific Reports.2021;[Epub]     CrossRef
  • Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
    Jin Won Chang, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Gut and Liver.2021; 15(1): 117.     CrossRef
  • Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
    Kwang Min Kim, Ji-Hye Roh, Sangjin Lee, Jeong-Hyun Yoon
    Scientific Reports.2021;[Epub]     CrossRef
  • Nonalcoholic Fatty Liver Disease: A Global Perspective
    Wei-Kei Wong, Wah-Kheong Chan
    Clinical Therapeutics.2021; 43(3): 473.     CrossRef
  • Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver
    Min-Kyu Kang, Jung-Hun Baek, Young-Oh Kweon, Won-Young Tak, Se-Young Jang, Yu-Rim Lee, Keun Hur, Gyeonghwa Kim, Hye-Won Lee, Man-Hoon Han, Joon-Hyuk Choi, Soo-Young Park, Jung-Gil Park
    Diagnostics.2021; 11(6): 1061.     CrossRef
  • Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
    Tae Hyung Kim, Yoonseok Lee, Young-Sun Lee, Jeong-An Gim, Eunjung Ko, Sun Young Yim, Young Kul Jung, SeongHee Kang, Moon Young Kim, Hayeon Kim, Baek-hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun
    Scientific Reports.2021;[Epub]     CrossRef
  • Inhaled exposure to air fresheners aggravated liver injury in a murine model of nonalcoholic fatty acid liver disease
    Sanghwa Kim, Ah Young Lee, Myung-Haing Cho
    Heliyon.2021; 7(3): e06452.     CrossRef
  • Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease
    Min-Kyu Kang, Jung-Gil Park
    Diagnostics.2021; 11(5): 854.     CrossRef
  • Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease
    Hee Kyung Shin, Jeong Hwan Park, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee, Won Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Metabolic disease as a risk of hepatocellular carcinoma
    Naoshi Nishida
    Clinical and Molecular Hepatology.2021; 27(1): 87.     CrossRef
  • Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression
    Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila
    PLOS ONE.2021; 16(8): e0255822.     CrossRef
  • Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non‐alcoholic fatty liver disease
    Jung Gil Park, Jinho Jung, Kritin K. Verma, Min Kyu Kang, Egbert Madamba, Scarlett Lopez, Aed Qas Yonan, Amy Liu, Ricki Bettencourt, Claude Sirlin, Rohit Loomba
    Alimentary Pharmacology & Therapeutics.2021; 53(9): 1030.     CrossRef
  • Systematic review with meta‐analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma
    Daryl Ramai, Jameel Singh, Janice Lester, Shahab R. Khan, Saurabh Chandan, Nicola Tartaglia, Antonio Ambrosi, Gaetano Serviddio, Antonio Facciorusso
    Alimentary Pharmacology & Therapeutics.2021; 53(9): 977.     CrossRef
  • Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women
    S. H. Park, Y. E. Park, J. Lee, J. H. Choi, N. Y. Heo, J. Park, T. O. Kim, Y. S. Moon, H. K. Kim, H. J. Jang, H. Y. Park, C.-H. Jeong, K. T. Suk, D. J. Kim
    Climacteric.2020; 23(2): 173.     CrossRef
  • Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017
    Seung Ha Park, Lindsay D. Plank, Ki Tae Suk, Yong Eun Park, Jin Lee, Joon Hyuk Choi, Nae Yun Heo, Jongha Park, Tae Oh Kim, Young Soo Moon, Hyun Kuk Kim, Hang Jea Jang, Ha Young Park, Dong Joon Kim
    Clinical and Molecular Hepatology.2020; 26(2): 209.     CrossRef
  • Liver involvement in patients with Gaucher disease types I and III
    Rodrigo Tzovenos Starosta, Filippo Pinto e Vairo, Alícia Dorneles Dornelles, Suélen Porto Basgalupp, Marina Siebert, Maria Lúcia Alves Pedroso, Carlos Thadeu Schmidt Cerski, Mário Reis Álvares-da-Silva, Ida Vanessa Doederlein Schwartz
    Molecular Genetics and Metabolism Reports.2020; 22: 100564.     CrossRef
  • Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators
    Seung Ha Park, Dong Joon Kim, Lindsay D. Plank
    European Journal of Clinical Nutrition.2020; 74(10): 1401.     CrossRef
  • Analysis of the dietary factors associated with suspected pediatric nonalcoholic fatty liver disease and potential liver fibrosis: Korean National Health and Nutrition Examination Survey 2014-2017
    Mi Jin Kim, Kyung Jae Lee
    BMC Pediatrics.2020;[Epub]     CrossRef
  • Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease
    Young-Sun Lee, Yang Jae Yoo, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, In Hee Kim, Soo Yeon Lee, Baek-Hui Kim, Jeong Woo Kim, Chang Hee Lee, Jong Eun Yeon, So Young Kwon, Soon Ho Um, Kwan Soo Byun
    Clinical and Translational Gastroenterology.2020; 11(4): e00157.     CrossRef
  • Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
    Soung Won Jeong
    Clinical and Molecular Hepatology.2020; 26(2): 185.     CrossRef
  • Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?
    Hyuk Soo Eun
    Clinical and Molecular Hepatology.2020; 26(2): 236.     CrossRef
  • Survival Outcomes According to Body Mass Index in Hepatocellular Carcinoma Patient: Analysis of Nationwide Cancer Registry Database
    Boram Cha, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee
    Scientific Reports.2020;[Epub]     CrossRef
  • Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
    Seon Young Ahn, Suk Bae Kim, Il Han Song
    Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1.     CrossRef
  • Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years
    Young Chang, Jun Il Kim, Bora Lee, Sang Gyune Kim, Min Jung Jung, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Jeong-Ju Yoo
    Clinical and Molecular Hepatology.2020; 26(3): 318.     CrossRef
  • Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The Fatty Liver in Obesity study
    Bertha Araceli Marin-Alejandre, Itziar Abete, J. Ignacio Monreal, Mariana Elorz, Alberto Benito-Boillos, José Ignacio Herrero, Iñigo Navarro-Blasco, Josep A. Tur, Narcisa M. Bandarra, M. Angeles Zulet, J. Alfredo Martinez
    Journal of Clinical Lipidology.2020; 14(6): 837.     CrossRef
  • Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
    Min Kyu Kang, Jung Gil Park, Min Cheol Kim
    Yonsei Medical Journal.2020; 61(10): 860.     CrossRef
  • Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis
    Jung Gil Park, Gyeonghwa Kim, Se Young Jang, Yu Rim Lee, Eunhye Lee, Hye Won Lee, Man-Hoon Han, Jae Min Chun, Young Seok Han, Jun Sik Yoon, Min Kyu Kang, Young Oh Kweon, Won Young Tak, Soo Young Park, Keun Hur
    Life.2020; 10(10): 230.     CrossRef
  • Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women
    Mi Na Kim, Chun-Han Lo, Kathleen E. Corey, Po-Hong Liu, Wenjie Ma, Xuehong Zhang, Manol Jovani, Mingyang Song, Andrew T. Chan, Tracey G. Simon
    Metabolism.2020; 113: 154398.     CrossRef
  • Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
    Soung Won Jeong
    Diabetes & Metabolism Journal.2020; 44(5): 640.     CrossRef
  • Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
    Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang
    Digestive Diseases.2020; 38(6): 507.     CrossRef
  • Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2019; 92: 82.     CrossRef
  • Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans
    Kan Chen, Jianbo Ma, Xiaoyuan Jia, Wen Ai, Zhongren Ma, Qiuwei Pan
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2019; 1871(1): 117.     CrossRef
  • Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B
    Beom Kyung Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2019; 50(3): 333.     CrossRef
  • Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study
    Beom Kyung Kim, Do Young Kim, Kwang-Hyub Han, Jinsil Seong, Jung Weon Lee
    PLOS ONE.2019; 14(10): e0223678.     CrossRef
  • The evaluation of complications and mortality in non-alcoholic steatohepatitis-related cirrhosis
    Sezgin VATANSEVER, Zehra Betül PAKÖZ
    Marmara Medical Journal.2019; 32(1): 44.     CrossRef
  • 23,050 View
  • 743 Download
  • 77 Web of Science
  • Crossref

Original Articles

Liver Transplantation

Resection plane-dependent error in computed tomography volumetry of the right hepatic lobe in living liver donors
Heon-Ju Kwon, Kyoung Won Kim, Bohyun Kim, So Yeon Kim, Chul Seung Lee, Jeongjin Lee, Gi Won Song, Sung Gyu Lee
Clin Mol Hepatol 2018;24(1):54-60.
Published online August 1, 2017
DOI: https://doi.org/10.3350/cmh.2017.0023
Background/Aims
Computed tomography (CT) hepatic volumetry is currently accepted as the most reliable method for preoperative estimation of graft weight in living donor liver transplantation (LDLT). However, several factors can cause inaccuracies in CT volumetry compared to real graft weight. The purpose of this study was to determine the frequency and degree of resection plane-dependent error in CT volumetry of the right hepatic lobe in LDLT.
Methods
Forty-six living liver donors underwent CT before donor surgery and on postoperative day 7. Prospective CT volumetry (VP) was measured via the assumptive hepatectomy plane. Retrospective liver volume (VR) was measured using the actual plane by comparing preoperative and postoperative CT. Compared with intraoperatively measured weight (W), errors in percentage (%) VP and VR were evaluated. Plane-dependent error in VP was defined as the absolute difference between VP and VR. % plane-dependent error was defined as follows: |VP–VR|/W∙100.
Results
Mean VP, VR, and W were 761.9 mL, 755.0 mL, and 696.9 g. Mean and % errors in VP were 73.3 mL and 10.7%. Mean error and % error in VR were 64.4 mL and 9.3%. Mean plane-dependent error in VP was 32.4 mL. Mean % plane-dependent error was 4.7%. Plane-dependent error in VP exceeded 10% of W in approximately 10% of the subjects in our study.
Conclusions
There was approximately 5% plane-dependent error in liver VP on CT volumetry. Plane-dependent error in VP exceeded 10% of W in approximately 10% of LDLT donors in our study. This error should be considered, especially when CT volumetry is performed by a less experienced operator who is not well acquainted with the donor hepatectomy plane.

Citations

Citations to this article as recorded by  Crossref logo
  • Radiomics Beyond Radiology: Literature Review on Prediction of Future Liver Remnant Volume and Function Before Hepatic Surgery
    Fabrizio Urraro, Giulia Pacella, Nicoletta Giordano, Salvatore Spiezia, Giovanni Balestrucci, Corrado Caiazzo, Claudio Russo, Salvatore Cappabianca, Gianluca Costa
    Journal of Clinical Medicine.2025; 14(15): 5326.     CrossRef
  • The Effect of Portal Vein Variants on the Margin of Error in Graft Volume Calculation in Living Donor Right Lobe Liver Transplantation
    Feyza Sönmez Topcu, Veysel Ersan, Emrah Şahin, Adem Tunçer, Hasret Ayyıldız Civan, Abuzer Dirican, Bülent Ünal
    Transplantation Proceedings.2025; 57(9): 1773.     CrossRef
  • Optimizing accuracy: a comparative analysis of preoperative liver volumetry in living donor liver transplantation from a surgeon’s perspective – a retrospective cohort study
    EunJin Choi, Seok-Hwan Kim
    International Journal of Surgery.2025; 111(11): 8149.     CrossRef
  • 3-D reconstruction in liver surgery: a systematic review
    Filippo Banchini, Patrizio Capelli, Anis Hasnaoui, Gerardo Palmieri, Andrea Romboli, Mario Giuffrida
    HPB.2024; 26(10): 1205.     CrossRef
  • Fully automated assessment of the future liver remnant in a blood-free setting via CT before major hepatectomy via deep learning
    Tingting Xie, Jingyu Zhou, Xiaodong Zhang, Yaofeng Zhang, Xiaoying Wang, Yongbin Li, Guanxun Cheng
    Insights into Imaging.2024;[Epub]     CrossRef
  • Accuracy of preoperative liver volumetry in living donor liver transplantation—A systematic review and meta-analysis
    Mika S. Buijk, Marcel Dijkshoorn, Roy S. Dwarkasing, Alicia C. Chorley, Robert C. Minnee, Markus U. Boehnert
    Journal of Liver Transplantation.2023; 10: 100150.     CrossRef
  • Prediction of Posthepatectomy Liver Failure with a Combination of Albumin-Bilirubin Score and Liver Resection Percentage
    Kazuhiro Takahashi, Masahiko Gosho, Jaejeong Kim, Osamu Shimomura, Yoshihiro Miyazaki, Kinji Furuya, Yoshimasa Akashi, Tsuyoshi Enomoto, Shinji Hashimoto, Tatsuya Oda
    Journal of the American College of Surgeons.2022; 234(2): 155.     CrossRef
  • CT and MR imaging evaluation of living liver donors
    Federica Vernuccio, Susan A. Whitney, Kadiyala Ravindra, Daniele Marin
    Abdominal Radiology.2021; 46(1): 17.     CrossRef
  • Estimation of the Right Posterior Section Volume in Live Liver Donors: Semiautomated CT Volumetry Using Portal Vein Segmentation
    So Yeong Jeong, Jeongjin Lee, Kyoung Won Kim, Jin Kyoo Jang, Heon-Ju Kwon, Gi Won Song, Sung Gyu Lee
    Academic Radiology.2020; 27(2): 210.     CrossRef
  • Reproducibility and reliability of computed tomography volumetry in estimation of the right‐lobe graft weight in adult‐to‐adult living donor liver transplantation: Cantlie’s line vs portal vein territorialization
    Heon‐Ju Kwon, Kyoung Won Kim, Jin Kyoo Jang, Jeongjin Lee, Gi‐Won Song, Sung‐Gyu Lee
    Journal of Hepato-Biliary-Pancreatic Sciences.2020; 27(8): 541.     CrossRef
  • Liver Graft Volume Estimation by Manual Volumetry and Software-Aided Interactive Volumetry: Which is Better?
    Birkan Bozkurt, Ertan Emek, Turkmen Arikan, Ozgur Ceyhan, Pinar Yazici, Tolga Sahin, Elmar Mammadov, Ayfer Serin, Nagihan Inan Gurcan, Yildiray Yuzer, Yaman Tokat
    Transplantation Proceedings.2019; 51(7): 2387.     CrossRef
  • Clinical implication of hepatic volumetry for living donor liver transplantation
    Woo Kyoung Jeong
    Clinical and Molecular Hepatology.2018; 24(1): 51.     CrossRef
  • MRI in donor candidates for living donor liver transplant: Technical and practical considerations
    Bohyun Kim, So Yeon Kim, Kyoung Won Kim, Hye Young Jang, Jong Keon Jang, Gi Won Song, Sung Gyu Lee
    Journal of Magnetic Resonance Imaging.2018; 48(6): 1453.     CrossRef
  • 12,764 View
  • 184 Download
  • 15 Web of Science
  • Crossref

Liver Transplantation

Influence of ultrasound contrast agents on spectral Doppler analysis in recipients of liver transplantation
Young Seo Cho, Kyoung Won Kim, Hye Young Jang, Bo Hyun Kim, Jeongjin Lee, Gi Won Song, Sung Gyu Lee, Dagvasumberel Munkhbaatar
Clin Mol Hepatol 2017;23(3):224-229.
Published online July 4, 2017
DOI: https://doi.org/10.3350/cmh.2016.0064
Background/Aims
Clinical validation is required to determine whether Doppler measurements are comparable before and after administering ultrasound contrast agent (USCA). The purpose of this study is to explore whether the use of USCA affects spectral Doppler analysis in recipients of liver transplantation (LT).
Methods
For this study, 36 patients were examined using Doppler ultrasonography (US) along with a contrast-enhanced US for surveillance of vascular complications after LT. The following spectral Doppler US parameters were measured before and after administration of USCA: peak systolic velocity, end-diastolic velocity, resistive index, and systolic acceleration time of the graft hepatic artery; peak flow velocity of the graft portal vein; and peak flow velocity and venous pulsatility index of the graft hepatic vein.
Results
The mean peak systolic and end-diastolic velocities of the hepatic artery and the peak flow velocity of the portal and hepatic veins were increased after intravenously administration of the USCA, ranging from 10% to 13%. However, the changes were not statistically significant (P=0.097, 0.103, 0.128, and 0.190, respectively). There were no significant differences in other measured parameters, including the resistive index (P=0.205) and systolic acceleration time (P=0.489) of the hepatic artery and venous pulsatility index (P=0.494) of the hepatic vein.
Conclusions
The measured velocities of graft hepatic vessels tended to increase after administration of USCA, but without statistical significance. The comparison of serial Doppler parameters with or without injection of USCA is valid during Doppler surveillance in recipients of LT.

Citations

Citations to this article as recorded by  Crossref logo
  • Effect of contrast-enhanced ultrasound (CEUS) on liver stiffness measurements obtained by transient and shear-wave elastography
    Stefano KAYALI, Andrea PASTA, Rinaldo PELLICANO, Sharmila FAGOONEE, Elisabetta GIULIANA, Chiara FACCHINI, Simona PILI, Silvia BUCCILLI, Sara LABANCA, Paolo BORRO
    Panminerva Medica.2022;[Epub]     CrossRef
  • 11,276 View
  • 128 Download
  • 1 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Cyanoacrylate injection versus band ligation for bleeding from cardiac varices along the lesser curvature of the stomach
Sang Jung Park, Yong Kwon Kim, Yeon Seok Seo, Seung Woon Park, Han Ah Lee, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jae Young Jang, Jong Eun Yeon, Kwan Soo Byun
Clin Mol Hepatol 2016;22(4):487-494.
Published online December 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0050
Background/Aims
Practice guidelines recommend endoscopic band ligation (EBL) and endoscopic variceal obturation (EVO) for bleeding from esophageal varices and fundal varices, respectively. However, the optimal treatment for bleeding from cardiac varices along the lesser curvature of the stomach (GOV1) remains undefined. This retrospective study compared the efficacy between EBL and EVO for bleeding from GOV1.
Methods
Patients treated by EBL or EVO via cyanoacrylate injection for bleeding from GOV1 were enrolled. Patients diagnosed with hepatocellular carcinoma or treated with endoscopic injection sclerotherapy were excluded.
Results
The study included 91 patients treated for bleeding from GOV1. The mean age was 56.3±10.9 years (mean±SD), and 78 of them (85.7%) were men. Overall, 51 and 40 patients were treated with EBL and EVO, respectively. A trend for a higher hemostasis rate was noted in the EVO group (100%) than in the EBL group (82.6%, P=0.078). Varices rebled in 15 patients during follow-up. The rebleeding rate was significantly higher in the EBL group than in the EVO group (P=0.004). During follow-up, 13 patients died (11 in the EBL group and 2 in the EVO group); the survival rate was marginally significant between two groups (P=0.050). The rebleeding-free survival rate was significantly higher in the EVO group than in the EBL group (P=0.001).
Conclusions
Compared to EBL, EVO offered significantly lower rebleeding rates, significantly higher rebleeding-free survival rates, and a trend for higher hemostasis and survival rates. EVO appears to be the better therapeutic option for bleeding from GOV1.

Citations

Citations to this article as recorded by  Crossref logo
  • Short-term efficacy and safety of endoscopic injection of low dose of sclerotherapy and cyanoacrylate injection for type GOV1 gastric varices combined with endoscopic variceal ligation for esophageal varices
    Tingting Zhang, Chuangyang Xin, Xueyun Guo, Sihai Chen, Xuelian Zheng, Wen Xu, Dongjing Zhang, Biming Li, Ye Chen, Xuan Zhu, Anjiang Wang
    Surgical Endoscopy.2025; 39(1): 280.     CrossRef
  • Emergency Plug-Assisted Retrograde Transvenous Obliteration for Active Bleeding from Ruptured Gastric Varices
    Eunbyeol Ko, Jeongyeon Kim, Dong Il Gwon, Hee Ho Chu, Gun Ha Kim, Gi-Young Ko
    Journal of Vascular and Interventional Radiology.2025; 36(6): 994.     CrossRef
  • A randomized controlled trial comparing large-volume band ligator and cyanoacrylate injection in the endoscopic management of actively bleeding gastric varices
    Ding Shi, Guojing Xu, Weijin Pan
    Scientific Reports.2025;[Epub]     CrossRef
  • Evaluation of the efficacy and safety of endoscopic band ligation in the treatment of bleeding from mild to moderate gastric varices type 1
    Yue Deng, Ya Jiang, Tong Jiang, Ling Chen, Hai-Jun Mou, Bi-Guang Tuo, Guo-Qing Shi
    World Journal of Gastroenterology.2024; 30(5): 440.     CrossRef
  • Gastric variceal obstruction improves the efficacy of endoscopic management of esophageal variceal bleeding in GOV type I
    Xiaoquan Huang, Detong Zou, Huishan Wang, Wei Chen, Lili Zhang, Feng Li, Lili Ma, Chunqing Zhang, Ying Chen, Shiyao Chen
    Endoscopy International Open.2024; 12(08): E940.     CrossRef
  • Aluminum phosphate gel reduces early rebleeding in cirrhotic patients with gastric variceal bleeding treated with histoacryl injection therapy
    Hao-Tian Zeng, Zhu-Liang Zhang, Xi-Min Lin, Min-Si Peng, Li-Sheng Wang, Zheng-Lei Xu
    World Journal of Gastrointestinal Endoscopy.2023; 15(3): 153.     CrossRef
  • A case report of an endoscopic approach to life‐threatening cecal variceal hemorrhage
    Kirsty E MacFarlane, Nicholas J Fischer
    JGH Open.2022; 6(4): 277.     CrossRef
  • Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis
    Han Ah Lee, Jungwon Kwak, Sung Bum Cho, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Seung Up Kim, Hyonggin An, Hyung Joon Yim, Jong Eun Yeon, Yeon Seok Seo
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis
    Min Kyung Park, Yun Bin Lee
    The Korean Journal of Gastroenterology.2021; 78(3): 152.     CrossRef
  • Endoscopic Removal of Inflated Transected Sengstaken–Blakemore Tube Using Endoscopic Scissors
    Jun Ho Lee, Eu-Kwon Hwang, Chanmesa Doeun, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Clinical Endoscopy.2019; 52(2): 182.     CrossRef
  • Prevention and management of gastroesophageal varices
    Yeon Seok Seo
    Clinical and Molecular Hepatology.2018; 24(1): 20.     CrossRef
  • The Choice of Interventional Treatment of Gastric Variceal Hemorrhage: What Is Better?
    Moon Young Kim
    Gut and Liver.2018; 12(6): 611.     CrossRef
  • Endoscopic Therapy for Variceal Bleeding: from Patient Preparation to Available Techniques and Rescue Therapies
    Philippe Sultanik, Dominique Thabut
    Current Hepatology Reports.2017; 16(4): 398.     CrossRef
  • 12,613 View
  • 156 Download
  • 14 Web of Science
  • Crossref

Liver Imaging

Liver fibrosis, cirrhosis, and portal hypertension

What we need to know when performing and interpreting US elastography
So Hyun Park, So Yeon Kim, Chong Hyun Suh, Seung Soo Lee, Kyoung Won Kim, So Jung Lee, Moon-Gyu Lee
Clin Mol Hepatol 2016;22(3):406-414.
Published online September 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0106
According to the increasing need for accurate staging of hepatic fibrosis, the ultrasound (US) elastography techniques have evolved significantly over the past two decades. Currently, US elastography is increasingly used in clinical practice. Previously published studies have demonstrated the excellent diagnostic performance of US elastography for the detection and staging of liver fibrosis. Although US elastography may seem easy to perform and interpret, there are many technical and clinical factors which can affect the results of US elastography. Therefore, clinicians who are involved with US elastography should be aware of these factors. The purpose of this article is to present a brief overview of US techniques with the relevant technology, the clinical indications, diagnostic performance, and technical and biological factors which should be considered in order to avoid misinterpretation of US elastography results.

Citations

Citations to this article as recorded by  Crossref logo
  • Prospective Comparison of 2D-Shear Wave Elastography and Vibration-Controlled Transient Elastography in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Qingxin Li, Yanhang Gao, Dongxuan Wang, Xiaoxue Zhu, Jing Jia, Lili Liu, Huining Tian, Lishuang Wang, Yingwen Zhang, Dezhi Zhang
    Academic Radiology.2025; 32(9): 5100.     CrossRef
  • Reference values for liver stiffness in children using shear-wave elastography
    Célia Charlier, Saskia Vande Perre, Béatrice Dubern, Claire Apte-Dubuisson, Etienne Audureau, Margaux Bertrand, Hubert Ducou le Pointe, Eléonore Blondiaux
    Archives de Pédiatrie.2025; 32(5): 322.     CrossRef
  • Effect of breath control on hepatic shear wave elasticity and dispersion in pediatric patients
    Chanyoung Rhee, Seunghyun Lee, Young Hun Choi, Jae-Yeon Hwang, Jung-Eun Cheon
    Ultrasonography.2025; 44(5): 380.     CrossRef
  • Commercialization of Elastography in India: A Critical Analysis of Screening Practices and Healthcare Policy Implications
    Atul Kapoor
    International Journal of Gastroenterology.2025; 9(2): 122.     CrossRef
  • Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
    Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva
    Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1299.     CrossRef
  • Shear wave elastography in chronic kidney disease – the physics and clinical application
    Kwan Hoong Ng, Jeannie Hsiu Ding Wong, Sook Sam Leong
    Physical and Engineering Sciences in Medicine.2024; 47(1): 17.     CrossRef
  • Diagnostic accuracy of liver stiffness on two-dimensional shear wave elastography for detecting clinically significant portal hypertension: a meta-analysis
    Bingtian Dong, Yuping Chen, Yongjian Chen, Huaming Wang, Guorong Lyu
    Expert Review of Medical Devices.2023; 20(2): 141.     CrossRef
  • Clinical application of two dimensional shear wave elastography with a propagation map in evaluating liver fibrosis in patients with liver tumors
    Kun Wang, Yi Dong, Hong Han, Jiaying Cao, Jingwen Bao, Wen-Ping Wang
    Clinical Hemorheology and Microcirculation.2023; 85(2): 93.     CrossRef
  • Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey
    Quentin M Anstee, Kate Hallsworth, Niall Lynch, Adrien Hauvespre, Eid Mansour, Sam Kozma, Juliana Bottomley, Gary Milligan, James Piercy, Victoria Higgins
    Pragmatic and Observational Research.2023; Volume 14: 13.     CrossRef
  • Evaluation of the stiffness of normal cervix and its change with different factors using transvaginal two-dimensional shear wave elastography under strict quality control
    Hui-Ping Zhang, Jing-Jing Wu, Wen-Ying Zhang, Jiu-Zhi Tao, Cheng-Bin Ma, Yu-Qing Zhou
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Diagnostic Accuracy of Transient Elastography and Two-Dimensional Shear Wave Elastography for Staging Liver Fibrosis in Children or Adolescents: A Systematic Review and Meta-Analysis
    Xiuru Gong, Tingting Zhu, Xiaolin Peng, Dongwei Xing, Minguang Zhang
    Current Medical Imaging Formerly Current Medical Imaging Reviews.2023;[Epub]     CrossRef
  • Diagnostic Performance of 2-D Shear Wave Elastography on the Evaluation of Hepatic Fibrosis with Emphasis on Impact of the Different Region-of-Interest Methods
    Eun Mi Kim, Ji-Won Park, Sang Min Lee, Min-Jeong Kim, Hong Il Ha, Sung-Eun Kim, Eun Soo Kim, Young Chul Kim, Kwanseop Lee
    Ultrasound in Medicine & Biology.2022; 48(2): 198.     CrossRef
  • Applications of elastography in operative neurosurgery: A systematic review
    Andrew M. Hersh, Carly Weber-Levine, Kelly Jiang, Lisa Young, Max Kerensky, Denis Routkevitch, Yohannes Tsehay, Alexander Perdomo-Pantoja, Brendan F. Judy, Daniel Lubelski, Nicholas Theodore, Amir Manbachi
    Journal of Clinical Neuroscience.2022; 104: 18.     CrossRef
  • The diagnostic performance of ultrasound elastography for biliary atresia: A meta-analysis
    Bingtian Dong, Zongjie Weng, Guorong Lyu, Xiaocen Yang, Huaming Wang
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Impact of respiratory motion on liver stiffness measurements according to different shear wave elastography techniques and region of interest methods: a phantom study
    Jee Hyeon Lee, Sang Min Lee, Jeong Hee Yoon, Min-Jeong Kim, Hong Il Ha, Sung-Joon Park, Eun Soo Kim, Kwanseop Lee, Jeong Min Lee
    Ultrasonography.2021; 40(1): 103.     CrossRef
  • Test-retest repeatability of ultrasonographic shear wave elastography in a rat liver fibrosis model: toward a quantitative biomarker for preclinical trials
    Youngbin Shin, Jimi Huh, Su Jung Ham, Young Chul Cho, Yoonseok Choi, Dong-Cheol Woo, Jeongjin Lee, Kyung Won Kim
    Ultrasonography.2021; 40(1): 126.     CrossRef
  • Risk assessment of hepatocellular carcinoma and liver‐related events using ultrasonography and transient elastography in patients with chronic hepatitis B
    Sung Hwan Yoo, Tae Seop Lim, Hyun Woong Lee, Ja Kyung Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jung Il Lee, Kwan Sik Lee, Seung Up Kim
    Journal of Viral Hepatitis.2021; 28(10): 1362.     CrossRef
  • Comparison of 2‐Dimensional Shear Wave Elastographic Measurements Using ElastQ Imaging and SuperSonic Shear Imaging: Phantom Study and Clinical Pilot Study
    Jisun Hwang, Hee Mang Yoon, Ah Young Jung, Jin Seong Lee, Young Ah Cho
    Journal of Ultrasound in Medicine.2020; 39(2): 311.     CrossRef
  • Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study
    Jeong-Ju Yoo, Yang Jae Yoo, Woo Ram Moon, Seung Up Kim, Soung Won Jeong, Ha Na Park, Min Gyu Park, Jae Young Jang, Su Yeon Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Jong
    The Korean Journal of Internal Medicine.2020; 35(6): 1346.     CrossRef
  • Intraoperative Ultrasonographic Elastography: A Semi-Quantitative Analysis of Brain Tumor Elasticity Patterns and Peritumoral Region
    Santiago Cepeda, Cristina Barrena, Ignacio Arrese, Gabriel Fernandez-Pérez, Rosario Sarabia
    World Neurosurgery.2020; 135: e258.     CrossRef
  • Comparison of point and 2-dimensional shear wave elastography for the evaluation of liver fibrosis
    Sang Min Lee, Min-Jeong Kim, Jeong Hee Yoon, Wonju Hong, Hong Il Ha, Kwanseop Lee, Ji-Young Choe, Jung Woo Lee, Sam-Youl Yoon, Junhee Han
    Ultrasonography.2020; 39(3): 288.     CrossRef
  • Diagnostic Performance of Ultrasound Elastography and Serologic Fibrosis Indices for Evaluation of Hepatic Involvement in Wilson Disease
    Jisun Hwang, Hee Mang Yoon, Ah Young Jung, Jin Seong Lee, Kyung Mo Kim, Seak Hee Oh, Young Ah Cho
    Journal of Ultrasound in Medicine.2020; 39(11): 2231.     CrossRef
  • Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome
    Sherwin S. Chan, Antonio Colecchia, Rafael F. Duarte, Francesca Bonifazi, Federico Ravaioli, Jean Henri Bourhis
    Biology of Blood and Marrow Transplantation.2020; 26(10): 1770.     CrossRef
  • The Emergence of Elastography for Cystic Fibrosis Liver Disease
    P.M. Masand, M.R. Narkewicz, D.H. Leung
    Journal of Cystic Fibrosis.2020; 19(3): 339.     CrossRef
  • Two-Dimensional-Shear Wave Elastography with a Propagation Map: Prospective Evaluation of Liver Fibrosis Using Histopathology as the Reference Standard
    Dong Ho Lee, Eun Sun Lee, Jae Young Lee, Jae Seok Bae, Haeryoung Kim, Kyung Bun Lee, Su Jong Yu, Eun Ju Cho, Jeong-Hoon Lee, Young Youn Cho, Joon Koo Han, Byung Ihn Choi
    Korean Journal of Radiology.2020; 21(12): 1317.     CrossRef
  • Mechanical properties of human glioma
    Abraham Tsitlakidis, Elias C. Aifantis, Aristeidis Kritis, Anastasia S. Tsingotjidou, Angeliki Cheva, Panagiotis Selviaridis, Nicolas Foroglou
    Neurological Research.2020; 42(12): 1018.     CrossRef
  • Shear Wave Dispersion Predicts Liver Fibrosis and Adverse Outcomes in Patients with Heart Failure
    Himika Ohara, Akiomi Yoshihisa, Shinji Ishibashi, Mitsuko Matsuda, Yukio Yamadera, Yukiko Sugawara, Yasuhiro Ichijo, Yu Hotsuki, Koichiro Watanabe, Fumiya Anzai, Yu Sato, Yusuke Kimishima, Tetsuro Yokokawa, Tomofumi Misaka, Takamasa Sato, Masayoshi Oikawa
    Journal of Clinical Medicine.2020; 9(12): 3953.     CrossRef
  • Diagnostic Performance of Ultrasound Elastography for Evaluating Portal Hypertension in Children: A Systematic Review and Meta‐analysis
    Dong Wook Kim, Hee Mang Yoon, Ah Young Jung, Jin Seong Lee, Seak Hee Oh, Kyung Mo Kim, Young Ah Cho
    Journal of Ultrasound in Medicine.2019; 38(3): 747.     CrossRef
  • Technical performance of shear wave elastography for measuring liver stiffness in pediatric and adolescent patients: a systematic review and meta-analysis
    Dong Wook Kim, Chan Park, Hee Mang Yoon, Ah Young Jung, Jin Seong Lee, Seung Chai Jung, Young Ah Cho
    European Radiology.2019; 29(5): 2560.     CrossRef
  • Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
    Hye Won Lee, Seung Up Kim, Oidov Baatarkhuu, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease
    Dong Won Park, Yoon Jin Lee, Won Chang, Ji Hoon Park, Kyoung Ho Lee, Young Hoon Kim, Nam Kyu Kang, Jung Wha Chung, Hee Yoon Jang, Soomin Ahn, Haeryoung Kim, Sook-Hyang Jeong, Jin-Wook Kim, Eun Sun Jang, Silvia C. Sookoian
    PLOS ONE.2019; 14(3): e0212771.     CrossRef
  • Addition of Reliability Measurement Index to Point Shear Wave Elastography: Prospective Validation via Diagnostic Performance and Reproducibility
    Hyo-Jin Kang, Jae Young Lee, Kyung Boon Lee, Ijin Joo, Kyung-Suk Suh, Hyoung-Ki Lee, Joon Koo Han
    Ultrasound in Medicine & Biology.2019; 45(7): 1594.     CrossRef
  • Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals
    Hye Won Lee, Seung Up Kim, Jun Yong Park, Oidov Baatarkhuu, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2019; 10(6): e00036.     CrossRef
  • Accuracy and precision of ultrasound shear wave elasticity measurements according to target elasticity and acquisition depth: A phantom study
    Chong Hyun Suh, Hee Mang Yoon, Seung Chai Jung, Young Jun Choi, Guy Cloutier
    PLOS ONE.2019; 14(7): e0219621.     CrossRef
  • Shear-Wave Dispersion Slope from US Shear-Wave Elastography: Detection of Allograft Damage after Liver Transplantation
    Dong Ho Lee, Jae Young Lee, Jae Seok Bae, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Haeryoung Kim, Kyung Bun Lee, Joon Koo Han
    Radiology.2019; 293(2): 327.     CrossRef
  • Validation of a New Point Shear-Wave Elastography Method for Noninvasive Assessment of Liver Fibrosis: A Prospective Multicenter Study
    Ijin Joo, So Yeon Kim, Hee Sun Park, Eun Sun Lee, Hyo Jeong Kang, Jeong Min Lee
    Korean Journal of Radiology.2019; 20(11): 1527.     CrossRef
  • The diagnostic performance of shear-wave elastography for liver fibrosis in children and adolescents: A systematic review and diagnostic meta-analysis
    Jeong Rye Kim, Chong Hyun Suh, Hee Mang Yoon, Jin Seong Lee, Young Ah Cho, Ah Young Jung
    European Radiology.2018; 28(3): 1175.     CrossRef
  • Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus‐related advanced fibrosis or cirrhosis
    Byung Seok Kim, Yeon Seok Seo, Young Seok Kim, Chang Hyeong Lee, Han Ah Lee, Soon Ho Um, Jeong‐Ju Yoo, Sang Gyune Kim, Sang Jun Suh, Young Kul Jung, Sang Hoon Ahn, Kwang‐Hyub Han, Hyung Joon Yim, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2018; 33(2): 503.     CrossRef
  • Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B
    Ja Yoon Heo, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Hyon-Suk Kim, Young Nyun Park, Kwang-Hyub Han, Kijun Song, Seung Up Kim
    Gut and Liver.2018; 12(2): 190.     CrossRef
  • Shear Wave Elastography as a Quantitative Biomarker of Clinically Significant Portal Hypertension: A Systematic Review and Meta-Analysis
    Chong Hyun Suh, Kyung Won Kim, Seong Ho Park, Seung Soo Lee, Ho Sung Kim, Sree Harsha Tirumani, Jong Gu Lee, Junhee Pyo
    American Journal of Roentgenology.2018; 210(5): W185.     CrossRef
  • Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis
    Mi Young Jeon, Hye Won Lee, Seung Up Kim, Ja Yoon Heo, Sojung Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han
    Hepatology International.2017; 11(3): 268.     CrossRef
  • Liver Stiffness Measured by Shear‐wave Elastography for Evaluating Intrahepatic Portal Hypertension in Children
    Hee Mang Yoon, So Yeon Kim, Kyung Mo Kim, Seak Hee Oh, Gi‐Young Ko, Yangsoon Park, Jin Seong Lee, Ah Young Jung, Young Ah Cho
    Journal of Pediatric Gastroenterology and Nutrition.2017; 64(6): 892.     CrossRef
  • Shear-Wave Elastography for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis
    Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim
    American Journal of Roentgenology.2017; 209(4): 806.     CrossRef
  • Prospective Validation of Intra- and Interobserver Reproducibility of a New Point Shear Wave Elastographic Technique for Assessing Liver Stiffness in Patients with Chronic Liver Disease
    Su Joa Ahn, Jeong Min Lee, Won Chang, Sang Min Lee, Hyo-Jin Kang, Hyunkyung Yang, Jeong Hee Yoon, Sae Jin Park, Joon Koo Han
    Korean Journal of Radiology.2017; 18(6): 926.     CrossRef
  • Real-time two-dimensional Shear-wave elastography for liver stiffness in children: Interobserver variation and effect of breathing technique
    Hee Mang Yoon, Young Ah Cho, Jeong Rye Kim, Seung Soo Lee, Ah Young Jung, Jin Seong Lee, Seak Hee Oh, Kyung Mo Kim
    European Journal of Radiology.2017; 97: 53.     CrossRef
  • 16,556 View
  • 288 Download
  • 43 Web of Science
  • Crossref

Case Report

Drug induced liver injury

Drug-induced liver injury caused by iodine-131
Chei Won Kim, Ji Sun Park, Se Hwan Oh, Jae-Hyung Park, Hyun-Ik Shim, Jae Woong Yoon, Jin Seok Park, Seong Bin Hong, Jun Mi Kim, Trong Binh Le, Jin Woo Lee
Clin Mol Hepatol 2016;22(2):272-275.
Published online May 20, 2016
DOI: https://doi.org/10.3350/cmh.2015.0037
Iodine-131 is a radioisotope that is routinely used for the treatment of differentiated thyroid cancer after total or near-total thyroidectomy. However, there is some evidence that iodine-131 can induce liver injury . Here we report a rare case of drug-induced liver injury (DILI) caused by iodine-131 in a patient with regional lymph node metastasis after total thyroidectomy. A 47-year-old woman was admitted with elevated liver enzymes and symptoms of general weakness and nausea. Ten weeks earlier she had undergone a total thyroidectomy for papillary thyroid carcinoma and had subsequently been prescribed levothyroxine to reduce the level of thyroid-stimulating hormone. Eight weeks after surgery she underwent iodine-131 ablative therapy at a dose of 100 millicuries, and subsequently presented with acute hepatitis after 10 days. To rule out all possible causative factors, abdominal ultrasonography, endoscopic ultrasonography (on the biliary tree and gall bladder), and a liver biopsy were performed. DILI caused by iodine-131 was suspected. Oral prednisolone was started at 30 mg/day, to which the patient responded well.

Citations

Citations to this article as recorded by  Crossref logo
  • Protective Role of Vitamin D in Attenuating RAI-Induced Liver Injury in Rats
    Muzaffer Atli, Aylin Akbulut, Serdar Kuru, Nadide Koca, Koray Demirel, Gökhan Koca, Mehmet Şeneş, Nihat Yumuşak, Meliha Korkmaz
    Bratislava Medical Journal.2025; 126(12): 3406.     CrossRef
  • Early effects of radioactive iodine (I-131) therapy on liver function in patients with Graves’ disease: a 48-h analysis
    Rui-Ting Hu, Bin Li
    BMC Research Notes.2025;[Epub]     CrossRef
  • Hepatotoxicity of iodine-131 ablation for post-surgical differentiated thyroid cancer patients with hepatitis B virus infection
    Zhishuo Mo, Ziying Lei, Peipei Wang, Zhebin Wu, Haijuan Yuan, Dongying Xie, Zeqian Wu, Zenan Huang
    Clinics and Research in Hepatology and Gastroenterology.2021; 45(6): 101631.     CrossRef
  • Challenges in early identification of causes and treatment of cholestasis in patients with hyperthyroidism: a case report and literature review
    Baimei Zeng, Ling Yuan, Jun Chu, Yanqing Yang, Shide Lin
    Journal of International Medical Research.2020;[Epub]     CrossRef
  • The interplay between thyroid and liver: implications for clinical practice
    E. Piantanida, S. Ippolito, D. Gallo, E. Masiello, P. Premoli, C. Cusini, S. Rosetti, J. Sabatino, S. Segato, F. Trimarchi, L. Bartalena, M. L. Tanda
    Journal of Endocrinological Investigation.2020; 43(7): 885.     CrossRef
  • Perioperative considerations of hyperthyroidism in a patient with liver failure: case report
    Byung Hwa Kim, Yun Hee Kim, Yoon Sook Lee, Woon Young Kim, Jae Hwan Kim
    Medical Biological Science and Engineering.2019; 2(2): 60.     CrossRef
  • Recent Advances in the Histopathology of Drug-Induced Liver Injury
    David E. Kleiner
    Surgical Pathology Clinics.2018; 11(2): 297.     CrossRef
  • Iodine-131

    Reactions Weekly.2016; 1617(1): 140.     CrossRef
  • 17,170 View
  • 154 Download
  • 5 Web of Science
  • Crossref

Liver Imagings

Vascular disorders of liver

Focal type of peliosis hepatis
Gil-Sun Hong, Kyoung Won Kim, Jihyun An, Ju Hyun Shim, Jihun Kim, Eun Sil Yu
Clin Mol Hepatol 2015;21(4):398-401.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.398

Citations

Citations to this article as recorded by  Crossref logo
  • Focal peliosis hepatis with undefined etiology:: Diagnostic elucidation via ultrasonography, CT, and MRI; case report with literature review
    Tingting Geng, Sumei Gao, Olena Kovalska, Zhijian Liu
    Medicine.2025; 104(51): e44151.     CrossRef
  • A unique presentation of peliosis hepatis: A case report and comprehensive review of the literature
    Alex Teshon, Crystal Walker, David P Schammel, Christine Marie-Gilligan Schammel, A Michael Devane
    International Journal of Hepatobiliary and Pancreatic Diseases.2023; 13(1): 16.     CrossRef
  • Histologic and microbiological findings of the defunctionalized loop in sleeve gastrectomy with jejunal bypass
    Matías Sepúlveda, Munir Alamo, Cristián Astorga, Yudith Preiss, Sebastián Saavedra
    Surgery for Obesity and Related Diseases.2021; 17(1): 131.     CrossRef
  • Hepatic disorders associated with exogenous sex steroids: MR imaging findings
    Cathryn L. Hui, Zhen Jiang Lee
    Abdominal Radiology.2019; 44(7): 2436.     CrossRef
  • Hepatic complications of oral contraceptive pills and estrogen on MRI: Controversies and update - Adenoma and beyond
    Janardhana Ponnatapura, Ania Kielar, Lauren M.B. Burke, Mark E. Lockhart, Abdul-Rahman Abualruz, Rafel Tappouni, Neeraj Lalwani
    Magnetic Resonance Imaging.2019; 60: 110.     CrossRef
  • Peliosis Hepatis Simulates Liver Metastases
    Bruna Migliavacca Zucchetti, Andrea Shimada, Luiz Tenorio Siqueira
    Journal of Global Oncology.2018; (4): 1.     CrossRef
  • A case of multiple spontaneous hepatic ruptures and literature review
    N. V. Tytarenko, O. V. Sergiychuk
    Perioperaciina Medicina.2018; 1(1): 60.     CrossRef
  • 12,346 View
  • 114 Download
  • 4 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Portal flow steal after liver transplantation
Bohyun Kim, Kyoung Won Kim, Gi-Won Song, Sung-Gyu Lee
Clin Mol Hepatol 2015;21(3):314-317.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.314

Portal flow steal occasionally persists even after the liver transplantation, which may reduce the portal flow and thus threaten the patients' outcome. Therefore, pre- and peri-operative detection of portal steal phenomenon requiring radiological or surgical interruption is essential for the liver transplantation candidates as well as for the recipients.

Citations

Citations to this article as recorded by  Crossref logo
  • Late Onset Hepatic Encephalopathy after Living Donor Liver Transplant: Successful Reversal by Plug Embolization of Shunt—A Report of Two Cases
    Shahnawaz Bashir, Dibyalochan Praharaj, Adnan Khan, Subhash Gupta, Pragati Gakher
    Journal of Clinical Interventional Radiology ISVIR.2025; 09(03): 189.     CrossRef
  • Portal Steal During Liver Transplantation in a 31-Year-Old: When Absent Varices Signal Extensive Splenorenal Shunting
    Noor Abu Zar, Chia Chey
    Cureus.2025;[Epub]     CrossRef
  • Clinical Impact of Spontaneous Portosystemic Shunts in Liver Transplantation: A Comprehensive Assessment Through Total Shunt Area Measurement
    Leonardo Centonze, Giovanna Gorga, Riccardo De Carlis, Davide Bernasconi, Andrea Lauterio, Luca Carbonaro, Ivan Vella, Cristiano Sgrazzutti, Niccolò Incarbone, Francesco Rizzetto, Maria Grazia Valsecchi, Angelo Vanzulli, Luciano De Carlis
    Transplantation.2023; 107(4): 913.     CrossRef
  • Short-Term Results of Plug-Assisted Retrograde Transvenous Obliteration for Portal Steal from Complicated Portosystemic Shunts in Living-Donor Liver Transplantation
    Gun Ha Kim, Dong Il Gwon, Gi-Young Ko, Hee Ho Chu, Deok-Bog Moon, Dong-Hwan Jung, Sung-Gyu Lee
    Journal of Vascular and Interventional Radiology.2023; 34(4): 645.     CrossRef
  • Imaging and Intervention in the Management of Vascular Complications Following Liver Transplantation
    Vijay Kubihal, Shridhar Sasturkar, Amar Mukund
    Journal of Clinical and Experimental Hepatology.2023; 13(5): 854.     CrossRef
  • Role of portocaval shunts in development of complications after liver transplantation
    D. L. Tsoy, M. I. Prudkov, O. G. Orlov, E. N. Bessonova, I. G. Leshchenko, L. V. Kardopoltsev, A. N. Ageev, S. I. Solodushkin
    Transplantologiya. The Russian Journal of Transplantation.2022; 14(2): 159.     CrossRef
  • Understanding Local Hemodynamic Changes After Liver Transplant: Different Entities or Simply Different Sides to the Same Coin?
    Francisco Calderon Novoa, Juan Mattera, Martín de Santibañes, Victoria Ardiles, Adrian Gadano, Daniel E D’Agostino, Eugenia Fratantoni, Eduardo De Santibañes, Juan Pekolj
    Transplantation Direct.2022; 8(9): e1369.     CrossRef
  • Life-Threatening Portal Flow Steal Reappearing Under Increased Intrahepatic Vascular Resistance After Living Donor Liver Transplantation
    Jae-Hyun Kwon, Young-In Yoon, Deok-Bog Moon, Gil-Chun Park, Gi-Won Song, Dong-Hwan Jung, Kyu-Bo Sung, Gi-Young Ko, Dong-Il Gwon, Yong-Kyu Jung, I-Ji Jeong, Jin-Uk Choi, Min-Jae Kim, Sang-Hoon Kim, Sung-Gyu Lee
    Transplantation Proceedings.2021; 53(1): 166.     CrossRef
  • Endovascular management of portal steal syndrome due to portosystemic shunts after living donor liver transplantation
    Surabhi Jajodia, Anubhav H Khandelwal, Rohit Khandelwal, Abhay K Kapoor, Sanjay S Baijal
    JGH Open.2021; 5(5): 599.     CrossRef
  • Post-transplant inflow modulation for early allograft dysfunction after living donor liver transplantation
    Mohamed Elshawy, Takeo Toshima, Yoshiki Asayama, Yuichiro Kubo, Shinichiro Ikeda, Toru Ikegami, Shingo Arakaki, Tomoharu Yoshizumi, Masaki Mori
    Surgical Case Reports.2020;[Epub]     CrossRef
  • N-butyl-2 cyanoacrylate (NBCA) embolus in the graft portal vein after portosystemic collateral embolization in liver transplantation recipient: what is the clinical significance?
    Hye Young Jang, Kyoung Won Kim, Jae Hyun Kwon, Heon-Ju Kwon, Bohyun Kim, Nieun Seo, Jeongjin Lee, Gi-Won Song, Sung-Gyu Lee
    Acta Radiologica.2017; 58(11): 1326.     CrossRef
  • 10,722 View
  • 104 Download
  • 8 Web of Science
  • Crossref

Hepatic neoplasm

Recent advances in the imaging of hepatocellular carcinoma
Myung-Won You, So Yeon Kim, Kyoung Won Kim, So Jung Lee, Yong Moon Shin, Jin Hee Kim, Moon-Gyu Lee
Clin Mol Hepatol 2015;21(1):95-103.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.95

The role of imaging is crucial for the surveillance, diagnosis, staging and treatment monitoring of hepatocellular carcinoma (HCC). Over the past few years, considerable technical advances were made in imaging of HCCs. New imaging technology, however, has introduced new challenges in our clinical practice. In this article, the current status of clinical imaging techniques for HCC is addressed. The diagnostic performance of imaging techniques in the context of recent clinical guidelines is also presented.

Citations

Citations to this article as recorded by  Crossref logo
  • PEGylated gas vesicles: a promising novel ultrasound contrast agent for diagnosis and guiding radiofrequency ablation of liver tumor
    Kezhi Yu, Yongquan Huang, Yuanyuan Wang, Qunyan Wu, Zihang Wang, Fei Li, Jianri Chen, Maierhaba Yibulayin, Shushan Zhang, Zhongzhen Su, Fei Yan
    Journal of Nanobiotechnology.2025;[Epub]     CrossRef
  • Tumor‐Targeted FABP5/STING Cascade Promote Radiofrequency Ablation Induced Ferroptosis and Intratumoral Immune Rewiring in Hepatocellular Carcinoma
    Bufu Tang, Xiaojie Zhang, Yiting Sun, Jinhua Luo, Qiaoyou Weng, Cong Zhang, Zilin Wang, Shiji Fang, Yangrui Xiao, Liyun Zheng, Jianfei Tu, Rongfang Qiu, Yang Yang, Zhongwei Zhao, Weiqian Chen, Minjiang Chen, Jiansong Ji
    Advanced Science.2025;[Epub]     CrossRef
  • Trends of liver cell carcinoma mortality in the United States by demographics and geography
    Sishir Doddi, Oscar Salichs, Taryn Hibshman, Puneet Bhargava
    Current Problems in Diagnostic Radiology.2024; 53(2): 208.     CrossRef
  • Synthesis of Ultrasmall Fe3O4 Nanoparticles as T1–T2 Dual-Modal Magnetic Resonance Imaging Contrast Agents in Rabbit Hepatic Tumors
    Chen Bai, Pengcheng Hu, Nianlong Liu, Guodong Feng, Di Liu, Yi Chen, Ming Ma, Ning Gu, Yu Zhang
    ACS Applied Nano Materials.2020; 3(4): 3585.     CrossRef
  • Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System
    Sonal Krishan, Radha K. Dhiman, Navin Kalra, Raju Sharma, Sanjay S. Baijal, Anil Arora, Ajay Gulati, Anu Eapan, Ashish Verma, Shyam Keshava, Amar Mukund, S. Deva, Ravi Chaudhary, Karthick Ganesan, Sunil Taneja, Ujjwal Gorsi, Shivanand Gamanagatti, Kumble
    Journal of Clinical and Experimental Hepatology.2019; 9(5): 625.     CrossRef
  • Highly Sensitive Diagnosis of Small Hepatocellular Carcinoma Using pH-Responsive Iron Oxide Nanocluster Assemblies
    Jingxiong Lu, Jihong Sun, Fangyuan Li, Jin Wang, Jianan Liu, Dokyoon Kim, Chunhai Fan, Taeghwan Hyeon, Daishun Ling
    Journal of the American Chemical Society.2018; 140(32): 10071.     CrossRef
  • Austrian consensus guidelines on imaging requirements prior to hepatic surgery and during follow-up in patients with malignant hepatic lesions
    Dietmar Tamandl, Ahmed Ba-Ssalamah, Gernot Böhm, Klaus Emmanuel, Rosemarie Forstner, Reinhold Függer, Benjamin Henninger, Oliver Koch, Claus Kölblinger, Hans-Jörg Mischinger, Wolfgang Schima, Helmut Schöllnast, Stefan Stättner, Klaus Kaczirek
    Wiener klinische Wochenschrift.2018; 130(21-22): 665.     CrossRef
  • Potential ultrastructure predicting factors for hepatocellular carcinoma in HCV infected patients
    Soheir S. Mansy, Eman El-Ahwany, Soheir Mahmoud, Sara Hassan, Mohammed I. Seleem, Amr Abdelaal, Ahmed H. Helmy, Mona K. Zoheiry, Ahmed S. AbdelFattah, Moataz H. Hassanein
    Ultrastructural Pathology.2017; 41(3): 209.     CrossRef
  • Liver resection for intermediate hepatocellular carcinoma
    Peng-Sheng Yi, Ming Zhang, Ji-Tong Zhao, Ming-Qing Xu
    World Journal of Hepatology.2016; 8(14): 607.     CrossRef
  • 14,094 View
  • 128 Download
  • 9 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma
Hyo Jeong Lee, Hyo Jeong Kang, Kang Mo Kim, Eun Sil Yu, Ki Hun Kim, Seung-Mi Kim, Tae Won Kim, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Clin Mol Hepatol 2015;21(1):60-70.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.60
Background/Aims

Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study was to determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) and neighboring nonneoplastic liver tissue, and elucidate its prognostic implications.

Methods

Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboring nonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patients who underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotype expression and overall survival was evaluated (development set). This association was also validated in 73 independent samples (validation set) by Western blot analysis.

Results

FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-year survival rate, 35.3% vs. 61.8%; P=0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgical prognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statistically significant in the validation set.

Conclusions

FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival.

Citations

Citations to this article as recorded by  Crossref logo
  • Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
    Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Mas
    Scientific Reports.2024;[Epub]     CrossRef
  • Evolving therapeutic landscape of advanced hepatocellular carcinoma
    Chen Yang, Hailin Zhang, Linmeng Zhang, Andrew X. Zhu, René Bernards, Wenxin Qin, Cun Wang
    Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 203.     CrossRef
  • Dietary Fat Composition Affects Hepatic Angiogenesis and Lymphangiogenesis in Hepatitis C Virus Core Gene Transgenic Mice
    Pan Diao, Yaping Wang, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Yoshiko Sato, Kyoji Moriya, Kazuhiko Koike, Jun Nakayama, Naoki Tanaka
    Liver Cancer.2023; 12(1): 57.     CrossRef
  • Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients
    Walizeb Khan, Washaakh Ahmad, Anwar M. Hashem, Shadi Zakai, Shafiul Haque, Muhammad Faraz Arshad Malik, Steve Harakeh, Farhan Haq
    Journal of Clinical Medicine.2022; 11(11): 3093.     CrossRef
  • Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy
    Lucia Cerrito, Maria Elena Ainora, Carolina Mosoni, Raffaele Borriello, Antonio Gasbarrini, Maria Assunta Zocco
    Cancers.2022; 14(19): 4647.     CrossRef
  • AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy
    Yun Feng, Dan Zhang, Gaixia He, Yaping Liu, Yan Zhao, Xiaoyang Ren, Huanhuan Sun, Guifang Lu, Zhiyong Zhang, Li Ren, Yan Yin, Hongxia Li, Shuixiang He
    Anti-Cancer Agents in Medicinal Chemistry.2022; 22(18): 3107.     CrossRef
  • Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
    Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu, Jiang Chen
    Therapeutic Advances in Medical Oncology.2021;[Epub]     CrossRef
  • Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
    Matthias Ocker
    World Journal of Gastroenterology.2020; 26(3): 279.     CrossRef
  • Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma
    Yuri Cho, Min Ji Park, Koeun Kim, Jae-Young Park, Jihye Kim, Wonjin Kim, Jung-Hwan Yoon
    International Journal of Molecular Sciences.2020; 21(2): 472.     CrossRef
  • Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
    Makoto Chuma, Haruki Uojima, Kazushi Numata, Hisashi Hidaka, Hidenori Toyoda, Atsushi Hiraoka, Toshifumi Tada, Shunji Hirose, Masanori Atsukawa, Norio Itokawa, Taeang Arai, Makoto Kako, Takahide Nakazawa, Naohisa Wada, Shuitirou Iwasaki, Yuki Miura, Satos
    Cancers.2020; 12(2): 293.     CrossRef
  • First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
    Sung-Bae Kim, Funda Meric-Bernstam, Aparna Kalyan, Aleksei Babich, Rong Liu, Takahiko Tanigawa, Anette Sommer, Motonobu Osada, Frank Reetz, Dirk Laurent, Sabine Wittemer-Rump, Jordan Berlin
    Targeted Oncology.2019; 14(5): 591.     CrossRef
  • The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma
    Prachi Rana, John Haydek, Anjana Pillai
    Current Hepatology Reports.2019; 18(4): 371.     CrossRef
  • Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma
    Oleg V. Grinchuk, Surya P. Yenamandra, Ramakrishnan Iyer, Malay Singh, Hwee Kuan Lee, Kiat Hon Lim, Pierce Kah‐Hoe Chow, Vladamir A. Kuznetsov
    Molecular Oncology.2018; 12(1): 89.     CrossRef
  • Molecular therapies and precision medicine for hepatocellular carcinoma
    Josep M. Llovet, Robert Montal, Daniela Sia, Richard S. Finn
    Nature Reviews Clinical Oncology.2018; 15(10): 599.     CrossRef
  • Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib
    Hyo Jung Cho, Soon Sun Kim, Ji Sun Nam, Min Jung Oh, Dae Ryong Kang, Jai Keun Kim, Jei Hee Lee, Bohyun Kim, Min Jae Yang, Jae Chul Hwang, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Sung Won Cho, Jae Youn Cheong
    Cytokine.2017; 95: 118.     CrossRef
  • Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis
    Gang Liu, Disheng Xiong, Rui Xiao, Zhengjie Huang
    Tumor Biology.2017; 39(6): 101042831770742.     CrossRef
  • Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma
    Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Chung Yong Kim, Jung-Hwan Yoon
    Digestive Diseases and Sciences.2016; 61(9): 2568.     CrossRef
  • 125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma
    Peng-Hui Hu, Lan-Hong Pan, Patrick Ting-Yat Wong, Wen-Hui Chen, Yan-Qing Yang, Hong Wang, Jun-Jian Xiang, Meng Xu
    World Journal of Gastroenterology.2016; 22(21): 5033.     CrossRef
  • Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor
    Wenya Zhou, Xiaoling Du, Fengju Song, Hong Zheng, Kexin Chen, Wei Zhang, Jilong Yang
    Oncotarget.2016; 7(16): 22234.     CrossRef
  • MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression
    Ming-Hua Hu, Chen-Yang Ma, Xiao-Ming Wang, Chen-Dong Ye, Guang-Xian Zhang, Lin Chen, Jin-Guo Wang
    Oncotarget.2016; 7(41): 66922.     CrossRef
  • NGS-based identification of druggable alterations and signaling pathways – hepatocellular carcinoma case report
    E. A. Kotelnikova, M. D. Logacheva, E. R. Nabieva, M. A. Pyatnitskiy, D. V. Vinogradov, A. S. Makarova, A. V. Demin, A. G. Paleeva, O. S. Kremenetskaya, A. A. Penin, A. V. Klepikova, A. S. Kasianov, D. A. Shavochkina, N. E. Kudashkin, Yu. I. Patyutko, N.
    Biopolymers and Cell.2015; 31(6): 436.     CrossRef
  • 11,835 View
  • 135 Download
  • 21 Web of Science
  • Crossref

Liver Imaging

Benign liver tumors and cystic disease of liver

Sonography of hepatic hemangioma accompanied by arterioportal shunt
Sang Hyun Choi, Kyoung Won Kim, Gil Sun Hong, So Jung Lee, So Yeon Kim, Jong Seok Lee, Hyoung Jung Kim
Clin Mol Hepatol 2014;20(1):85-87.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.85
  • 10,552 View
  • 121 Download

Original Article

Viral hepatitis

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
Dae Won Jun, Byung Ik Kim, Yong Kyun Cho, Hong Ju Kim, Young Oh Kwon, Soo Young Park, Sang Young Han, Yang Hyun Baek, Yong Jin Jung, Hwi Young Kim, Won Kim, Jeong Heo, Hyun Young Woo, Seong Gyu Hwang, Kyu Sung Rim, Jong Young Choi, Si Hyun Bae, Young Sang Lee, Young Suck Lim, Jae Youn Cheong, Sung Won Cho, Byung Seok Lee, Seok Hyun Kim, Joo Hyun Sohn, Tae Yeob Kim, Yong Han Paik, Ja Kyung Kim, Kwan Sik Lee
Clin Mol Hepatol 2013;19(2):165-172.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.165
Background/Aims

Carnitine and vitamin complex (Godex®) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients.

Methods

130 treatment-naïve patients with CHB were enrolled from 13 sites. The patients were randomly selected to the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level after 12 months.

Results

Among the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was. Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment.

Conclusions

ALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials
    Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari
    Arabian Journal of Chemistry.2023; 16(8): 105013.     CrossRef
  • Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients
    Hyung Joon Yim, Won Kim, Sang Hoon Ahn, Young Kul Jung, Soon Ho Um, Joo Hyun Sohn, Jae Young Jang, Dong Joon Kim, Eun‐Sook Park, So‐Young Jin, Kyun‐Hwan Kim
    Journal of Gastroenterology and Hepatology.2022; 37(2): 378.     CrossRef
  • Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center–Related Immune Cells
    Shuqin Gu, Weibin Wang, Guofu Ye, Chengcong Chen, Yang Zhou, Ling Guo, Shihong Zhong, Xiaoyi Li, Xin Fu, Chunhua Wen, Libo Tang, Jian Sun, Jinlin Hou, Yongyin Li
    The Journal of Infectious Diseases.2022; 225(11): 1955.     CrossRef
  • Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study
    Eileen L. Yoon, Sang Bong Ahn, Dae Won Jun, Yong Kyun Cho, Do Seon Song, Jae Yoon Jeong, Hee Yeon Kim, Young Kul Jung, Myeong Jun Song, Sung Eun Kim, Hyoung Su Kim, Soung Won Jeong, Sang Gyune Kim, Tae Hee Lee
    The Korean Journal of Internal Medicine.2022; 37(4): 757.     CrossRef
  • Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Randomized Trials
    Hyunwoo Oh, Chan Hyuk Park, Dae Won Jun
    Journal of Personalized Medicine.2022; 12(7): 1053.     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study
    Kye-Yeung Park, Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
    Journal of Personalized Medicine.2022; 12(12): 1970.     CrossRef
  • Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
    Na Li, Hui Zhao
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection
    Shuqin Gu, Xin Fu, Guofu Ye, Chengcong Chen, Xiaoyi Li, Shihong Zhong, Libo Tang, Haitao Chen, Deke Jiang, Jinlin Hou, Yongyin Li
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B
    Jeong Eun Song, Jun Yong Park
    Expert Opinion on Pharmacotherapy.2021; 22(18): 2427.     CrossRef
  • Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway
    Jung-Hee Hong, Moon-Kyu Lee
    Diabetes & Metabolism Journal.2021; 45(6): 933.     CrossRef
  • Does l-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials
    Farzaneh Pirmadah, Nahid Ramezani-Jolfaie, Mohammad Mohammadi, Nasir Talenezhad, Cain C. T. Clark, Amin Salehi-Abargouei
    European Journal of Nutrition.2020; 59(5): 1767.     CrossRef
  • The protective role of l-carnitine against 1st- and 2nd-generation antihistamine-induced liver injury in mice
    Rania A. Abdel-Emam, Esraa A. Ahmed, Marwa F. Ali
    Comparative Clinical Pathology.2020; 29(1): 213.     CrossRef
  • Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
    Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials
    Esmaeil Yousefi Rad, Elham Eslampour, Ebrahim Falahi, Mahnaz Mardani, Azita Hekmatdoost, Omid Asbaghi, Somayeh Saboori
    Indian Journal of Gastroenterology.2019; 38(6): 470.     CrossRef
  • L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
    Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi,
    Hepatology Communications.2018; 2(8): 910.     CrossRef
  • Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature
    Rachael R. Schulte, Manasi V. Madiwale, Allyson Flower, Jessica Hochberg, Michael J. Burke, Jennifer L. McNeer, Adam DuVall, Archie Bleyer
    Leukemia & Lymphoma.2018; 59(10): 2360.     CrossRef
  • Anti-adipogenic and antiviral effects ofl-carnitine on hepatitis C virus infection
    Yoko Tsukuda, Goki Suda, Seiji Tsunematsu, Jun Ito, Fumiyuki Sato, Katsumi Terashita, Masato Nakai, Takuya Sho, Osamu Maehara, Tomoe Shimazaki, Megumi Kimura, Kenichi Morikawa, Mitsuteru Natsuizaka, Koji Ogawa, Shunsuke Ohnishi, Makoto Chuma, Naoya Sakamo
    Journal of Medical Virology.2017; 89(5): 857.     CrossRef
  • Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition
    Qianying Chen, Hongzhu Chen, Wenjie Wang, Jiali Liu, Wenyue Liu, Ping Ni, Guowei Sang, Guangji Wang, Fang Zhou, Jingwei Zhang
    European Journal of Pharmaceutical Sciences.2017; 106: 313.     CrossRef
  • A Case of Therapeutic Laser for Suggested Drug Induced Liver Injury Patient during Treatment of Korean Medicine
    Kyeong-Tae Lim, Byung-Cheul Shin, Eui-Hyoung Hwang, In Heo, Byung-Jun Kim, Kwang-Ho Heo
    Journal of Korean Medicine Rehabilitation.2016; 26(3): 183.     CrossRef
  • Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition
    Zhongqi Dong, Sean Ekins, James E. Polli
    European Journal of Pharmaceutical Sciences.2015; 66: 1.     CrossRef
  • Comparison on the Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid in Patients with Abnormal Alanine Aminotransferase: Multicenter, Double-blinded, Randomized, Active-controlled Clinical Trial
    Sae Hwan Lee, Gab Jin Cheon, Hong Soo Kim, Young Don Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
    The Korean Journal of Gastroenterology.2014; 64(1): 31.     CrossRef
  • 13,832 View
  • 177 Download
  • Crossref
Liver Imaging

Benign liver tumors and cystic disease of liver

Hepatic angiomyolipoma with minimal fat, mimicking hepatocellular carcinoma
So Jung Lee, So Yeon Kim, Kyoung Won Kim, Yong Moon Shin, Hyoung Jung Kim, Jong Seok Lee, Sun A Kim
Korean J Hepatol 2012;18(3):330-335.
Published online September 25, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.3.330

Citations

Citations to this article as recorded by  Crossref logo
  • Hepatic Angiomyolipoma Mimicking Hepatocellular Carcinoma: Another Rare Case Report
    M Azzakhmam, M Allaoui, R Elochi, A Elktaibi, M Oukabli
    Archives of Pathology and Clinical Research.2025; : 001.     CrossRef
  • Puzzling hepatic tumor: Epithelioid angiomyolipoma
    Faten Limaiem, Seifeddine Baccouch, Nadia Boujelbene, Aziz Atallah, Mohamed Hajri, Sofiène Gabsi, Leila Ben Farhat, Saâdia Bouraoui
    Clinical Case Reports.2022;[Epub]     CrossRef
  • Retrospective analysis of hepatic perivascular epithelioid cell tumour (PEComa) in a single centre for clinical diagnosis and treatment clinical diagnosis and treatment of hepatic PEComa
    Xiao Yang, Qingyuan Wang, Xiao Zhou, Haoming Zhou, Wenbo Jia, Chunyang Hu, Jian Chu, Lianbao Kong
    Medicine.2022; 101(25): e29506.     CrossRef
  • An MRI Image Analysis of Primary Cardiac Neoplasms
    Ya-Nan Jin, Jing-Liang Cheng, Yan Zhang, Xiao-Ning Shao, Xiao-pan Zhang, Wen-Bo Zhang
    International Journal of General Medicine.2021; Volume 14: 2943.     CrossRef
  • FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background
    Kumi Ozaki, Kenichi Harada, Noboru Terayama, Nobuyuki Kosaka, Hirohiko Kimura, Toshifumi Gabata
    Japanese Journal of Radiology.2020; 38(8): 697.     CrossRef
  • Challenging liver lesions in noncirrhotic patients: Report of three cases
    Tania Franceschini, Deborah Malvi, Lorenzo Maroni, Matteo Ravaioli, Matteo Cescon, Antonia D’Errico, Francesco Vasuri
    Therapeutic Advances in Gastrointestinal Endoscopy.2019;[Epub]     CrossRef
  • Angiomyolipoma of the Liver without a Fat Component, Mimicking a Hepatocellular Carcinoma
    Yong Moon Woo, Soo Hyung Ryu, Jeong Wha Min, Mi Ryeong Kim, Tae Young Park, Jeong Seop Moon, Yun Kyung Kang
    The Korean Journal of Gastroenterology.2018; 71(1): 49.     CrossRef
  • Hepatic Angiomyolipoma Versus Hepatocellular Carcinoma in the Noncirrhotic Liver on Gadoxetic Acid–Enhanced MRI: A Diagnostic Challenge
    So Jung Lee, So Yeon Kim, Kyoung Won Kim, Jin Hee Kim, Hyoung Jung Kim, Moon-Gyu Lee, Eun Sil Yu
    American Journal of Roentgenology.2016; 207(3): 562.     CrossRef
  • Epithelioid Angiomyolipoma in a Patient With Li-Fraumeni Syndrome: Rare Pathologic Diagnosis
    Sina Jasim, Pheroze Tamboli, Soo-Chin Lee, Louise C. Strong, Khaled Elsayes, Montserrat Ayala-Ramirez, Mouhammed Amir Habra
    AACE Clinical Case Reports.2016; 2(3): e251.     CrossRef
  • Imaging findings of mimickers of hepatocellular carcinoma
    Tae Kyoung Kim, Eunchae Lee, Hyun-Jung Jang
    Clinical and Molecular Hepatology.2015; 21(4): 326.     CrossRef
  • Hepatic Angiomyolipoma Mimicking Hepatocellular Carcinoma
    Chun-Ping Wang, Hong-Yan Li, Hong Wang, Xiao-Dong Guo, Chang-Chun Liu, Shu-Hong Liu, Xu-Dong Gao, Jian-Hui Qu, Ze Liu, Xiu-Juan Chang, Yin-Ying Lu, Zhen Zeng, Min Lou, Yong-Ping Yang
    Medicine.2014; 93(28): e194.     CrossRef
  • Myomatous hepatic angiomyolipoma: imaging findings in 14 cases with radiological–pathological correlation and review of the literature
    Z Zhu, L Yang, X-M Zhao, D-Q Luo, H-T Zhang, C-W Zhou
    The British Journal of Radiology.2014; 87(1038): 20130712.     CrossRef
  • MR Characterization of Focal Liver Lesions
    Evan S. Siegelman, Anil Chauhan
    Magnetic Resonance Imaging Clinics of North America.2014; 22(3): 295.     CrossRef
  • A case of multiple hepatic angiomyolipomas with high 18 F-fluorodeoxyglucose uptake
    Soma Kumasaka, Yukiko Arisaka, Azusa Tokue, Tetsuya Higuchi, Takahito Nakajima, Yoshito Tsushima
    BMC Medical Imaging.2014;[Epub]     CrossRef
  • Epithelioid angiomyolipoma of the liver: a clinicopathologic study of 5 cases
    Regina Cheuk-lam Lo
    Annals of Diagnostic Pathology.2013; 17(5): 412.     CrossRef
  • 12,112 View
  • 74 Download
  • Crossref
First First Prev Prev
Page of 1
Next Next Last Last
CMH : Clinical and Molecular Hepatology
Twitter